EP4178458A1 - Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables - Google Patents

Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables

Info

Publication number
EP4178458A1
EP4178458A1 EP22724894.5A EP22724894A EP4178458A1 EP 4178458 A1 EP4178458 A1 EP 4178458A1 EP 22724894 A EP22724894 A EP 22724894A EP 4178458 A1 EP4178458 A1 EP 4178458A1
Authority
EP
European Patent Office
Prior art keywords
staple
staples
patent application
entitled
application serial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22724894.5A
Other languages
German (de)
English (en)
Inventor
Jason L. Harris
Chad E. ECKERT
Mark H. Ransick
William J. K. Crone
Stephen R. Lovelock
Haruka Kobayashi
Richard T. Bown
Richard J. Andrews
Sophie K. Trott
Ailsa G. Bradbury
Howell T. Goldrein
Shashi S. Pathak
Jason M. Rector
Michael J. Vendely
Shannon L. Jones
Ryan W. McGhee
Frederick E. Shelton Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Cilag GmbH International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/718,838 external-priority patent/US20220354486A1/en
Application filed by Cilag GmbH International filed Critical Cilag GmbH International
Publication of EP4178458A1 publication Critical patent/EP4178458A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/064—Surgical staples, i.e. penetrating the tissue
    • A61B17/0644—Surgical staples, i.e. penetrating the tissue penetrating the tissue, deformable to closed position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B17/07207—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously the staples being applied sequentially
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B17/07292—Reinforcements for staple line, e.g. pledgets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A61B50/33—Trays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/082—Inorganic materials
    • A61L31/086—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00004—(bio)absorbable, (bio)resorbable or resorptive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017—Electrical control of surgical instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00115—Electrical control of surgical instruments with audible or visual output
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00367—Details of actuation of instruments, e.g. relations between pushing buttons, or the like, and activation of the tool, working tip, or the like
    • A61B2017/00398—Details of actuation of instruments, e.g. relations between pushing buttons, or the like, and activation of the tool, working tip, or the like using powered actuators, e.g. stepper motors, solenoids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00526—Methods of manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00526—Methods of manufacturing
    • A61B2017/0053—Loading magazines or sutures into applying tools
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/0084—Material properties low friction
    • A61B2017/00849—Material properties low friction with respect to tissue, e.g. hollow organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00889—Material properties antimicrobial, disinfectant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00938—Material properties hydrophobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B2017/0688—Packages or dispensers for surgical staplers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B2017/07214—Stapler heads
    • A61B2017/07228—Arrangement of the staples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B2017/07214—Stapler heads
    • A61B2017/07235—Stapler heads containing different staples, e.g. staples of different shapes, sizes or materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B2017/07214—Stapler heads
    • A61B2017/07257—Stapler heads characterised by its anvil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B2017/07214—Stapler heads
    • A61B2017/07271—Stapler heads characterised by its cartridge
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/068—Surgical staplers, e.g. containing multiple staples or clamps
    • A61B17/072—Surgical staplers, e.g. containing multiple staples or clamps for applying a row of staples in a single action, e.g. the staples being applied simultaneously
    • A61B2017/07214—Stapler heads
    • A61B2017/07278—Stapler heads characterised by its sled or its staple holder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B2050/005—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers with a lid or cover
    • A61B2050/0065—Peelable cover
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A61B2050/3004—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments containing desiccant means, e.g. desiccant pouches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A61B2050/314—Flexible bags or pouches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/03—Automatic limiting or abutting means, e.g. for safety
    • A61B2090/038—Automatic limiting or abutting means, e.g. for safety during shipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/08—Accessories or related features not otherwise provided for
    • A61B2090/0807—Indication means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/90—Identification means for patients or instruments, e.g. tags
    • A61B90/92—Identification means for patients or instruments, e.g. tags coded with colour
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/90—Identification means for patients or instruments, e.g. tags
    • A61B90/94—Identification means for patients or instruments, e.g. tags coded with symbols, e.g. text
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/90—Identification means for patients or instruments, e.g. tags
    • A61B90/98—Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders

Definitions

  • the present invention relates to surgical staples that compress and appose patient tissue.
  • a clinician can utilize a surgical stapling instrument to staple, and cut, the patient tissue.
  • the surgical stapling instrument can include a staple cartridge that includes staples removably stored therein that are deployed into the patient tissue by a firing drive of the surgical stapling instrument.
  • the staples puncture a first side of the tissue and are then deformed by an anvil of the surgical stapling instrument positioned on a second, or opposite, side of the tissue.
  • the deformed staples clench, or compress, the tissue to prevent, or at least reduce, bleeding from the incision created by the stapling instrument.
  • the staples can be made of a bioabsorbable material such that the staples can dissolve and release the tissue after a sufficient amount of time has elapsed following the surgical procedure. While it is desirable that the staples ultimately dissolve and release the tissue, the staples must maintain their structural integrity for an amount of time, i.e., the biocorrosion timeframe, to allow for sufficient healing of the tissue.
  • the staples When selecting appropriate bioabsorbable materials such that the staples can meet the biocorrosion timeframe, many factors are considered, such as the stiffness of the staples, the strength of the staples, the ductility of the staple materials, the safety of the materials being utilized (such as toxicity concerns), and/or the compatibility of the materials with electrosurgical instruments, for example.
  • stents which are often implanted to hold open an artery are often comprised of alloys which resist or impede biocorrosion of the underlying structure eventhough a surface of the stent may comprise a dissolvable coating. 2
  • FIG. 1 is a perspective view of a staple for use with a surgical stapling instrument
  • FIG. 2 is a side elevation view of the staple of FIG. 1;
  • FIG. 3 is a top view of the staple of FIG 1 ;
  • FIG. 4 is a cross-sectional view of the staple of FIG. 1 taken along line 4-4 in FIG. 3;
  • FIG. 5 is a partial cross-sectional perspective view of a staple cartridge assembly illustrating staples being ejected from the staple cartridge assembly by a firing member;
  • FIG. 6 depicts a plan view of a staple cartridge installed in an end effector
  • FIG. 7 is an enlarged plan view of a portion of a staple cartridge
  • FIG. 8 is a side view of a wire staple
  • FIG. 9 is an isometric view of an end effector of a surgical stapling instrument comprising an anvil illustrated in an open position;
  • FIG. 10 is an elevational view of a staple
  • FIG. 11 is an elevational view of an asymmetrical staple
  • FIG. 12 is an elevational view of another asymmetrical staple
  • FIG. 13 is an elevational view of another asymmetrical staple
  • FIG. 14 is a perspective view of an end effector assembly configured to engage, cut, staple, and apply a piece of buttress material to tissue;
  • FIG. 15 is a perspective view of the end effector assembly of FIG. 14 after the end effector has been utilized to engage, cut, staple, and apply the piece of buttress material to the tissue;
  • FIG. 16 is an elevational view of a staple having round corners in accordance with at least one embodiment
  • FIG. 16A illustrates a wire staple implanted in patient tissue in accordance with at least one embodiment
  • FIG. 16B illustrates the wire staple of FIG. 16A in a partially-dissolved functional state
  • FIG. 16C illustrates the wire staple of FIG. 16A in a mostly-dissolved non- functional state
  • FIG. 16D illustrates the wire staple of FIG. 16A in a completely-dissolved state
  • FIG. 17 is a perspective view of a wire staple comprising an abraded surface in accordance with at least one embodiment
  • FIG. 18 is a perspective view of a wire staple comprising knurls in accordance with at least one embodiment
  • FIG. 19 is a perspective view of a wire staple comprising stamped spots defined therein in accordance with at least one embodiment
  • FIG. 20 is an elevational view of the wire staple of FIG. 19;
  • FIG. 21 is a cross-sectional view of the wire staple of FIG. 19 taken along line 21-21 in FIG. 20;
  • FIG. 22 is a cross-sectional view of the wire staple of FIG. 19 taken along line 22-22 in FIG. 20;
  • FIG. 23 is an elevational view of a wire staple and a staple driver in accordance with at least one embodiment
  • FIG. 24 is an elevational view of a wire staple and a staple driver in accordance with at least one embodiment
  • FIG. 25 is an elevational view of a wire staple and a staple driver in accordance with at least one embodiment
  • FIG. 26 is an elevational view of a wire staple in accordance with at least one embodiment comprising staple tips that are sharper than the staple tips of the staple of FIG. 25;
  • FIG. 27 is a perspective view of a wire staple and a staple driver in accordance with at least one embodiment;
  • FIG. 28 is an elevational view of the wire staple and staple driver of FIG. 27;
  • FIG. 29 is a perspective view of the staple driver of FIG. 27;
  • FIG. 30 is a cross-sectional view of the wire staple and staple driver of FIG. 27;
  • FIG. 31 is a cross-sectional view of the wire staple and staple driver of FIG. 27;
  • FIG. 32 is a cross-sectional view of the wire staple and staple driver of FIG. 27;
  • FIG. 33 is a perspective view of a wire staple and a staple driver in accordance with at least one embodiment
  • FIG. 34 is a cross-sectional view of a wire staple positioned in a different staple driver in accordance with at least one embodiment
  • FIG. 35 is a cross-sectional view of a wire staple and a staple driver in accordance with at least one embodiment illustrating the wire staple deflecting into contact with the staple driver during the staple firing process;
  • FIG. 36 is a cross-sectional view of a wire staple and a staple driver in accordance with at least one embodiment illustrating the wire staple deflecting downwardly toward a seat of the staple driver during the staple firing process;
  • FIG. 37 is a partial cross-sectional view of a staple cartridge include staple cavities, staple drivers movably positioned within the staple cavities, and staples ejectable from the staple cavities;
  • FIG. 38 is a perspective view of a staple and a staple driver in accordance with at least one embodiment
  • FIG. 38A depicts the staple of FIG. 38 in a fired configuration
  • FIG. 39 is a graph depicting the healing time of tissue
  • FIG. 40 is a graph depicting the healing of tissue
  • FIG. 41 is a graph depicting the strength of tissue during the healing process
  • FIG. 42 depicts the healing process of tissue
  • FIG. 43 is a graph depicting the elongation and stress of certain metals
  • FIG. 44 is a graph depicting the corrosion rate and the alloying percentage of certain metals.
  • FIG. 45A illustrates a coated wire staple implanted in patient tissue in accordance with at least one embodiment
  • FIG. 45B illustrates the coated wire staple of FIG. 45 A in a partially-dissolved functional state
  • FIG. 45C illustrates the coated wire staple of FIG. 45 A in a mostly-dissolved functional state
  • FIG. 45D illustrates the wire staple of FIG. 45 A in a completely-dissolved state
  • FIG. 46 is a cross-sectional view of a staple wire in accordance with at least one embodiment
  • FIG. 47 is a cross-sectional view of a coated staple wire in accordance with at least one embodiment
  • FIG. 48 is a cross-sectional view of a staple wire comprising a thin coating in accordance with at least one embodiment
  • FIG. 49 is a cross-sectional view of a staple wire comprising a thick coating in accordance with at least one embodiment
  • FIG. 50 is a cross-sectional view of a staple wire comprising a powder coating in accordance with at least one embodiment
  • FIG. 51 is a cross-sectional view of a staple wire comprising two coatings in accordance with at least one embodiment
  • FIG. 52 is a cross-sectional view of a staple wire comprising an impregnated coating in accordance with at least one embodiment
  • FIG. 53 is a cross-sectional view of a staple wire comprising an impregnated coating and a topical coating in accordance with at least one embodiment
  • FIG. 54 is a cross-sectional view of a hollow staple wire in accordance with at least one embodiment
  • FIG. 55 is a cross-sectional view of a staple wire comprising an internal substrate and an external substrate in accordance with at least one embodiment
  • FIG. 56 is a cross-sectional view of a therapeutic-filled staple wire in accordance with at least one embodiment
  • FIG. 57 is a cross-sectional view of the staple wire of FIG. 55 including a coating in accordance with at least one embodiment
  • FIG. 58 is a cross-sectional view of a coated staple in accordance with at least one embodiment
  • FIG. 59 is a cross-sectional view of a coated staple having different coating thicknesses in accordance with at least one embodiment
  • FIG. 60 depicts a wire staple manufacturing process in accordance with at least one embodiment
  • FIG. 61 depicts a staple manufacturing process in which a first coating is applied before a staple forming step in the process and a second coating is applied after the staple forming step in accordance with at least one embodiment
  • FIG. 62 depicts a process in which a staple is coated while the staple is positioned in a staple cartridge in accordance with at least one embodiment
  • FIG. 63 depicts a staple manufacturing process in accordance with at least one embodiment
  • FIG. 64 depicts a staple manufacturing process including a coating reflow process in accordance with at least one embodiment
  • FIG. 65 depicts a staple being cut from a multi-layered sheet of material
  • FIG. 66 is a perspective view of the staple of FIG. 65;
  • FIG. 67 is a cross-sectional view of the staple of FIG. 66 taken along line 67-67 in FIG.
  • FIG. 67A illustrates a coating on the staple of FIG. 66
  • FIG. 68 is a perspective view of a surgical staple cartridge including staples, staple drivers, and a sled configured to eject the staples from the staple cartridge;
  • FIG. 69 is a perspective view of another surgical staple cartridge including staples having integral staple drivers, and a sled configured to eject the staples from the staple cartridge;
  • FIG. 70 is a perspective view of a surgical system including a staple assembly tool for inserting staples into a staple cartridge;
  • FIG. 71 is a plan view of a plurality of staple lines after being implanted into the tissue of a patient
  • FIG. 72 is a partial plan view of a staple cartridge comprising wire staples and stamped staples stored therein in accordance with at least one embodiment
  • FIG. 73A depicts a staple pattern implanted into patient tissue in an unabsorbed state in accordance with at least one embodiment
  • FIG. 73B depicts the staple pattern of FIG. 73 A in a partially absorbed state
  • FIG. 73C depicts the staple pattern of FIG. 73 A in a further absorbed state as compared to FIG. 73B;
  • FIG. 73D depicts the staple pattern of FIG. 73 A in a further absorbed state as compared to FIG. 73 C illustrated with the outer two longitudinal staple rows in a nearly completely absorbed state;
  • FIG. 74 depicts tissue stapled with multiple staple firings that overlap in accordance with at least one embodiment
  • FIG. 75 A depicts a staple pattern implanted in patient tissue which also includes a decoy staple configured to be bioabsorbed before the staples in the staple pattern in accordance with at least one embodiment
  • FIG. 75B depicts the staple decoy of FIG. 75 A starting to be bioabsorbed before the staples are bioabsorbed;
  • FIG. 75C depicts further bioabsorption of the staple decoy of FIG. 75A while the staples are starting to be bioabsorbed;
  • FIG. 75D depicts the dissolution of the staple decoy of FIG. 75A prior to the dissolution of the staples
  • FIG. 76 depicts wire staples having different wire diameters implanted into patient tissue in accordance with at least one embodiment
  • FIG. 77 depicts staples having different sizes and coatings implanted into patient tissue in accordance with at least one embodiment
  • FIG. 78 is a partial plan view of a staple cartridge comprising staple cavities and two staples stored in each staple cavity in accordance with at least one embodiment
  • FIG. 79 is a partial plan view of a staple cartridge comprising longitudinal rows of staple cavities which have one staple stored in each staple cavity and a longitudinal row of staple cavities which has two staples stored in each staple cavity in accordance with at least one embodiment;
  • FIG. 80 is a partial plan view of a staple cartridge comprising one staple stored in proximal staple cavities and two staples stored in distal staple cavities in accordance with at least one embodiment
  • FIG. 81 is a partial plan view of a staple cartridge comprising coated and uncoated staples in accordance with at least one embodiment
  • FIG. 82 is a partial plan view of a staple cartridge comprising uncoated staples in proximal staple cavities and coated staples in distal staple cavities in accordance with at least one embodiment
  • FIG. 83 is a partial plan view of a staple cartridge comprising staples having different wire diameters in accordance with at least one embodiment
  • FIG. 84 is a partial plan view of a staple cartridge comprising thin staples in proximal staple cavities and thick staples in distal staple cavities in accordance with at least one embodiment
  • FIG. 85 is a partial plan view of a staple cartridge comprising thick staples in proximal staple cavities and thin staples in distal staple cavities in accordance with at least one embodiment
  • FIG. 86 depicts a bioabsorbable patch applied on top of a staple line in accordance with at least embodiment
  • FIG. 87 is perspective view of a surgical stapling assembly and tissue prior to incision and stapling of the tissue, according to various aspects of the present disclosure
  • FIG. 88 is a perspective view of the surgical stapling assembly and tissue of FIG. 87 after incision and stapling of the tissue and depicting layers of buttress stapled to the tissue, according to various aspects of the present disclosure
  • FIG. 89 is a perspective view of the surgical stapling assembly and tissue of FIG. 87 after the incision and stapling of the tissue and after dissolution of the layers of buttress into the patient, according to various aspects of the present disclosure
  • FIG. 90 is a timeline schematic depicting degradation and bioabsorption of a staple and buttress of the surgical stapling assembly of FIG. 87, according to various aspects of the present disclosure
  • FIG. 91 is a timeline schematic depicting degradation and bioabsorption of a staple and buttress of anther surgical stapling assembly, according to various aspects of the present disclosure
  • FIG. 92 is a perspective view of a surgical stapling assembly and tissue, further depicting layers of buttress releasably secured to the surgical stapling assembly, in which the layers of buttress include an array of through-holes aligned with the staple legs, according to various aspects of the present disclosure
  • FIG. 93 is a perspective view of a surgical stapling assembly and tissue, further depicting layers of buttress releasably secured to the surgical stapling assembly, in which the layers of buttress include an array of longitudinal ridges aligned with the rows of staples, according to various aspects of the present disclosure
  • FIG. 94 is a perspective view of a surgical stapling assembly and tissue, further depicting layers of buttress releasably secured to the surgical stapling assembly, in which the layers of buttress include an array of slots positioned and dimensioned to accommodate projections from the deck, according to various aspects of the present disclosure;
  • FIG. 95 is a perspective view of a surgical stapling assembly and tissue, further depicting multilayer buttresses releasably secured to the tissue, according to various aspects of the present disclosure
  • FIG. 96 is a perspective view of a surgical stapling assembly and tissue, further depicting corrugated buttresses releasably secured to the surgical stapling assembly, according to various aspects of the present disclosure
  • FIG. 97 is a cross-sectional elevation view of a staple cartridge and a buttress releasably secured to the staple cartridge, according to various aspects of the present disclosure
  • FIG. 98 is a cross-sectional elevation view of a portion of a surgical stapling assembly including a staple cartridge, a buttress releasably secured to the staple cartridge, and an anvil, depicting a firing element within the staple cartridge mid-firing stroke, according to various aspects of the present disclosure
  • FIG. 99 is a cross-sectional elevation view of a portion of a surgical stapling assembly including the staple cartridge and anvil of FIG. 98 mid-firing stroke, the surgical stapling assembly further including a buttress releasably secured to the staple cartridge, in which the buttress includes through-holes adapted to receive staple legs therethrough during the firing stroke, according to various aspects of the present disclosure;
  • FIG. 100 is a block diagram of a surgical instrument programmed to control the distal translation of a displacement member, according to various aspects of the present disclosure
  • FIG. 101 is a perspective view of an end effector assembly configured to engage, cut, staple, and apply an implantable adjunct material to tissue, in accordance with at least one aspect of the present disclosure
  • FIG. 102 is a perspective view of the end effector assembly of FIG. 101 after the end effector has been utilized to engage, cut, staple, and apply an implantable adjunct material to the tissue;
  • FIG. 103 is a perspective view of a stapled tissue and an implantable adjunct applied to the stapled tissue, in accordance with at least one aspect of the present disclosure
  • FIG. 104 is a partial perspective view of the stapled tissue of FIG. 102;
  • FIG. 105 illustrates a degradation sequence of a staple and an implantable adjunct portion held to a tissue portion by the staple, in accordance with at least one aspect of the present disclosure
  • FIG. 106 is a top view of an implantable adjunct including implantable adjunct portions, and staples deployed from a staple cartridge into the implantable adjunct portions, in accordance with at least one aspect of the present disclosure
  • FIG. 107 is a top view of an implantable adjunct including implantable adjunct portions, and staples deployed from a staple cartridge into the implantable adjunct portions, in accordance with at least one aspect of the present disclosure
  • FIG. 108 is perspective view of a stapled tissue showing multiple firings of a surgical stapler, with overlapping staples from subsequent firings, in accordance with at least one aspect of the present disclosure
  • FIG. 109 is a perspective view of an end effector assembly configured to engage, cut, staple, and apply an implantable adjunct material containing a medicament to tissue, in accordance with at least one aspect of the present disclosure
  • FIG. 110 illustrates a degradation sequence of a staple including a material configured to yield a radiotherapy to stapled tissue, in accordance with at least one aspect of the present disclosure
  • FIG. Ill is a perspective view of a surgical stapling instrument comprising a handle, a shaft assembly, and a surgical end effector;
  • FIG. 112 is a perspective view of a portion of the shaft assembly and handle of FIG. 1;
  • FIG. 113 is an exploded assembly view of the surgical end effector of FIG. 1 ;
  • FIG. 114 is a perspective view of the surgical end effector of FIG. 1 with an anvil thereof in an open position, and wherein a cartridge/retainer assembly comprising a staple retainer attached to a surgical staple cartridge is illustrated removed from a channel of the surgical end effector;
  • FIG. 115 is perspective view of the surgical end effector of FIG. 114, with the surgical staple cartridge of the cartridge/retainer assembly seated in the channel of the surgical end effector, and with the staple retainer removed from the surgical staple cartridge; 11
  • FIG. 116 is a perspective view of a packaging assembly embodiment comprising the cartridge/retainer assembly of FIG. 114 stored inside a hermetically-sealed container comprising a pouch, and wherein a desiccant element is also contained within the hermetically-sealed pouch;
  • FIG.117 is a perspective view of another packaging assembly embodiment, wherein a cartridge/retainer assembly is non-movably seated in a cartridge tray that is stored within a hermetically-sealed container comprising a pouch, and wherein a desiccant element is also contained within the hermetically-sealed pouch;
  • FIG. 118 is a perspective view of another packaging assembly embodiment, wherein a cartridge/retainer assembly is non-movably seated in a cartridge tray component of a hermetically-sealable container and the container further comprises a top member in a partially opened position that is attached to the cartridge tray and configured to establish a hermetic seal therewith, and wherein the container further includes a desiccant element therein;
  • FIG. 119 is an exploded assembly view of a staple retainer embodiment, a desiccant element, and a surgical staple cartridge, wherein the desiccant element is positioned between the staple retainer and the surgical staple cartridge;
  • FIG. 120 is a side view of the staple retainer of FIG. 119 coupled to the surgical staple cartridge, and wherein the desiccant element of FIG. 119 is captured between the staple retainer and a deck of the surgical staple cartridge to form a cartridge/retainer assembly;
  • FIG. 121 is an exploded assembly view of the staple retainer of 119, wherein another desiccant element embodiment is positioned between the staple retainer and a surgical staple cartridge, wherein the desiccant element is formed with a plurality of staple retention protrusions configured to be inserted into corresponding staple cavities in the surgical staple cartridge to restrain the staples therein;
  • FIG. 122 is a cross-sectional view of a portion of the staple retainer of FIG. 121 coupled to the surgical staple cartridge of FIG. 121, wherein the desiccant element of FIG. 121 is captured between the staple retainer and a deck of the surgical staple cartridge, and wherein a staple retention protrusion of the staple retainer is received within a corresponding staple cavity of the surgical staple cartridge to restrain the staple contained therein on a corresponding staple driver;
  • FIG. 123 is a perspective view of another packaging assembly embodiment comprising a cartridge/retainer assembly stored inside a hermetically-sealed container comprising a pouch, 12 wherein the cartridge/retainer assembly comprises a staple retainer coupled to a surgical staple cartridge, and wherein a desiccant element is attached to the staple retainer;
  • FIG. 124 is a perspective view of another packaging assembly embodiment comprising a cartridge/retainer assembly stored inside a container comprising a hermetically-sealed pouch, wherein the cartridge/retainer assembly comprises a staple retainer coupled to a surgical staple cartridge, and wherein the cartridge/retainer assembly is received between an upper desiccant element and a lower desiccant element supported within the hermetically-sealed pouch;
  • FIG. 125 is a perspective view of another packaging assembly embodiment, wherein the cartridge/retainer assembly of FIG. 124 and the upper desiccant element and lower desiccant element of FIG. 124 are contained within a retainer tube stored within a container comprising a hermetically-sealed pouch;
  • FIG. 126 is an exploded assembly view of a staple retainer, a tubular desiccant element, and a surgical staple cartridge wherein the surgical staple cartridge is to be received within the tubular desiccant element and the staple retainer is to be attached to the surgical staple cartridge to capture a portion of the tubular desiccant element between the staple retainer and a deck surface of the surgical staple cartridge;
  • FIG. 127 is an end exploded view of the staple retainer, tubular desiccant element, and surgical staple cartridge of FIG. 126, and wherein the surgical staple cartridge has been inserted into the tubular desiccant element;
  • FIG. 128 is a perspective view of another packaging assembly embodiment comprising a staple retainer attached to a surgical staple cartridge to form a cartridge/ retainer assembly, wherein the cartridge/retainer assembly is received within a tubular desiccant element and is stored inside a container comprising a hermetically-sealed pouch;
  • FIG. 129 is a perspective view of another desiccant element embodiment, wherein the desiccant element is removably mounted to a deck surface of a surgical staple cartridge, and wherein the surgical staple cartridge is stored in a hermetically-sealed container;
  • FIG. 130 is a perspective view of another desiccant element embodiment that is configured to non-movably support a cartridge/retainer assembly within a hermetically-sealable container for storage and shipment purposes;
  • FIG. 131 is a perspective view of another packaging assembly embodiment comprising a staple retainer attached to a surgical staple cartridge to form a cartridge/ retainer assembly, 13 wherein the cartridge/retainer assembly is stored inside a container comprising a hermetically- sealed pouch, and wherein the surgical staple cartridge comprises an RFID chip associated with a sensor;
  • FIG. 132 is a flow chart representative of a process of controller of a surgical stapling instrument, wherein a sensor communicating with the controller monitors an amount of moisture experienced by the surgical staple cartridge of FIG. 131 while stored within the hermetically- sealed pouch of FIG. 131, and wherein the controller prevents operation of the surgical stapling instrument when a detected amount of moisture exceeds a predetermined acceptable moisture level;
  • FIG. 133 is a flow chart representative of another process of controller of a surgical stapling instrument, wherein a sensor communicating with the controller monitors an amount of temperature experienced by the surgical staple cartridge of FIG. 131 while stored within the hermetically-sealed pouch of FIG. 131, and wherein the controller prevents operation of the surgical stapling instrument when a detected amount of temperature exceeds a predetermined acceptable temperature level;
  • FIG. 134 is a flow chart representative of another process of controller of a surgical stapling instrument, wherein a sensor communicating with the controller monitors an amount of moisture and temperature experienced by the surgical staple cartridge of FIG. 131 while stored within the hermetically-sealed pouch of FIG. 131, and wherein the controller prevents operation of the surgical stapling instrument when a detected amount of moisture exceeds a predetermined moisture level and/or a detected amount of temperature exceeds a predetermined temperature level;
  • FIG. 135 is a perspective view of another packaging assembly embodiment comprising a staple retainer attached to a surgical staple cartridge to form a cartridge/ retainer assembly, wherein the cartridge/retainer assembly is stored inside a container comprising a hermetically- sealed pouch, and wherein the pouch comprises an indicator associated with a sensor;
  • FIG. 136 is a perspective view of another packaging assembly embodiment comprising a staple retainer attached to a surgical staple cartridge to form a cartridge/ retainer assembly, wherein the cartridge/retainer assembly is stored inside a container comprising a hermetically- sealed pouch, and wherein the pouch is filled with a Nitrogen or Argon gas; 14
  • FIG. 137 is an exploded assembly view of another staple retainer embodiment and surgical staple cartridge, wherein the staple retainer comprises a plurality of staple retention protrusions protruding from an undersurface thereof, and wherein the staple retention protrusions are configured to be inserted into corresponding staple cavities in the surgical staple cartridge to restrain the staples therein;
  • FIG. 138 is a cross-sectional view pf a portion of the staple retainer of FIG. 137 coupled to the surgical staple cartridge of FIG. 137, wherein a staple retention protrusion of the staple retainer is received within a corresponding staple cavity of the surgical staple cartridge to restrain the staple contained therein in position on a staple driver;
  • FIG. 139 is cross-sectional view of a portion of a cartridge body of a surgical staple cartridge, wherein a bio-absorbable staple is received within a corresponding staple cavity in the cartridge body that comprises inner cavity walls, wherein the bio-absorbable staple is supported on a staple driver within the staple cavity, wherein the bio-absorbable staple comprises a staple coating, and wherein heat is applied to the bio-absorbable staple to cause portions of the staple coating to become tacky to temporarily adhere portions of the bio-absorbable staple to corresponding portions of the inner cavity walls and the staple driver;
  • FIG. 140 is cross-sectional view of a portion of a cartridge body of another surgical staple cartridge, wherein a bio-absorbable staple is received within a corresponding staple cavity in the cartridge body, wherein the bio-absorbable staple is supported on a staple driver within the staple cavity, and wherein a Vapor Corrosion Inhibitor is applied to the bio-absorbable staple while in the staple cavity;
  • FIG. 141 is an exploded assembly view of a cartridge/retainer assembly and a surgical end effector of a surgical stapling instrument, wherein an anvil of the surgical end effector is in an open position, wherein the cartridge/retainer assembly comprises a staple retainer coupled to a surgical staple cartridge, and wherein a pretreatment element is attached to the staple retainer and is saturated with a pretreatment medium configured to treat a staple-forming undersurface of the anvil;
  • FIG. 142A is a side view of the cartridge/retainer assembly of FIG. 141 being positioned for insertion into the surgical end effector of FIG. 141;
  • FIG. 142B is another side view of the cartridge/retainer assembly of FIG. 141 partially inserted into a channel of the surgical end effector of FIG. 141; 15
  • FIG. 142C is another side view of the cartridge/retainer assembly of FIG. 141, wherein the anvil of the surgical end effector has been closed onto the pretreatment element to cause the surgical staple cartridge to be seated in the channel and the pretreatment medium to be transferred to the staple-forming undersurface of the anvil;
  • FIG. 142D is another side view of the cartridge/retainer assembly of FIG. 141 after the anvil has been moved to an open position and the staple retainer has been detached from the surgical staple cartridge;
  • FIG. 143 is a perspective view of a surgical staple cartridge seated in a channel of a surgical end effector of a surgical stapling instrument, wherein an anvil thereof is in an open position, wherein a pretreatment element is positioned on a deck surface of the surgical staple cartridge, and wherein the pretreatment element is saturated with a pretreatment medium configured to treat a staple-forming undersurface of the anvil;
  • FIG. 144A is a side view of the surgical end effector of FIG. 143, wherein the anvil thereof is in the open position, wherein a cartridge/retainer assembly is being positioned for insertion into a channel of the surgical end effector, and wherein the cartridge/retainer assembly comprises a staple retainer attached to the surgical staple cartridge of FIG. 143;
  • FIG. 144B is another side view of the surgical end effector of FIG. 144A with the cartridge/retainer assembly partially seated in the channel;
  • FIG. 144C is another side view of the surgical end effector of FIG. 144A after the surgical staple cartridge has been seated in the channel and the staple retainer has been detached from the surgical staple cartridge;
  • FIG. 144D is another side view of the surgical end effector, surgical staple cartridge, and pretreatment element of FIG. 143;
  • FIG. 144E is another side view of the surgical end effector, surgical staple cartridge and pretreatment element of FIG. 143, wherein the anvil has been moved to a closed position to cause the pretreatment medium to be transferred to a staple-forming undersurface of the anvil;
  • FIG. 144F is another side view of the surgical end effector and surgical staple cartridge of FIG. 143 after the anvil has been moved to an open position and the pretreatment element has been removed from the deck of the surgical staple cartridge;
  • FIG. 145 is a perspective view of a staple cartridge assembly including an identifying chip in accordance with at least one embodiment
  • FIG. 146 is an exploded view of a staple cartridge assembly including a visual indicia thereon for identifying the bioabsorbability of the staples contained therein in accordance with at least one embodiment
  • FIG. 146A is a perspective view of a staple cartridge including an identification feature on its distal end;
  • FIG. 146B is a perspective view of a staple cartridge including a cartridge body molded with metallic flakes for identification purposes;
  • FIG. 146C is a perspective view of a staple cartridge including a cartridge body comprising an identification symbol
  • FIG. 146D is a perspective view of a staple cartridge including a cartridge body comprising protrusions selectively positioned for identification purposes;
  • FIG. 146E is a perspective view of a staple cartridge having a cartridge body and a cartridge pan where the cartridge pan includes an identification symbol;
  • FIG. 146F is a perspective view of a staple cartridge assembly including an implantable layer having an identification symbol
  • FIG. 147 is a perspective view of a staple cartridge that is insertable into an end effector of a surgical stapling instrument in accordance with at least one embodiment
  • FIG. 148 depicts the compatibility of certain staple cartridges with the surgical stapling instrument of FIG. 147;
  • FIG. 149 depicts the compatibility and incompatibility of the staple cartridges of FIG. 148 with a different surgical stapling instrument
  • FIG. 149A illustrates a side-elevation view of a surgical instrument including an end effector and a firing member where the end effector is in a closed or clamped position and the firing member is in a proximal or unfired position;
  • FIG. 149B illustrates a side-elevation view of the surgical instrument of FIG. 149A with the end effector in the closed or clamped position and the firing member in a distal or fired position;
  • FIG. 149C illustrates a cross-section end view of the surgical instrument of FIG. 149A with the end effector in the closed or clamped position;
  • FIG. 150 illustrates a logic diagram of a control system of a surgical instrument or tool, in accordance with at least one aspect of the present disclosure.
  • FIG. 151 illustrates a method of adaptively controlling a surgical stapling instrument based on the type of staple cartridge identified by a clinician or a control circuit, in accordance with at least one aspect of the present disclosure.
  • proximal and distal are used herein with reference to a clinician manipulating the handle portion of the surgical instrument.
  • proximal refers to the 54 portion closest to the clinician and the term “distal” refers to the portion located away from the clinician.
  • distal refers to the portion located away from the clinician.
  • spatial terms such as “vertical”, “horizontal”, “up”, and “down” may be used herein with respect to the drawings.
  • surgical instruments are used in many orientations and positions, and these terms are not intended to be limiting and/or absolute.
  • a surgical stapling system can comprise a shaft and an end effector extending from the shaft.
  • the end effector comprises a first jaw and a second jaw.
  • the first jaw comprises a staple cartridge.
  • the staple cartridge is insertable into and removable from the first jaw; however, other embodiments are envisioned in which a staple cartridge is not removable from, or at least readily replaceable from, the first jaw.
  • the second jaw comprises an anvil configured to deform staples ejected from the staple cartridge.
  • the second jaw is pivotable relative to the first jaw about a closure axis; however, other embodiments are envisioned in which the first jaw is pivotable relative to the second jaw.
  • the surgical stapling system further comprises an articulation joint configured to permit the end effector to be rotated, or articulated, relative to the shaft.
  • the end effector is rotatable about an articulation axis extending through the articulation joint.
  • Other embodiments are envisioned which do not include an articulation joint.
  • the staple cartridge comprises a cartridge body.
  • the cartridge body includes a proximal end, a distal end, and a deck extending between the proximal end and the distal end.
  • the staple cartridge is positioned on a first side of the tissue to be stapled and the anvil is positioned on a second side of the tissue.
  • the anvil is moved toward the staple cartridge to compress and clamp the tissue against the deck.
  • staples removably stored in the 55 cartridge body can be deployed into the tissue.
  • the cartridge body includes staple cavities defined therein wherein staples are removably stored in the staple cavities.
  • the staple cavities are arranged in six longitudinal rows. Three rows of staple cavities are positioned on a first side of a longitudinal slot and three rows of staple cavities are positioned on a second side of the longitudinal slot. Other arrangements of staple cavities and staples may be possible.
  • the staples are supported by staple drivers in the cartridge body.
  • the drivers are movable between a first, or unfired position, and a second, or fired, position to eject the staples from the staple cavities.
  • the drivers are retained in the cartridge body by a retainer which extends around the bottom of the cartridge body and includes resilient members configured to grip the cartridge body and hold the retainer to the cartridge body.
  • the drivers are movable between their unfired positions and their fired positions by a sled.
  • the sled is movable between a proximal position adjacent the proximal end and a distal position adjacent the distal end.
  • the sled comprises a plurality of ramped surfaces configured to slide under the drivers and lift the drivers, and the staples supported thereon, toward the anvil.
  • the sled is moved distally by a firing member.
  • the firing member is configured to contact the sled and push the sled toward the distal end.
  • the longitudinal slot defined in the cartridge body is configured to receive the firing member.
  • the anvil also includes a slot configured to receive the firing member.
  • the firing member further comprises a first cam which engages the first jaw and a second cam which engages the second jaw. As the firing member is advanced distally, the first cam and the second cam can control the distance, or tissue gap, between the deck of the staple cartridge and the anvil.
  • the firing member also comprises a knife configured to incise the tissue captured intermediate the staple cartridge and the anvil. It is desirable for the knife to be positioned at least partially proximal to the ramped surfaces such that the staples are ejected ahead of the knife.
  • Various staples disclosed herein comprise a flat-formed staple which can be cut and/or stamped from a sheet of material, for example.
  • the sheet of material can be metallic and can comprise stainless steel and/or titanium, for example.
  • outlines can be traced, etched, and/or cut into the sheet of material which are machined and/or laser cut to form the staples into a manufactured shape.
  • the staples comprise a pair of staple legs and a staple base portion, or crown, from which the staple legs extend.
  • Each staple leg comprises a staple tip, or piercing portion, which is configured to pierce the tissue and contact a corresponding forming 56 pocket of the anvil of the surgical stapling instrument.
  • the staple legs are configured to be deformed to assume a formed configuration to fasten the tissue.
  • the staple legs define a plane which is laterally offset from but at least substantially parallel to a plane defined by the base of the staple. Embodiments are envisioned where the first and second planes are not parallel.
  • a stamped staple 100 is depicted in FIGS. 1-4.
  • the staple 100 comprises a proximal staple leg 110, a distal staple leg 120, and a staple base portion 130.
  • the staple 100 further comprises vertical transition portions, or bends, 118, 128 and lateral transition portions, or bends, 116, 126.
  • the vertical transition portions 118, 128 bend, or extend, the legs 110, 120 vertically, or upward, from the staple base portion 130.
  • the lateral transition portions 116, 126 extend the staple legs 110, 120 laterally outward, or at least substantially perpendicularly with respect to the staple base portion 130.
  • the staple legs 110, 120 define a first plane and the staple base portion 130 defines a second plane.
  • the vertical transition portions 118, 128 and the lateral transition portions 116, 126 permit the staple legs 110, 120 to be laterally offset and parallel with respect to the staple base portion 130.
  • the first plane is offset from and at least substantially parallel to the second plane.
  • the first plane is offset in a negative Y direction, which is orthogonal to a vertical Z direction.
  • Other staples may be used in conjunction with a plurality of staples 100 where the other staples comprise a first plane which is offset in the positive Y direction.
  • the use of both types of staples permits staple rows to be nested, or interwoven, where staple legs of neighboring rows may be at least substantially aligned and/or share a common longitudinal axis. In various instances, the staple rows can be nested to provide denser staple rows.
  • the proximal staple leg 110 comprises a generally rectangular cross-section including flat surfaces and corners.
  • the corners of the cross-section comprise bevels, radiuses, and/or coined edges 114 which reduce the exposure of sharp edges to the patient tissue. That said, the proximal staple leg 110 comprises a sharp tip 112 configured to incise the patient tissue.
  • the distal staple leg 120 comprises a generally rectangular cross-section including flat surfaces 125 and corners 124 which are beveled, radiused, and/or coined to reduce the exposure of sharp edges to the patient tissue. Fike the proximal leg 110, the distal staple leg 120 comprises a sharp tip 122 configured to incise the patient tissue.
  • the staple base 130 comprises an upper portion 136 configured to contact and support patient tissue.
  • the upper portion 136 of the staple base 130 comprises tissue contacting surfaces 57
  • the staple base 130 further comprises a lower portion 135 which includes a drive cam 132 configured to be directly engaged by a sled.
  • the lower portion 135 further comprises a bottom edge 131 which rides over the apex of a sled rail and a distal shoulder 133 which loses contact with the sled rail as the sled moves distally.
  • the legs 110 and 120 of the staple 100 extend in a first plane and the drive cam 132 of the staple 100 is defined in a second plane.
  • the second plane is parallel to, or at least substantially parallel to, the first plane.
  • the legs 110 and 120 capture patient tissue within the staple 100 outside of the second plane.
  • such an arrangement allows a larger volume of tissue to be captured within the staple 100 as compared to wire staples that are defined in a single plane. That said, such wire staples are desirable in many instances and, in some instances, can be used in conjunction with stamped staples.
  • a staple cartridge 2100 is illustrated in FIG. 5 comprising a cartridge body 2110.
  • the cartridge body 2110 comprises a deck 2114, a plurality of staple cavities 2120a, and a plurality of staple cavities 2120b.
  • the staple cavities 2120a are similar to the staple cavities 2120b in many respects.
  • the staple cavities 2120a and 2120b both comprise a central slot 2121 having a proximal end and a distal end, a proximal staple leg guide 2122 extending laterally from the proximal end of the central slot 2121, and a distal staple leg guide 2123 extending laterally from the distal end of the central slot 2121. That said, the staple cavities 2120a and the staple cavities 2120b are oriented in different directions.
  • the staple leg guides 2122, 2123 of the staple cavities 2120a extend toward the staple cavities 2120b and, similarly, the staple leg guides 2122, 2123 of the staple cavities 2120b extend toward the staple cavities 2120a; however, any suitable arrangement can be utilized.
  • a staple 2130a which is similar to staple 100 in many respects, is positioned in each staple cavity 2120a and a staple 2130b, which is also similar to staple 100 in many respects, is positioned in each staple cavity 2120b.
  • the staples 2130a and the staples 2130b are similar to one another in many respects.
  • each staple 2130a comprises a base, or crown, 2131, a proximal leg 2132 extending from a proximal end of the base 2131, and a distal leg 2133 extending from a distal end of the base 2131. That said, the staples 2130a, 2130b are adapted in a manner to fit within the staple cavities 2120a, 2120b, respectively.
  • the legs 2132, 2133 of the staples 2130a extend toward the staples 2130b and the legs 2132, 2133 of the staples 2130b extend toward the staples 2130a; however, other arrangements are possible.
  • the staples 2130 are driven from unfired positions to fired positions by a firing member, such as sled 2140, for example.
  • the sled 2140 comprises wedges 2145 which are configured to directly engage the staples 2130 and lift the staples 2130 toward an anvil, such as anvil 2190, for example.
  • the sled 2140 comprises a wedge, or rail, 2145 for each longitudinal row of staples 2130; however, the sled 2140 may have any suitable number of wedges 2145.
  • Each wedge 2145 comprises an angled drive surface 2141 which slides under the staples 2130 as the sled 2140 is advanced from the proximal end of the staple cartridge 2100 toward the distal end of the staple cartridge 2100.
  • the base 2131 of each staple 2130 comprises an angled drive surface 2135 which is directly contacted by a drive surface 2141.
  • each staple 2130 comprises its own integrally-formed driver having a drive surface 2135.
  • the staples 2130 are comprised of metal and, as a result, the integrally-formed driver is also comprised of metal. That said, the staples disclosed herein can be comprised of any suitable material. Additional details can be found in U.S. Patent Application No. 14/836,411, which issued on July 23, 2019 as U.S. Patent No. 10,357,251, which is hereby incorporated by reference in its entirety herein.
  • FIG. 6 depicts a staple cartridge 300 that includes staple cavities 320a-320f formed within a cartridge body 302 that are arranged in six laterally-spaced longitudinal rows 500, 502, 504, 506, 508, 510, with three rows on each side of an elongated slot 310 defined in the cartridge body 302.
  • a staple 222 seen in FIG. 8, is positioned in each staple cavity 320a-320f.
  • the staple cartridge 300 further includes four laterally-spaced longitudinal rows of staple drivers 330a,
  • the inside staple drivers 330a are slideably mounted within corresponding staple cavities 320b and 320c such that each driver 330a supports two staples 222 - one in a staple cavity 320b and one in a staple cavity 320c.
  • the inside drivers 330b are slideably mounted within staple cavities 320d and 320e such that each driver 330b supports two staples 222 - one in a staple cavity 320d and one in a staple cavity 320e.
  • the outside drivers 370a and 370b are slideably mounted within the staple cavities 320a and 320f, respectively. Each of the outside drivers 370a and 370b supports a single staple 222. 59
  • a portion of the staple cartridge 300 is removed to expose portions of the elongate channel 16, such as recesses 212, 214 and to expose some components of the staple cartridge 300 in their unfired positions.
  • the cartridge body 302 has been removed.
  • a wedge sled 400 is shown in its proximal, unfired position and is in longitudinal sliding contact upon a cartridge tray, or pan, 224 of the staple cartridge 300.
  • the wedge sled 400 includes wedges sled cams 410, 420 that force upward the double drivers 330a, 330b and the single drivers 370b, 370b as the wedge sled 400 moves distally.
  • Staples 222 (not shown in FIG.
  • a staple 2230 is illustrated in FIG. 10.
  • the staple 2230 comprises a base 2231, a first leg 2232a extending from the base 2231, and a second leg 2232b extending from the base 2231.
  • the first leg 2232a comprises a first portion 2233a connected to the base 2231 and a second portion 2234a extending from the first portion 2233a.
  • the second leg 2232b comprises a first portion 2233b connected to the base 2231 and a second portion 2234b extending from the first portion 2233b.
  • the base 2231, the first portion 2233a, and the first portion 2233b can comprise a generally V-shaped configuration, for example.
  • the second portion 2234a extends inwardly from the first portion 2233a at a joint 2235a and, similarly, the second portion 2234b extends inwardly from the first portion 2233b at a joint 2235b.
  • the base 2231, the first leg 2232a, and the second leg 2232b can be configured and arranged such that the staple 2230 is symmetrical in its unformed, or unfired, configuration illustrated in FIG. 10.
  • the first leg 2232a is positioned distally with respect to the second leg 2232b.
  • the first leg 2232a is positioned proximally with respect to the second leg 2232b.
  • a staple 2330 is illustrated in FIG. 11.
  • the staple 2330 comprises a base 2331, a first leg 2332a extending from the base 2331, and a second leg 2332b extending from the base 2331.
  • the first leg 2332a comprises a straight portion 2333 a connected to the base 2331 which extends along an axis.
  • the second leg 2332b comprises a first portion 2333b connected to the base 2331 and a second portion 2334b extending from the first portion 2333b.
  • the base 2331, the straight portion 2333a, and the first portion 2333b comprise a generally V-shaped configuration, for 60 example.
  • the second portion 2334b extends inwardly from the first portion 2333b at a joint 2335b.
  • the base 2331, the first leg 2332a, and the second leg 2332b can be configured and arranged such that the staple 2330 is asymmetrical in its unformed, or unfired, configuration illustrated in FIG. 11.
  • the first leg 2332a is positioned distally with respect to the second leg 2332b.
  • the first leg 2332a is positioned proximally with respect to the second leg 2332b.
  • a staple 2430 is illustrated in FIG. 12.
  • the staple 2430 comprises a base 2431, a first leg 2432a extending from the base 2431, and a second leg 2432b extending from the base 2431.
  • the first leg 2432a comprises a first portion 2433a connected to the base 2431 and a second portion 2434a extending from the first portion 2433a.
  • the second leg 2432b comprises a first portion 2433b connected to the base 2431 and a second portion 2434b extending from the first portion 2433 b.
  • the base 2431, the first portion 2433 a, and the first portion 2433 b comprise a generally V-shaped configuration, for example.
  • the second portion 2434a extends inwardly from the first portion 2433a at a first angle at a joint 2435a and, similarly, the second portion 2434b extends inwardly from the first portion 2433b at a second angle at a joint 2435b.
  • the first angle and the second angle can be different.
  • the base 2431, the first leg 2432a, and the second leg 2432b can be configured and arranged such that the staple 2430 is asymmetrical in its unformed, or unfired, configuration illustrated in FIG. 12.
  • the first leg 2432a is positioned distally with respect to the second leg 2432b.
  • the first leg 2432a is positioned proximally with respect to the second leg 2432b.
  • a staple 2530 is illustrated in FIG. 13.
  • the staple 2530 comprises a base 2531, a first leg 2532a extending from the base 2531, and a second leg 2532b extending from the base 2531.
  • the first leg 2532a comprises a first portion 2533a connected to the base 2531 and a second portion 2534a extending from the first portion 2533a.
  • the second leg 2532b comprises a first portion 2533b connected to the base 2531 and a second portion 2534b extending from the first portion 2533b.
  • the base 2531, the first portion 2533a, and the first portion 2533b comprise a generally V-shaped configuration, for example.
  • the second portion 2534a extends inwardly from the first portion 2533a at a first angle at a joint 2535a and, similarly, the second portion 2534b extends inwardly from the first portion 2533b at a second angle at a joint 2535b.
  • the first angle and the second angle can be different.
  • the base 2531, the first leg 2532a, and the second leg 2532b are configured and arranged such that the staple 2530 is asymmetrical 61 in its unformed, or unfired, configuration illustrated in FIG. 13.
  • the staple 2530 can be similar to the staple 2430 in many respects and, in at least one instance, can include a wider base 2531 than the base 2431, for example.
  • a wider staple base can be accommodated within a given staple cavity when the staple leg 2532a and/or the staple leg 2532b extend in directions which are closer to the vertical direction.
  • the first leg 2532a is positioned distally with respect to the second leg 2532b.
  • the first leg 2532a is positioned proximally with respect to the second leg 2532b. Additional details can be found in U.S. Patent Application No. 14/318,996, which published on October 22, 2015 as U.S. Patent Application Publication No. 2015/0297228, the entire disclosure of which is hereby incorporated by reference in its entirety.
  • an end effector of a surgical instrument can include at least one implantable adjunct, such as a piece of buttress material “B”, releasably attached thereto.
  • the end effector is configured to engage and clamp tissue “T”, deploy staples into the tissue, and cut the tissue and the piece of buttress material.
  • the end effector can then be removed from the tissue leaving the staples and the piece of buttress material attached to the tissue on both sides of an incision “I”. Additional details regarding the buttress material “B” can be found in U.S. Patent Application No. 12/032,002, which issued on February 12, 2013 as U.S. Patent No. 8,371,491, the entire disclosure of which is hereby incorporated by reference in its entirety.
  • the staples of a staple cartridge can be comprised of any suitable material to provide a desired biocorrosion timeframe of the staples. In many instances, it may be desirable that this amount of time be within a year of the surgical procedure and, in some instances, within 6 months. In other instances, it may be desirable that this amount of time be about 3-4 months and/or any other suitable amount of time.
  • the staples can be comprised of magnesium, iron, zinc, and/or alloys thereof, for example.
  • the staples of a staple cartridge can comprise a coating, coatings, and/or an at least partial coating which can increase and/or otherwise control the rate in which the staples bioabsorb after being implanted in the patient tissue.
  • a staple cartridge can comprise an implantable adjunct, or layer, which is implanted against the patient tissue by the staples which increases and/or otherwise controls the rate in which the implanted staples bioabsorb. 62
  • the staples of a staple cartridge are comprised of a metal material that biocorrodes, or degrades, after being implanted in patient tissue owing to the bioabsorption of the staples.
  • the tissue healing window is about 30 days, depending on the type of tissue such as lung tissue, colon tissue, and/or stomach tissue, for example.
  • the staples it is desirable for the staples to release the tissue after the tissue heals such that the tissue regains its flexibility, or at least a substantial portion of its flexibility, after being stapled.
  • the tissue healing window is a factor that can be used to define both ends of the desired biocorrosion time frame.
  • a base metal can be alloyed to tune the degradation properties of the base metal and control the biocorrosion time frame of the staples.
  • magnesium for example, can be alloyed with lithium, zinc, iron, tin, aluminum, silver, zirconium, strontium, and/or calcium, for example, to tune the degradation rate of the magnesium. In other instances, magnesium can be alloyed into other metals, such as zinc, for example, to tune the degradation rate of the zinc.
  • the electrode potential of pure magnesium, or high-purity magnesium can be reduced by the introduction of one or more other elements to increase the degradation rate of the magnesium.
  • the presence of another element within magnesium can create a duplex microstructure which establishes microgalvanic cells within the alloy.
  • the presence of these other elements can create secondary phases within the magnesium which act as cathodes and accelerate the anodic dissolution, or biocorrosion, of the magnesium.
  • microgalvanic corrosion can be employed by alloying magnesium with iron. Iron at >170 ppm within high-purity magnesium, for example, greatly increases the corrosion rate of the magnesium as compared to high-purity magnesium.
  • a staple can be comprised of a Mg-Al-Fe alloy, for example.
  • the aluminum is between 3-8 wt% and the iron is between 5-7 wt%.
  • a staple is comprised of magnesium-iron alloy, such as Mg-0. IFe and/or Mg-0.5Fe, for example.
  • the staples of a staple cartridge are comprised of a magnesium-iron alloy including 1 wt% or less iron.
  • the staples of a staple cartridge are comprised of a magnesium-iron alloy including 1 wt% iron. In at least one embodiment, the staples of a staple cartridge are comprised of a magnesium-iron alloy including 0.5 wt% iron. In at least one embodiment, the staples of a staple cartridge are comprised of a magnesium-iron alloy including 0.1 wt% iron. In some embodiments, annealing the magnesium- iron alloy can increase the presence of iron precipitates within the magnesium and, therefore, increase the degradation rate of the staples. Moreover, annealing can be used to control the grain size within the magnesium-iron staple alloy which, as a result, can control the corrosion rate of the staples.
  • microgalvanic corrosion can be employed by alloying magnesium with lithium.
  • lithium-containing magnesium alloys can comprise a duplex structure of a-Mg and b-Li phases which establishes galvanic cells.
  • the staples of a staple cartridge are comprised of a magnesium-lithium alloy containing lithium between 1 wt% and 11 wt%, for example.
  • the staples of a staple cartridge are comprised of Mg-9Li.
  • the staples of a staple cartridge are comprised of a magnesium-lithium alloy containing lithium between 8 wt% and 14 wt% for example.
  • Lithium-containing magnesium alloys with greater than 11 wt% lithium may comprise excellent mechanical properties; however, such alloys sometimes corrode slower than magnesium-lithium alloys comprising less than 6 wt% lithium, which may be due to pH effects.
  • the staples of a staple cartridge are comprised of a magnesium-lithium alloy comprised of 2 wt% lithium. That said, an alloy can be selected to satisfy many parameters including, but not limited to, the degradation rate, ductility, and creep- resistance of the staple.
  • alloying magnesium with lithium can lower the electrode potential of the alloy in addition to creating microgalvanic corrosion within the staples.
  • the staples of a staple cartridge are comprised of a magnesium-lithium 64 alloy including aluminum, such as Mg-14Li-lAl, for example. In at least one embodiment, the staples of a staple cartridge are comprised of LAI 41 alloy, for example.
  • microgalvanic corrosion can be employed by alloying magnesium with zinc.
  • the zinc within magnesium alloys containing above 6.5 wt% zinc provide an accelerating effect on corrosion. That said, magnesium alloys containing below 6.5 wt% zinc, such as 3 wt% zinc, for example, can have a desirable degradation rate.
  • a staple is comprised of a magnesium alloy containing between 6 wt% and 10 wt% zinc, such as Mg-6Zn, for example.
  • a staple is comprised of a magnesium alloy containing between 5 wt% and 15 wt% zinc, such as Mg-14Zn, for example.
  • a staple is comprised of a magnesium-zinc-zirconium alloy, such as Mg-6Zn-0. IZr and/or Mg-3Zn-0.6Zr, for example.
  • zirconium is added to magnesium-zinc alloy at 1 wt% or less for grain refinement which, in various instances, can increase the degradation rate of the magnesium-zinc alloy.
  • the staples of a staple cartridge are comprised of ZK30 alloy, for example. The addition of zirconium can also increase the resistivity of the magnesium alloy which can have various other benefits, discussed further below.
  • a staple is comprised of a magnesium-zinc-zirconium-iron alloy, such as Mg-6Zn-0. lZr-0. IFe, for example.
  • a magnesium-zinc-zirconium-iron alloy such as Mg-6Zn-0. lZr-0. IFe, for example.
  • the addition of iron to a magnesium alloy can increase the degradation rate of the alloy.
  • the staples of a staple cartridge are comprised of a magnesium-zinc-zirconium alloy comprising 3 wt% zinc and less than 1 wt% zirconium, for example.
  • the staples of a staple cartridge are comprised of a magnesium-manganese alloy, such as Mg-IMn, for example.
  • magnesium alloys containing 1 wt% manganese or less have a desirable degradation rate and ductility.
  • the staples of a staple cartridge are comprised of a magnesium-manganese alloy comprising 1 wt% manganese.
  • the staples of a staple cartridge are comprised of Mg-lZn-0.3Ca-0.15Mn, for example.
  • the staples of a staple cartridge are comprised of a magnesium-manganese alloy comprising 0.15 wt% manganese. That said, staples can be comprised of a magnesium- manganese alloy having more than 1 wt% manganese. 65
  • a magnesium alloy can include aluminum.
  • the staples of a staple cartridge are comprised of Mg-2Al-lZn, for example, which has a high degradation rate.
  • the staples of a staple cartridge are comprised of Mg-3Al-lZn, for example, which also has a high degradation rate.
  • a staple is comprised of an magnesium-zinc-calcium alloy.
  • calcium is added to a magnesium-zinc alloy at 1 wt% or more which can provide grain refinement and can increase the degradation rate of the magnesium-zinc alloy.
  • the staples of a staple cartridge are comprised of Mg-1.34Ca-3Zn, for example.
  • the staples of a staple cartridge are comprised of ZX10 alloy, for example.
  • the staples of a staple cartridge are comprised of ZX20 alloy, for example.
  • the staples of a staple cartridge are comprised of ZX50 alloy, for example.
  • the staples of a staple cartridge are comprised of Mg-I.0Zn-0.3Ca.
  • the staples of a staple cartridge are comprised of Mg-l.5Zn 0.25Ca.
  • the staples of a staple cartridge are comprised of Mg-5Zn-0.3Ca.
  • the staples implanted within a patient are exposed to electrical energy during a surgical procedure.
  • a monopolar instrument can come into contact with the staples and transmit electricity to the staples. Such electricity heats the staples and can ignite the staples depending on the metal comprising the staples and how hot the staples get.
  • Adding calcium to magnesium and/or a magnesium alloy increases the ignition temperature thereof which can prevent the ignition of the staples.
  • the calcium comprises a less noble secondary phase within the magnesium which creates galvanic corrosion.
  • the staples of a staple cartridge are comprised of Mg-0.8Ca, for example.
  • calcium is added to magnesium between 0.1 wt% and 2 wt%, for example.
  • the staples of a staple cartridge are comprised of a magnesium-calcium alloy comprising 1 wt% or greater of calcium. Moreover, adding tin, aluminum, and/or zinc, for example, to magnesium and/or a magnesium alloy increases the resistivity thereof which can increase the time before the staples can ignite thereby possibly preventing the ignition of the staples.
  • staples can be comprised of zinc.
  • a staple can be comprised of wrought zinc, for example.
  • microgalvanic corrosion can be employed within zinc staples by alloying the zinc with magnesium, for example. The difference in nobility between the zinc and the magnesium in a zinc-magnesium alloy can create an anodic-cathodic relationship between the two elements.
  • the magnesium in the zinc-magnesium alloy can be greater than or equal to 0.1 wt%, for example. In at least one embodiment, the magnesium in the zinc-magnesium alloy can be between 0.1 wt% and 1 wt%, for example.
  • the magnesium in the zinc-magnesium alloy is 1 wt%, for example.
  • Zinc-magnesium alloys comprising less than 0.1 wt% magnesium are also envisioned but such alloys may or may not be sufficiently ductile for every application. That said, manganese can be alloyed with an alloy of zinc and magnesium to improve the ductility of the zinc-magnesium alloy.
  • a zinc- magnesium staple alloy comprises 1 wt% magnesium, for example.
  • a zinc-magnesium staple alloy comprises between 0.1 wt% and 5 wt% magnesium, for example.
  • the degradation rate of the zinc can be increased by alloying zinc with calcium, strontium, and/or iron, for example.
  • a zinc-iron staple alloy comprises 1 wt% or less iron. In at least one embodiment, a zinc-iron staple alloy comprises 1 wt% iron. In at least one embodiment, a zinc- iron staple alloy comprises 0.5 wt% iron. In at least one embodiment, a zinc-iron staple alloy comprises 0.1 wt% iron. In at least one embodiment, a zinc-strontium staple alloy comprises 1 wt% strontium, for example. In certain embodiments, a zinc-strontium staple alloy comprises between 0.1 wt% and 5 wt% strontium, for example. In at least one embodiment, a zinc-calcium staple alloy comprises 1 wt% calcium, for example.
  • a zinc-calcium staple alloy comprises between 0.1 wt% and 5 wt% calcium, for example.
  • a staple is comprised of Zn-Mg-0. ICa, for example.
  • a staple is comprised of a zinc-calcium alloy including 0.1 wt% calcium.
  • the degradation rate of zinc can be increased by alloying the zinc with aluminum, for example. Such embodiments can produce staples having excellent ductility.
  • staples comprised of zinc and/or zinc alloys can slowly relax, or creep, into a partially open configuration owing to the natural body temperature of the patient, i.e., around 98 degrees F.
  • alloying zinc with copper can create staples 67 that do not open, or at least substantially open, owing to creep.
  • alloying the zinc with copper can create microgalvanic corrosion within the staple and/or otherwise increase the degradation rate of the staple.
  • the copper in the zinc-copper alloy can be 1 wt%, for example. In certain embodiments, the copper in the zinc-copper alloy can be greater than or equal to 1 wt%, for example.
  • the copper in the zinc- copper staple alloy can be between 0.1 wt% and 2 wt%, for example. Adding titanium to a zinc- copper staple alloy can also reduce the creep of the implanted staples.
  • a zinc-copper-titanium alloy comprises 0.1 wt% titanium, for example.
  • a zinc-copper- titanium alloy comprises between 0.1 wt% and 1.0 wt% titanium, for example.
  • the zinc-copper-titanium alloy comprises 1 wt% copper and 0.1 wt% titanium, for example.
  • a staple can be comprised of Z41320 alloy and/or Z41321 alloy, for example.
  • a zinc-copper alloy can comprise titanium, manganese, and/or magnesium, for example.
  • the staples can also experience creep after being implanted in a patient.
  • the staples can be comprised of a magnesium alloy including rare earth elements, such as gadolinium, for example. Such alloys can be resistant, or at least more resistant, to creep.
  • the staples are comprised ofZXMlOO (1.07Zn-0.21Ca-0.31Mn) and/or ZXM120 (1.01Zn-1.63Ca-0.30Mn), for example.
  • BIOCORROSION AND MECHANICAL PROPERTIES OF ZXMI00 AND ZXMJ20 MAGNESIUM ALLOYS which published on January 25, 2019 m International Journal of Metalcasting is incorporated by reference herein.
  • the entire disclosure of International Patent Application Publication No. WO2020/247383A1, entitled MAGNESIUM-BASED ABSORBABLE ALLOYS is incorporated by reference herein.
  • the staples of a staple cartridge are comprised of Mg-lODy- lNd-lZn-0.2Zr, for example.
  • the Mg-10Dy-lNd-lZn-0.2Zr alloy may be further tuned and/or alloyed as described herein to achieve a desired degradation rate.
  • the staples of a staple cartridge are comprised of Mg-2.5Nd-lY, for example.
  • the Mg-2.5Nd-lY alloy may be further tuned and/or alloyed as described herein to achieve a desired degradation rate.
  • the staples of a staple cartridge are comprised of a magnesium alloy including yttrium, zirconium, and/or rare earth metals, for example. Similar to the above, such alloys may be further tuned and/or alloyed as described herein to achieve a desired degradation rate.
  • the staples of a staple cartridge are comprised of WE43, for example. Similar to the above, the WE43 alloy may be further tuned and/or alloyed as described herein to achieve a desired degradation rate, among other things.
  • the staple materials disclosed herein can be alloyed with silver and/or electroplated with silver, for example.
  • Silver has various antiseptic benefits.
  • magnesium is alloyed with silver, for example.
  • silver is highly soluble in magnesium and, as a result, a Mg-Ag alloy may be stronger than pure magnesium.
  • electroplating a staple can create a smooth surface which can prevent, or at least inhibit, the deposit of minerals and/or materials onto the staple. As a result, the degradation rate, or biocorrosion of, the staple will not be inhibited, or at least substantially inhibited, by deposited materials.
  • a staple cartridge comprises a cartridge body and a longitudinal slot defined in the cartridge body configured to receive a tissue cutting knife.
  • the staple cartridge further comprises longitudinal rows of staple cavities defined in the cartridge body on both sides of the longitudinal slot.
  • a staple cartridge can comprise three longitudinal rows of staple cavities on a first side of the longitudinal slot and three longitudinal rows of staple cavities on a second, or opposite, side of the longitudinal slot.
  • the longitudinal rows of staple cavities are arranged in an inner row adjacent the longitudinal slot, an intermediate row adjacent the inner row, and an outer row adjacent the intermediate row.
  • the staples positioned in the inner rows, intermediate rows, and outer rows are comprised of the same material.
  • all of the staples in the staple cartridge are comprised of the same magnesium alloy, for example.
  • the staples in the inner rows are comprised of a material that is different than the staples in the intermediate rows and the outer rows.
  • the staples in the inner rows are comprised of a 69 material that has a slower degradation rate, or biocorrosion rate, than the staples in the intermediate rows and the outer rows, for example.
  • the staples closest to the incision may be the last staples to release the patient tissue.
  • the intermediate and outer rows of staples can release the patient tissue before the inner rows of staples which re introduces flexibility into the patient tissue before the tissue at the incision margin is released by the inner rows of staples.
  • the staples in the intermediate rows are comprised of a material that is different than the staples in the inner rows and the outer rows.
  • the staples in the intermediate rows are comprised of a material that has a faster degradation rate than the staples in the inner rows but a slower degradation rate than the staples in the outer rows, for example.
  • the outer rows of staples can release the patient tissue before the intermediate rows of staples and, likewise, the intermediate rows of staples can release the patient tissue before the inner rows of staples.
  • the rows of staples can progressively release the patient tissue which, as a result, progressively re-introduces flexibility into the patient tissue as it heals.
  • the staples in the outer rows are comprised of a material that is different than the staples in the inner rows and the intermediate rows.
  • the staples in the outer rows are comprised of a material that has a faster degradation rate than the staples in the intermediate rows and inner rows, for example.
  • the physiological and/or environmental response of a patient can affect the corrosion process of the staples implanted within the patient.
  • phosphates and/or carbonates for example, can precipitate on the surface of the staples during the biocorrosion process, thereby slowing the rate in which the staples degrade, or biocorrode.
  • the biocorrosion of magnesium staples can lead to an increase in local pH which lowers the solubility of the corrosion products and the physiological phosphates, carbonates, and/or organics.
  • Preventing, or at least substantially minimizing, the deposition of such phosphates, carbonates, and/or organics on the staples during the healing process can increase or at least maintain the biocorrosion rate of the staples to meet the desired biocorrosion timeframe.
  • the staples comprise a coating that includes an absorbable polymer, such as polylactic acid (PLA), polylactic-co-glycolic acid 70
  • the staples comprise a coating that includes a calcification inhibitor, such as Fetuin A, citrate, and/or a chelating agent, such as phytic acid, for example.
  • a calcification inhibitor such as Fetuin A, citrate, and/or a chelating agent, such as phytic acid, for example.
  • the calcification inhibitor can slowly release from the staples.
  • the calcification inhibitor binds with calcium and phosphate ions to form calciprotein particles (CPP).
  • the calcification inhibitor is embedded within the absorbable polymer. In at least one such embodiment, the calcification inhibitor is continuously released as the absorbable polymer is bioabsorbed.
  • the staples comprise a coating that includes proteins that bind to magnesium ions to prevent, or at least significantly decrease, the formation of phosphates and carbonates thereon.
  • Such coatings keep the ions in solution and prevent, or at least significantly decrease, the extent of mineral deposition on the staples so as to preserve and/or increase the corrosion rate thereof.
  • the staples of a staple cartridge comprise a coating that can block nucleation sites thereon.
  • the staples comprise a coating that includes inorganic ions, such as pyrophosphate or bisphosphonates (polyphosphates), for example.
  • inorganic ions comprise a potent inhibitor of calcium crystallization and can bind to newly forming hydroxyapatite crystals and prevent further growth thereof, thereby preserving and/or increasing the corrosion rate of the staples.
  • the staples comprise a coating that includes polymers of acrylic acid that inhibit the precipitation of calcium phosphate by surface adsorption, thereby preserving and/or increasing the corrosion rate of the staples.
  • the staples comprise a coating that includes polycarboxylic acids, which can inhibit the precipitation of calcium phosphate by surface adsorption, thereby preserving and/or increasing the corrosion rate of the staples.
  • the staples comprise a coating that includes osteopontin, which has been shown to be an inhibitor of calcification in blood vessel walls.
  • the staples comprise a coating that includes inorganic ions, such as Mg2+ ions, for example, which inhibit the formation of the most stable calcium phosphate polymorph (hydroxyapatite) and also stabilize the amorphous calcium phosphate polymorph, thereby preserving and/or increasing the corrosion rate of the staples.
  • inorganic ions such as Mg2+ ions, for example, which inhibit the formation of the most stable calcium phosphate polymorph (hydroxyapatite) and also stabilize the amorphous calcium phosphate polymorph, thereby preserving and/or increasing the corrosion rate of the staples.
  • the staples comprise a coating that encourages movement of the dissolved metal, phosphate, and carbonate ions away from the staple, making corrosion products less likely to form directly on the surface thereof.
  • the staples comprise a coating that diverts, or encourages movement, of the corrosion products onto a buttress that is implanted in the patient tissue with the staples.
  • magnesium staples dissolves, magnesium ions are freed to form molecules and/or bonds with other elements surrounding the staple.
  • magnesium staples are at least partially-coated with a chlorine ion eluding material. In such embodiments, the magnesium ions from the dissolving staple and the chlorine ions that elude from the coating form magnesium chloride.
  • Magnesium chloride is a salt that tends to lower the pH of the surrounding environment and, moreover, is readily absorbed by the surrounding patient tissue. As such, the magnesium chloride created around the magnesium staples lowers the pH around the staples and, also, reduces the accumulation of scale on the staples. In many instances, scale can impede the absorption of the staples within a desired time window; however, owing to the chlorine-eluding coating on the staples, the effect of the scale can be reduced.
  • the staples comprise a coating that includes an acid that removes corrosion products from the staples and/or destabilizes corrosion products on the staples.
  • Metal carbonates for example, react with acids to produce soluble products, such as salts, carbon dioxide and/or water, for example.
  • a low pH will aid the dissolution of some of the corrosion products deposited on the staples.
  • PLA, PGLA, and/or PGA for example, lower the pH of the environment surrounding the staples. When PLA, PGLA, and/or PGA dissolve, more specifically, they generate acid which maintains a lower local pH, thereby increasing the corrosion rate of the staples.
  • the absorbable polymer comprises a layer, or an at least partial layer, on the metal staple material and the calcification inhibitor comprises a layer, or an at least partial layer, on the absorbable polymer layer.
  • the calcification inhibitor is immediately released, or at least quickly released, into 72 the environment immediately surrounding the staples.
  • the absorbable polymer comprises a partial layer on a first portion of the staples and the calcification inhibitor comprises a partial layer on a second, or different, portion of the staples.
  • the calcification inhibitor can release from the staples at a rate which is faster than the rate in which the absorbable polymer is bioabsorbed. In such instances, the calcification inhibitor deploys quickly to prevent, or at least inhibit, the calcification of the absorbable polymer and/or the underlying metal staple material.
  • the staples comprise a coating that decreases the early degradation rate thereof.
  • a rapid early degradation rate of the staples can be responsible for a dramatic change in the local conditions surrounding the staples, creating a strong initial driving force for mineral deposition onto the staples which, as discussed above, can slow the degradation rate of the staples.
  • a slower fundamental or initial degradation rate of the staples, via surface coatings can result in a faster overall bioabsorption of the staples in many instances.
  • surface coatings can create a more uniform initial corrosion of the staple, i.e., immediately after the staple is implanted or within a few weeks of it being implanted.
  • the staple coating delays galvanic corrosion of the staple and the bioabsorption and/or dissolution of the coating exposes the underlying metal structure of the staple to the surrounding environment thereby initiating galvanic corrosion.
  • the coating is applied on top of a metal wire and/or stamped metal structure of the staple.
  • the coating is comprised of one or more polymers, such as PGA, for example.
  • the staple coating comprises a conversion coating of the underlying base metal of the staple.
  • the outer surface of a magnesium staple is coated with and/or otherwise exposed to fluorine ions, for example, which converts the outer surface of the magnesium staple to magnesium fluoride, MgF2, for example. Coating the staples with a conversion coating may result in little, if any, change to the diameter of the underlying metal wire of the staples, for example.
  • a staple cartridge can further comprise an implantable adjunct, such as a buttress, for example, that is secured to the patient tissue by the deployed staples.
  • the implantable adjunct comprises a layer releasably secured to a top surface, or deck, of the staple cartridge.
  • the implantable adjunct is configured to release from the staple cartridge during the staple firing stroke and/or as the staple cartridge is moved away from the stapled tissue.
  • the adjunct is comprised of an absorbable polymer and/or a calcification inhibitor which can further decrease the local pH and decrease the extent of mineral deposition on the staples.
  • the corrosion rate of a staple can be increased by altering the physical design of the staple.
  • the corrosion rate of a staple is based on the volume/surface area ratio of the staple.
  • a staple can further comprise notches and/or recesses defined therein which increases surface area of the staple and lowers the volume, for example.
  • the geometry of the staple can affect the propensity of the staple to exhibit stress corrosion cracking.
  • the notches and/or recesses in the staples can comprise stress risers, or amplifiers, which can induce failure in the staples at the notches and recesses.
  • the notches and/or recesses can be present in the staple legs, for example.
  • the notches and/or recesses can be present in the joints connecting the staple legs to the staple base.
  • a staple comprises hollow portions defining a recess therein.
  • a staple comprises a base, a first leg extending from a first end of the base, and a second leg extending from a second end of the base.
  • the staples are comprised of a hollow wire which is cut to length and then bent into its unfired configuration.
  • the hollow staples are formed by a hollow extrusion process followed by a tube drawing process to reduce wall thickness and diameter, for example.
  • the staples are stamped from metal sheets.
  • the bases of the staples are solid, i.e., they do not comprise an internal aperture defined therein, and the first staple leg and/or the second staple leg comprise an internal aperture defined therein.
  • the legs of the staples are stamped flat and, during a secondary forming process, rolled into a round circumference defining the internal aperture therein.
  • a hollow staple design enables a staple to have sufficient 74 stiffness, but with a lower volume/surface area ratio which permits the staple to biocorrode and release the patient tissue within a desired window of time.
  • staples are comprised of round wire including a metal outer circumference defining an internal aperture and an inner core positioned in the internal aperture.
  • the wire is formed by a hollow extrusion process which co-extrudes the metal outer perimeter and a polymer inset.
  • the metal outer portion is extruded and the inner core is filled during an injection molding process, for example.
  • the staples are formed using a polymer extrusion process to create the inset which is then coated with metal using at least one of an electroplating process and/or a sputtering process, for example.
  • the hollow staples comprise a filler positioned in the internal apertures which is released as the staples are corroded.
  • the filler can be selected to mitigate and/or induce a physiological response within the patient.
  • the filler can comprise an absorbable polymer, such as PLA, PLGA, and/or PGA, for example.
  • the filler comprises a lithium carbonate layer, for example.
  • the staples can comprise a smooth surface.
  • corrosion products are more likely to adhere to rough surfaces of the staples, thereby lowering the corrosion rate of the staples. Maintaining a smooth staple surface on the staples will encourage the corrosion products to fall off the staples and/or not adhere to the staples.
  • an electroplating process is used to create the smoothness of the staples.
  • a staple cartridge comprises staples stored therein which have the same unformed height. By the same unformed height, the staples can have the exact same unformed height and/or an unformed height within a manufacturing tolerance range. In at least one embodiment, the staples have an unformed height of 3.5 mm.
  • the staples are comprised of wire having a wire diameter of 0.20 mm, for example. In at least one embodiment, the staples have an unformed height of 3.8 mm. In at least one such embodiment, the staples have a wire diameter of 0.22 mm, for example. In at least one embodiment, the staples have an unformed height of 4.1 mm. In at least once such embodiment, the staples have a wire diameter of 0.22 mm, for example.
  • a staple cartridge comprises staples have different unformed heights.
  • a staple 75 cartridge comprises a longitudinal slot configured to receive a tissue cutting knife therein and three longitudinal rows of staple cavities on each side of the longitudinal slot. Each side of the longitudinal slot comprises an inner row adjacent the longitudinal slot, an intermediate row adjacent the inner row, and an outer row adjacent the intermediate row.
  • the staples in the inner row of staple cavities comprise a first unformed height
  • the staples in the intermediate row of staple cavities comprise a second unformed height which is taller than the first unformed height
  • the staples in the outer row of staple cavities comprise a third unformed height is taller than the second unformed height.
  • the staples in the inner row have an unformed height of 3.5 mm
  • the staples in the intermediate row have an unformed height of 3.8 mm
  • the staples in the outer row have an unformed height of 4.1 mm.
  • the staples of a staple cartridge are deformed to the same formed height.
  • the staples can have the exact same formed height and/or a formed height within a tolerance range.
  • staples having an unformed height of 3.5 mm are deformed to a 1.5 mm formed height, for example.
  • staples having an unformed height of 3.8 mm are deformed to a 1.8 mm formed height, for example.
  • staples having an unformed height of 4.1 mm are deformed to a 2.0 mm formed height, for example.
  • the formed staples can apply different clamping pressures to the tissue.
  • the staples formed to 1.5 mm formed height apply about 78 kPa
  • the staples formed to 1.8 mm apply about 59 kPA
  • the staples formed to 2.0 mm apply about 30 kPa, for example.
  • Such pressures can be referred to as initial, or as-fired, clamping pressures.
  • Such embodiments apply the largest clamping pressure to the tissue adjacent the incised tissue margin which can, as a result, prevent, or at least reduce, bleeding therefrom, although other embodiments are envisioned in which larger pressures are applied by staples further away from the tissue incision.
  • the staples biocorrode, the clamping pressure that they apply to the patient tissue drops.
  • the staples disclosed herein gradually relax the clamping pressure being applied to the patient tissue as the patient tissue heals.
  • the staples of a staple cartridge can be formed to one or more formed heights. Such formed heights can be referred to as final formed heights. Stated another way, a staple deforms both plastically and elastically as it is being deformed and, after the staple has been deformed to an as-formed height, the staple height thereafter grows from its as-formed 76 height to its final formed height as a result of the release of the elastic energy stored in the staple. Such a process can be referred to as spingback. Notably, absent other considerations, titanium staples have more springback than magnesium staples. Thus, in various instances, titanium staples may need to be fired to a smaller as-fired height to arrive at the same final formed height as magnesium staples.
  • a wire can be deformed to manufacture a staple.
  • Such deformation typically includes both elastic deformation and plastic deformation.
  • the elastic deformation of the wire created during the manufacturing process naturally relieves itself when the forces applied to the wire by the manufacturing process are relieved.
  • the plastic deformation of the wire during the manufacturing process does not resiliently relieve itself.
  • the staple when wire is bent to form a substantially V-shaped staple, for example, the staple includes a crown and two legs where each leg is connected to the crown by a bend. These bends are the result of large plastic deformations and can include high residual stresses - especially on the inside surfaces of the bends.
  • the inside surfaces of the bends have a smaller radius than the outside surfaces and, in various instances, the inner surfaces can undergo larger amounts of work hardening than the outside surfaces.
  • work hardening can create cracks in the wire along the inner surfaces of the bends, especially when the wire is comprised of magnesium, for example.
  • the inner surfaces of the bends undergo compression when the V-shaped staple is manufactured while the outer surfaces of the bends undergo tension and, as a result, the inner radius bends may be more susceptible to cracking as magnesium and magnesium alloys may have a lower strength 77 in compression that in tension, for example. This phenomenon is more prevalent in staples have a thicker wire diameter than a thinner wire diameter owing to the larger moment arm between the inner surface of the bend and the center of mass.
  • the staples can be annealed to reduce the residual stresses contained therein and/or toughen them.
  • the staples are heated and then allowed to cool slowly before the staples are loaded into a staple cartridge.
  • the staples are loaded into a staple cartridge and then the whole staple cartridge is heated to anneal the staples while they are in the staple cartridge.
  • the plastic parts of the staple cartridge are comprised of a high-performance plastic that is able to withstand elevated temperatures without substantial degradation, such as polyether ether ketone, for example. After the staple cartridge has been heated, the staple cartridge is permitted to cool before it is used.
  • the annealing processes described above anneal the entire staple.
  • only portions of the staples may be treated to relieve residual stress and/or improve the toughness of the portions.
  • the bends of the staples are heated with a laser.
  • the wire used to form a staple has a constant cross-sectional thickness or diameter along the length thereof.
  • the cross- section of the wire can be changed to reduce the residual stress within the wire and/or reduce the possibility of the wire cracking and/or fracturing at a particular location.
  • the inside surface of the bends can be flattened. For instance, one or more flat spots can be stamped into a wire before it is deformed into a staple such that, once the wire is deformed into the staple, the flat spots are in the inside surfaces of the bends. Referring to FIGS.
  • a staple 3400 comprises a wire substrate including a crown 3410, legs 3420, and bends 3430 connecting the legs 3420 to the crown 3410.
  • the wire substrate of the staple 3400 comprises a round cross-section that is present in the crown 3410 and the legs 3420 and, referring to FIG. 22, a flattened cross-section including flat spots 3435 in the bends 3430.
  • the portions of the wire that will become the bends are worked to have a smaller cross-sectional area or diameter than the portions of the wire that will become the crown and the staple legs.
  • Such a process creates wire staples having a crown and staple legs which have larger cross-sections than the bends, or at least part of the bends, that connect them.
  • the bends are less likely to crack and/or fracture.
  • the portions of the wire that will become the bends and the staple legs are worked to have a smaller cross-sectional area or diameter than the portion of the wire that will become the crown.
  • wire staples can be heated and then permitted to cool slowly to reduce residual stresses within the wire and/or toughen the wire. In other instances, wire staples can be heated and then cooled quickly. In at least one instance, the staples are quenched in a liquid.
  • the staples of a staple cartridge are comprised of magnesium glass which comprises magnesium or a magnesium alloy that is heated and then cooled so quickly that the metal does not have time to form crystals, or a substantial amount of crystals, such that the metal has an amorphous, or an at least substantially amorphous, grain structure.
  • the staples of a staple cartridge are comprises of a magnesium shape-memory alloy.
  • the staples are comprised of a magnesium- scandium alloy, for example.
  • the staples are bent into a substantially V-shaped configuration from a wire comprised of a magnesium shape-memory alloy with residual stresses and strains locked therein.
  • the staples are then loaded into a staple cartridge and implanted in a patient. Applying heat to the staples unlocks the residual stresses and strains in the staples such that the staples move into a closed, or substantially B-shaped, configuration where the legs of the staples deflect inwardly to trap patient tissue within the staples.
  • forming, or closing, the staples ejected from a staple cartridge during a staple firing process comprises pushing the legs of the staples against an anvil positioned opposite the staple cartridge.
  • the staple cartridge comprises drivers which are pushed upwardly toward the anvil by a sled moving from a proximal end of the staple cartridge toward a distal end of the staple cartridge.
  • the anvil comprises forming pockets that guide the staple legs inwardly toward one another as the legs are being deformed to create a closed, or substantially B-shaped, fired configuration. In some instances, however, one or both of the staple legs may be bent outwardly during the staple firing process.
  • the staples may still be able to apply a sufficient clamping pressure to the tissue. Whether formed correctly of incorrectly, the staples undergo a significant amount of stress and strain during the formation process. Such stress and strain may cause the bends of the staples between the crown and the legs to crack and/or fracture even if they did not crack and/or fracture during the staple manufacturing process. Discussed below are 79 configurations of the staples and/or staple drivers that reduce the possibility of and/or reduce the severity of such cracking and/or fracturing.
  • a staple 3100 comprises a crown 3110, a first leg 3120, a first bend 3130 connecting the first leg 3120 to a first end of the crown 3110, a second leg 3120, and a second bend 3130 connecting the second leg 3120 to a second end of the crown 3110.
  • the first leg 3120, the second leg 3120, and the crown 3110 each comprises a straight, or an at least substantially straight, segment; however, examples are envisioned in which one or more of these segments is not straight.
  • the first bend 3130 is defined by a constant radius of curvature. The first bend 3130 extends between the crown 3110 and the first leg 3120 along a continuous constant radius.
  • the second bend 3130 is also defined by a constant radius of curvature. Like the first bend 3130, the second bend 3130 extends between the crown 3110 and the second leg 3120 along a continuous constant radius. In this example, the radius defining the first bend 3130 is the same as the radius defining the second bend 3130.
  • a staple can comprise a first bend defined by a first constant radius and a second bend defined by a second constant radius that is different than the first constant radius.
  • the second constant radius can be larger than or smaller than the first constant radius.
  • a staple comprises a substantially V-shaped configuration including a crown, a first leg, a first connection portion connecting the first leg to the crown, a second leg, and a second connection portion connecting the second leg to the crown.
  • the staple 3100 of FIG. 16 is substantially V-shaped, for example.
  • the first leg, the second leg, and the crown each comprise a straight, or an at least substantially straight, segment; however, examples are envisioned in which one or more of these segments are not straight.
  • the first connection portion comprises two bends and an intermediate portion - a first bend connects the first leg to the intermediate portion and a second bend connects the intermediate portion to the crown.
  • Each of the first and second bends within the first connection portion provides at least one degree of freedom within the staple permits the first staple leg to be bent into a closed, or 80 fired, configuration while reducing the possibility of the first connection portion cracking and/or fracturing during the staple firing process.
  • the second connection portion comprises a similar arrangement to that of the first connection portion; however, various examples are envisioned in which the multi-bend connection portions described above may only be used to connect one of the staple legs to crown. Such an example may be useful when one of the staple legs experiences more stress and strain than the other.
  • a wire staple comprises a crown, a first leg, a first bend connecting the first leg to the crown, a second leg, and a second bend connecting the second leg to the crown.
  • the crown comprises a wire diameter and extends along a line that is parallel to, or at least substantially parallel to, a deck, or top, surface of a staple cartridge when the staple is positioned in a staple cavity defined in the staple cartridge.
  • the staple cartridge comprises a driver that includes a seat defined in a top portion of the driver that supports the crown of the staple.
  • the seat comprises a trough or recess including a first sidewall that extends longitudinally along a first side of the staple and a second sidewall that extends longitudinally along a second side of the staple.
  • the seat of the staple driver is configured to support the entire bottom surface of the staple when the staple is in its unfired position and then push upwardly on the bottom surface of the staple as the staple driver is driven upwardly toward an anvil positioned opposite the staple cartridge during a staple firing stroke.
  • the drive surface of the seat that contacts the bottom surface of the staple is flat which matches the flat bottom surface of the crown.
  • a staple 9800 comprises a crown 9810 that has a downwardly- extending first portion 9815 and a downwardly-extending second portion 9815 that are connected at an intermediate vertex 9816.
  • the first portion 9815 comprises a linear segment of the crown 9810 that extends downwardly at about -5 degrees from a bend 9830 and the second portion 9815 also comprises a linear segment that extends downwardly at about - 5 degrees from an opposite bend 9830. That said, the linear segments 9815 can extend downwardly at any suitable angle.
  • the staple 9800 is driveable by a staple driver 9900.
  • the seat 9910 of the staple driver 9900 comprises a drive surface that matches the bottom surface of the staple 9800 as well as angled sidewalls that sufficiently envelop the crown 9810 of the staple 9800 to limit relative movement between the staple 9800 and the staple driver 9900.
  • the downwardly-descending first and second portions 9815 may be 81 non-linear, and may be curved, for example.
  • the seat of the corresponding staple driver is shaped to match the contours of the staple crown.
  • a staple 3500 comprises a crown 3510, a first leg 3520 extending from the crown 3510, and a second leg 3520 extending from the crown 3510.
  • the crown 3510 comprises three curved portions - a first curved portion 3512 connected to the first leg 3520, a second curved portion 3512 connected to the second leg 3520, and an intermediate curved portion 3514 intermediate the first curved portion 3512 and the second curved portion 3512.
  • the first curved portion 3512 and the second curved portion 3512 have a concave shape and the intermediate curved portion 3514 has a convex shape.
  • a staple driver 3600 used to drive the staple 3500 toward an anvil comprises a seat 3610 that matches, or at substantially matches, the undulating profile of the crown 3510.
  • the seat 3610 comprises first and second convex portions 3612 aligned with the first and second concave portions 3512 of the staple crown 3510 and, also, an intermediate concave portion 3614 aligned with the convex intermediate portion 3514 of the staple crown 3510.
  • a wire staple 3800 comprises a crown 3810, a first leg 3820 extending from the crown 3810, and a second leg 3820 extending from the crown 3810.
  • the wire staple 3800 comprises bends 3830 that connect the legs 3820 to the crown 3810.
  • the crown 3810 comprises a curved portion and the first and second legs 3820 extend from the ends of the curved portion.
  • the curved portion comprises a catenary shape, but could comprise any suitable shape.
  • the staple 3800 is driveable by a corresponding staple driver 3900 configured to drive the staple 3800 out of a staple cartridge which comprises a seat 3910 that pushes on a bottom surface of the staple 3800.
  • the driver seat 3910 is in full contact with the staple crown 3810 such that there are no gaps between the driver seat 3910 and the staple crown 3810.
  • a wire staple 4600 is configured to be driven by a staple driver 4700 during a staple firing stroke that deflects relative to the staple driver 4700.
  • the staple 4600 comprises a crown 4610, legs 4620, and bends 4630 that connect the legs 4620 to the crown 4610.
  • the staple driver 4700 comprises a seat 4710 defined therein configured to receive the staple crown 4610. As illustrated in FIG. 35, the driver seat 4710 does not fully contact the bottom surface of the staple crown 4610, at least not when the driver 4700 and the staple 4600 are in their unfired positions. Rather, only the ends 4730 of the driver seat 82
  • the middle 4715 of the driver seat 4710 is not in contact with the bottom drive surface of the staple 4600 when the driver 4700 and the staple 4600 are in their unfired positions.
  • the ends 4730 of the driver seat 4710 push the staple 4600 upwardly toward and anvil while the middle portion 4715 of the driver seat 4710 does not contact the staple 4600 until the staple legs 4620 contact the anvil.
  • the middle 4615 of the staple crown 4610 deflects into contact with the middle 4715 of the staple driver 4710 after the staple legs 4620 come into contact with the anvil and a significant firing force is transmitted through the staple 4600.
  • the middle portion 4615 of the staple crown 4610 deflects into contact with the driver seat 4710, the entire driver seat 4710, or substantially all of the driver seat 4710, is in contact with staple crown 4610 such that the firing force is distributed across the crown 4610.
  • the downward deflection of the staple crown 4610 causes plastic deformation within the crown 4610 such that the crown 4610 at least partially permanently assumes the shape of the driver seat 4710 during the staple firing process.
  • a wire staple 4800 is driven by a staple driver 4900 where, although the staple 4800 deflects downwardly toward the staple driver 4900 during the staple firing process, the entire crown of the staple 4800 does not come into contact with the staple driver 4900.
  • the staple 4800 comprises a crown 4810, legs 4820, and bends 4830 that connect the legs 4820 to the crown 4810.
  • the staple driver 4900 comprises a seat 4910 defined therein including seat ends 4930 which are in contact with the bends 4830 of the staple 4800 when the staple 4800 and the driver 4900 are in their unfired positions.
  • the center 4815 of the crown 4810 is not in contact with the center 4915 of the driver seat 4910 when the staple 4800 and the driver 4900 are in their unfired positions.
  • the center 4815 of the crown 4810 deflects downwardly toward the center 4915 of the driver seat 4910 but does not come into contact with the driver seat 4910.
  • the middle of the staple crown is in contact with the middle of the staple driver and the ends of the staple crown are not in contact 83 with the driver when the driver and the staple are in their unfired positions.
  • the driver seat pushes on the middle of the staple crown until the staple legs contact the anvil.
  • the bends connecting the staple legs to the crown are pushed down into contact with the driver seat such that the entire bottom drive surface of the staple, or nearly all of the bottom drive surface, is in contact with the staple driver such that the firing force transmitted through the staple is distributed across the crown.
  • Such an arrangement reduces the possibility of the staple bends cracking and/or fracturing during the staple firing process.
  • the downward deflection of the staple crown causes plastic deformation within the crown such that the crown at least partially permanently assumes the shape of the driver seat during the staple firing process.
  • the bends of the staple can be contoured by the driver seat as the staple is being deformed against the anvil.
  • the bends of the staple have a large radius of curvature when the staple is loaded into the staple cartridge which is reduced as the staple is being deformed.
  • a staple cartridge comprises a staple driver 4100 includes a seat 4110 that releasably holds a wire staple 4000 in the driver seat 4110.
  • the staple 4000 comprises a crown 4010, legs 4020, and bends 4030 connecting the legs 4020 to the crown 4010.
  • the staple driver 4100 further comprises a cam portion 4120 configured to be engaged by a sled during a staple firing stroke to lift the staple driver 4100 and the staple 4000 toward an anvil positioned opposite the staple cartridge.
  • the staple driver 4100 further comprises guides 4130 that interface with slots defined in the staple cartridge that keep the staple driver 4100 and the staple 4000 aligned with forming pockets positioned opposite the staple 4000.
  • the driver seat 4110 further comprises a first seat end that holds a first bend 4030 of the staple 4000 and a second seat end that holds a second bend 4030 of the staple 4000.
  • the first seat end comprises an internal slot that receives the first bend 4030 that is at least partially defined by sidewalls 4112 and 4114 forming a wedge configuration.
  • the distance between the sidewalls 4112 and 4114 is the same as, or slightly smaller than, the diameter of the staple wire such that there is an interference fit between the staple 4000 and the driver seat 4110.
  • the second seat end comprises a similar arrangement.
  • the staple driver 4100 grips and holds the staple 4000 thereby limiting relative movement between the staple 4000 and the staple driver 4100 during the staple firing process.
  • Such an arrangement reduces the possibility of the staple 4000 slipping or sliding relative to the staple driver 4100.
  • a staple driver 4500 comprises a seat 4510 including a wall and/or catch 4530 that extends over the crown 4410 of a staple 4400, for example, that releasably holds the staple 4400 to the staple driver 4500.
  • the catch 4530 deflects during the staple firing process to release the staple 4400 from the staple driver 4500.
  • a material is inserted into the staple cavities of a staple cartridge to hold the staples in their unfired position.
  • a mixture including sodium stearate and water is poured and/or otherwise deposited into the staple cavities of a staple cartridge. The mixture flows down over the staples and then dries. Once dried, or at least partially dried, the sodium stearate releasably holds the staples in their unfired positions and prevents, or at least inhibits, the staples from falling out of their staple cavities.
  • the staple cartridge is loaded into a stapling instrument and then inserted into a patient, fluids within the patient may come into contact with the dried sodium stearate and soften it. Whether or not the sodium stearate is softened, the staples break free from the sodium stearate as the staples are being fired. In various instances, portions of the sodium stearate may remain attached to the staples after the staples have been implanted.
  • a staple can undergo a hardening process while other portions of the staple can undergo a softening process.
  • a staple comprises a crown, legs, and bends connecting the legs to the crown wherein the bends are softened through an annealing process and the tips of the legs are hardened through a quenching process, for example.
  • the entire staple is heated which is permitted to cool slowly except for the tips of the staple legs which are exposed to a cold fluid such as cold gaseous nitrogen and/or dipped in a cold hydrocarbon, for example. In other processes, only portions of the staple are heated.
  • the tips of the staple legs are coated with a hard lubricious material to reduce the friction between the staple legs and the anvil.
  • a staple is comprised of a magnesium or magnesium alloy wire having staple legs at least partially covered with magnesium nitride. In other instances, boron nitride could be used, for example.
  • a sputtering process can be used to deposit the coating on the staple legs. In at least one example, only the tips of the staple legs are covered with the coating. In at least one such example, the portions of the staple that are not to be coated are masked and/or otherwise covered during the coating application process.
  • a process such as a sputtering process, for example, can apply the coating on the metal wire substrate in a stippled, or dot, pattern. In at least one instance, the coating is applied to the metal wire substrate at a constant density, or an at least substantially constant density, across the covered surface.
  • the density of the coating on a first section of the metal wire substrate has a first density and the density of the coating on a second section of the metal wire substrate has a second density than the first density.
  • the density of the coating at the tips of the staple legs is the highest and the density of the coating gradually decreases away from the tips of the staple legs.
  • an anvil can be at least partially coated with a hard lubricious coating.
  • the coating on the anvil is harder than the coating on the staples and harder than the metal wire substrate of the staples deformed against the anvil.
  • the anvil is comprised of at least one of stainless steel and titanium and at least portions of the anvil is coated with titanium nitride.
  • the anvil has forming pockets configured to receive and deform the legs of the staples and only the forming pockets are coated with titanium nitride, for example.
  • a length of metal wire is drawn form a spool of wire and cut to length.
  • the metal is sheared such that the ends of the wire length have sharp ends which become the staple tips when the wire length is formed into a staple.
  • the cutting process creates a transverse angled cut within the metal wire to create an angled flat penetration surface at each staple tip.
  • the angled flat penetration surfaces face outwardly but, in other embodiments, the angled flat penetration surfaces face inwardly.
  • a staple 3800 comprises legs 3825 having tips 86
  • the angled flat penetration surfaces extend at an angle that is larger than 45 degrees from a plane extending through the tips of the staple legs. In at least one example, the angle is about 50 degrees, for example. In another example, the angle is about 60 degrees, for example. In a different example, the angle is about 70 degrees, for example. In another example, the angle is about 80 degrees, for example.
  • the staple tips comprise a non-linear penetration surface, such as curved penetration surface, for example. In at least one instance, the curved penetration surface comprises a concave penetration surface while, in other instances, the curved penetration surface comprises a convex penetration surface. In at least one other example, each staple tip comprises two linear portions that define a penetration surface.
  • a staple 3800’ comprises leg tips 3825’ that are each defined by two flat surfaces that meet at a sharp point. Such embodiments are useful for penetrating tough tissue, especially when the metal comprising the substrate of the staple is soft and/or brittle, for example. Such embodiments are useful for staples comprised of pure magnesium, magnesium alloys, zinc, zinc alloys, iron, and/or iron alloys, for example.
  • the leg tips 3825’ are coated with a hard material such as a nitride, for example, to facilitate the insertion of the leg tips 3825’ through the patient tissue such that the leg tips 3825’ properly engage the anvil forming pockets during the staple firing process.
  • various staple cartridges comprise a cartridge body and staples removably stored in the cartridge body.
  • the cartridge body comprises a proximal end, a distal end, and a deck extending between the proximal end and the distal end.
  • the deck is configured to support the patient tissue clamped against the staple cartridge and includes longitudinal rows of staple cavities defined in the deck.
  • the deck further comprises a longitudinal slot extending from the proximal end toward the distal end that is configured to receive a tissue cutting knife.
  • the longitudinal slot extends between three longitudinal rows of staple cavities defined on one side of the longitudinal slot and three longitudinal rows of staple cavities on the opposite side of the longitudinal slot.
  • a single staple is stored in each staple cavity.
  • the staple cartridge further comprises a sled that is moved from the proximal end toward the distal end during a firing stroke that sequentially ejects the staples from the staple cartridges as the sled progressively moves distally from the proximal end.
  • An anvil positioned opposite the staple cartridge comprises six longitudinal rows of forming pockets 87 where each of the forming pockets is registered with a staple cavity defined in the staple cartridge such that each forming pocket deforms a single staple.
  • the staples stored within a staple cartridge are moved from an unfired position to a fired position during a staple firing stroke.
  • the tips of the staple legs are positioned below the deck of the staple cartridge when the staples are in their unfired position.
  • the tips of the staple legs emerge above the deck of the staple cartridge and puncture the patient tissue positioned above the staple.
  • the tips of the staple legs then exit the patient tissue and contact the anvil and are deformed back toward the tissue.
  • the tips of the staple legs re-puncture the patient tissue as the staple is being deformed into its fully-fired configuration.
  • the staples may assume a lightly-clenched formed configuration, a highly-clenched formed configuration, or somewhere in-between. All such formed configurations can be referred to as a B-shaped formed configuration; however, the lightly-clenched formed staples have a loose B-shaped configuration while the highly-clenched formed staples have a tight B-shaped configuration.
  • the tips of the staple legs may approach the crown of the staple during the forming process. In many instances, it is desirable for the staple tips to not be deformed past the crown.
  • a staple driver 4300 is configured to drive a staple 4200 during a staple firing stroke.
  • the staple 4200 comprises a crown 4210 and legs 4220 extending from the crown 4210 where each leg 4220 comprises a sharp staple tip 4225.
  • the staple driver 4300 comprises a seat 4310 that receives and pushes on the crown 4210 of the staple 4200.
  • the staple driver 4300 further comprises a platform and/or lateral flanges 4390 which comprise stop surfaces for the staple tips 4225 such that the staple 4200 does not become over-clenched during the staple firing process.
  • the staple driver 4300 is comprised of metal, such as stainless steel and/or titanium, for example, which is strong enough to stop further clenching of the staple 4200.
  • the staple drivers 4300 are comprised of plastic that is plated and/or coated with metal.
  • a staple cartridge is configured to prevent the staples deployed therefrom from being over-deformed or over-clenched.
  • a staple cartridge comprises a stop extending upwardly from the distal end of the 88 staple cartridge. The stop is sized and configured to set a minimum gap between the staple cartridge and an anvil positioned opposite the staple cartridge such that, when the staples are deformed against the anvil, the staples are formed to a desired height.
  • the stop is positioned distally with respect to all of the staple cavities.
  • one or more stops are positioned at the distal ends of the staple rows.
  • a staple cartridge comprises gap setting elements that are deployed during the staple firing stroke which, when lifted, can push the anvil to a desired minimum distance away from the staple cartridge.
  • the gap setting elements are positioned in a staple cavity in the outermost staple rows, for example, and are pushed upwardly toward the anvil by a sled moving distally during the staple firing stroke.
  • the deployable gap setting elements are comprised of solid plastic.
  • a deployable gap setting element comprises a first component, a second component, and a spring element positioned intermediate the first component and the second component which can provide for a variable gap height setting element.
  • the staple legs may begin to splay outwardly as the staple legs emerge above the deck. More specifically, the staples have a substantially V- shaped configuration before being loaded into the staple cavities that is resiliently deflected into a substantially U-shaped configuration as the staples are loaded into the staple cavities such that the staple legs, absent more, resiliently splay outwardly as they emerge from the constraints of the staple cavity side walls. In most instances, the splaying staple legs still contact the appropriate, or registered, forming pockets in the anvil during the staple firing process. That said, the splaying staple legs can be further deflected by the patient tissue and can miss the registered forming pockets in some instances. Discussed below are embodiments that limit and/or control the leg splay.
  • a staple 5300 comprises a crown 5310, legs 5320 extending from the crown 5310 comprising leg tips 5325, and a connector 5340 positioned above the crown 5310 that connects the legs 5320.
  • the crown 5310 and the legs 5320 are comprised of a metal wire and the connector 5340 comprises an absorbable polymer such as PGA and/or PLLA, for example.
  • the connector 5340 is positioned below the deck of a staple cartridge when the staple 5300 is in its unfired position and emerges above the deck as the staple 5300 is being fired, or pushed upwardly toward an anvil by a staple 89 driver 4100.
  • the connector 5340 prevents, or at least substantially limits, the staple legs 5320 from splaying outwardly until the connector 5340 contacts the patient tissue T.
  • the connector 5340 slides down the staple legs 5320 which allows the staple legs to splay outwardly.
  • the connector 5340 is parallel, or at least substantially parallel, to the crown 5310 and slides down toward the crown 5310 in a parallel manner.
  • one end of the connector 5340 is higher than the other.
  • the connector 5340 is frangible and is configured to break when the connector 5340 touches the patient tissue T.
  • the connector 5340 completely detaches from the staple legs 5320 during the staple firing process.
  • one or more portions of the connector 5340 remain attached to the staple legs 5320 which can slide down the staple legs 5320 as the staple 5300 is being fired.
  • a staple cartridge comprises a cartridge body 5000 including a deck 5030 and staple cavities 5010 defined in the deck 5030, staples 5100 removably stored in the staple cavities 5010, and staple drivers 5200 configured to drive the staples 5100 out of the staple cavities 5010.
  • Each staple 5100 comprises a crown 5110 and legs 5120 extending upwardly and outwardly from the crown 5120.
  • the staple legs 5120 are in contact with sidewalls 5020 of the staple cavities and are resiliently deflected inwardly by the sidewalls 5020.
  • staple cartridge comprises staple cavity extenders 5025 which extend upwardly from a deck 5030 of the cartridge body 5000.
  • the cartridge body 5000 further comprises staple cavity extenders 5025 that prevent, or at least inhibit, the staple legs 5120 from splaying outwardly and/or otherwise becoming misaligned with the forming pockets in the anvil positioned opposite the staple cartridge during the staple firing process.
  • the staple cavity extenders 5025 extend the sidewalls 5020 of the staple cavities 5010 above the deck 5030 such that the sidewalls 5020 extend in a continuous direction through the staple cavity extenders 5025.
  • the sidewalls 5020 of the staple cavities 5010 extending through the staple cavity extenders 5025 extend inwardly to camber the legs 5020 inwardly during the staple firing process to provide a greater control over the staple legs 5020.
  • the tips 5125 of the staple legs 5120 are positioned in and/or aligned with the staple cavity extenders 5025 when the staples 5100 are in their unfired position, as illustrated in FIG. 37.
  • the staple cavity extenders 5125 can maintain control of the staple legs 5120 90 throughout the staple firing process or at least until the staples 5100 are overdriven out of the staple cavities 5010 above the deck 5030.
  • the staple cavity extenders at the distal ends of the staple lines are taller than other staple cavity extenders in the staple lines.
  • the taller staple cavity extenders serve an additional purpose of setting a minimum tissue gap between the staple cartridge and the anvil.
  • a surgical stapling instrument comprises an end effector including first and second jaws, a motor-driven jaw closure system, and a separate and distinct motor-driven staple firing system.
  • the surgical stapling instrument further comprises a control system including a closure actuator that, when actuated, causes the jaw closure system to close the jaws of the end effector and a firing actuator that, when actuated, fires the staples from a staple cartridge seated in the end effector.
  • the motor- driven jaw closure system is actuated until the jaws are completely closed and then the motor-driven staple firing system is actuated.
  • the completely closed jaws may have a narrow gap therebetween resulting in the staples being overformed during the staple firing stroke.
  • the control system of the surgical stapling instrument is configured to run the closure drive in reverse to at least slightly back off or reduce the clamping pressure on the patient tissue while the staple firing stroke is being performed. Owing to the closure drive being partially backed up, the gap between the anvil and staple cartridge can increase thereby reducing the possibility of the staples being overformed during the staple firing stroke.
  • the closure drive is backed up at the beginning of the staple firing stroke. In at least one instance, the closure drive is backed up during the last half of the staple firing stroke.
  • the closure drive is backed up during the last quarter of the staple firing stroke.
  • the appropriate time for selecting when to back up the closure drive can be based off of previously collected data and/or real-time data collected by the control system during the staple firing stroke.
  • the control system comprises a circuit configured to detect the electric current to the motor and, when the current exceeds a predetermined threshold, back up the closure drive a predetermined distance and/or back up the closure drive until the current to the motor falls below the predetermined threshold, for example.
  • Various staples disclosed herein are comprised of metal or metal alloys such as stainless steel, titanium, magnesium, and/or magnesium alloy, for example.
  • a staple is manufactured by cutting and forming a wire which is then positioned in a staple cartridge.
  • staples are manufactured from a sheet of material that is cut and/or stamped which are then positioned in a staple cartridge.
  • the staples may be exposed to water, air, oxygen, carbon dioxide, or corrosive agents which can degrade the integrity of the raw material and/or the staple.
  • the staples are exposed to bodily fluids when implanted in a patient which can corrode the staples.
  • an initial coating and/or lubricant is applied to wire stock before it is cut and formed into staples.
  • additional coatings and/or lubricants can be applied to the staples.
  • the additional coatings and/or lubricants may be the same or different than the initial coating and/or lubricant, for example.
  • additional coatings and/or lubricants can be applied to the staples and/or portions of the staple cartridge, for example.
  • the coatings and/or lubricants applied during assembly may be the same or different than the previously-applied coatings and/or lubricants.
  • various combinations of coatings and/or lubricants can be utilized during the manufacture of surgical staples and/or the assembly of surgical staple cartridges.
  • a lubricant such as a soap, for example, is applied to a staple at various stages of its manufacture, during its assembly into a staple cartridge, and/or in use.
  • the lubricant can be applied directly onto the substrate of the staple if there is no coating already present on the staple or on top of an absorbable coating already on the substrate.
  • a lubricant can include, but is not limited to magnesium stearate, sodium stearate, calcium stearate, ethyl lauroyl arginate (LAE), a solution of LAE and sodium stearate, a solution of LAE and calcium stearate, a solution of LAE and magnesium stearate, and/or combinations thereof.
  • Ethyl lauroyl arginate LAE is a lubricant which acts as both an anti-microbial material and as a dried soap lubrication. Further, when LAE is combined with sodium stearate, calcium stearate, and/or magnesium stearate in a solution, the resulting solution may be thinner, have a 92 more consistent drying rate, and may better adhere to the staple surfaces it is applied to - and/or dried on - as compared to such substances without the use of LAE.
  • a lubricant such as those described above, is applied to the staple using a soap solution which can comprise water, alcohol, and/or other solvents which are aqueous, for example.
  • the soap solution further comprises a solute which is non aqueous.
  • the solvent will eventually evaporate leaving the solute behind to coat the surfaces covered in the soap solution.
  • the sodium stearate, LAE, sodium stearate with LAE, calcium stearate with LAE, magnesium stearate with LAE, and/or combinations thereof, for example, are left behind on the staples and/or staple cartridge.
  • the soap solution, or lubricant is applied onto wire stock or a sheet of material, whether previously coated or uncoated, and is dried, or permitted to dry, before it is cut and formed into staples.
  • the lubricant is still wet when the staples formed which can reduce damage to the substrate and/or coating during the staple manufacturing process.
  • the formed staples are coated with a lubricant before the formed staples are loaded into a staple cartridge.
  • the lubricant is still wet when the staples are loaded into the staple cartridge which can facilitate the insertion of the staples into the staple cartridge.
  • the staples are coated with a lubricant after the staples are loaded into the staple cartridge. In such instances, the lubricant can cover any exposed surfaces and facilitate the ejection of the staples from the staple cartridge.
  • FIG. 68 illustrates a staple cartridge 10100 including a cartridge body 10101 and staples 10120 positioned in staple cavities 10110 defined in the cartridge body 10101.
  • the staples 10120 are wire staples formed from a wire which has been cut and bent to form the staples 10120.
  • the staples 10120 are stamped from a sheet of material.
  • the staples 10120 are positioned into the cavities 10110 using a staple assembly tool 10310 illustrated in FIG. 70.
  • the staple cavities 10110 define openings in a staple deck surface 10105 of the cartridge body 10101 and the staples 10120 are configured to be ejected through the openings.
  • Each staple cavity 10110 comprises a proximal end wall 10112, a distal end wall 10114, and two opposing lateral sidewalls 10116 which form the staple cavity 10110.
  • staple legs 10122 of the staple 10120 are pressed, or resiliently biased, against the proximal and distal end walls 93
  • the staple drivers 10130 are movable from an unfired position (FIG. 68) to a fired position by a sled 10140 to eject the staples 10120 from the staple cavities 10110.
  • Each staple 10120 comprises staple legs 10122 that extend above the staple deck 10105 when the staples 10120 are in their unfired positions in the cartridge body 10101. Other embodiments are envisioned where the staple legs 10122 do not extend above the staple deck 10105 when the staples 10120 are in their unfired position.
  • Various combinations of different wire staple sizes and shapes as well as different driver sizes and shapes can determine whether or not the staple legs 10122 extend above the deck surface 10105.
  • FIG. 69 illustrates a staple cartridge 10200 comprising a cartridge body 10201 and staples 10220 positioned in staple cavities 10210 defined in the cartridge body 10201.
  • the staples 10120 are stamped staples formed from a sheet of material which is cut and/or stamped and then bent to form the staples 10120.
  • the stamped staples 10220 comprise integral staple drivers 10221, or ramps, formed thereon to facilitate ejection of the staples 10220.
  • the staples 10220 are positioned into the cavities 10210 using the staple assembly tool 10310 illustrated in FIG. 70.
  • the staple cavities 10210 define a plurality of openings 10211 in a staple deck surface 10205 of the cartridge body 10201 and the staples 10220 are configured to be ejected through the openings 10211.
  • Each staple cavity 10210 comprises a proximal end wall 10212, a distal end wall 10214, and two opposing lateral sidewalls 10216 which form the staple cavity 10210.
  • each staple 10220 comprises staple legs 10222 that extend above the staple deck 10205 when the staples 10220 are in their unfired positions in the cartridge body 10201.
  • the staple legs 10222 do not extend above the deck 10205 when the staples 10220 are in their unfired positions in the cartridge body 10201.
  • Various combinations of 94 different stamped staple sizes and shapes as well as different integral driver sizes and shapes can determine whether or not the staple legs 10222 extend above the deck surface 10205, for example.
  • the uncoated staple tips and/or uncoated portions of a staple resulting from the staple manufacturing process may be coated and/or lubricated after the staple has been loaded into a staple cartridge.
  • the staples 10120, 10220 illustrated in FIGS. 68 and 69 comprise uncoated and/or unlubricated portions due to the manufacturing process discussed above.
  • the staples 10120, 10220 are fully seated within the staple cavities 10110, 10210 of the staple cartridges 10100, 10200 and the uncoated and/or unlubricated staple tips extend above the deck surface 10105, 10205.
  • a second lubricant is applied to the exposed uncoated and/or unlubricated portions of the staples 10120, 10220 after the staples 10120, 10220 are positioned in the staple cartridge 10100, 10200.
  • the second lubricant may be the same, similar, or different than the lubricants applied prior to assembling the staples into the staple cartridge.
  • the second lubricant is applied by dipping the deck surface 10105, 10205 and exposed staple tips of the staples 10120, 10220 into the lubricant and then letting the lubricant dry.
  • the second lubricant is sprayed onto the deck surface 10105 and the uncoated portions of the staples 10120, 10220, for example.
  • the staples 10120, 10220 are at least partially retained in the staple cavities 10110, 10210 by the dried second lubricant.
  • the staples 10120, 10220 are not fully seated within the staple cavities 10110, 10210 when the second lubricant is applied to the deck surface 10105, 10205 and the exposed uncoated staple tips of the staples 10120, 10220.
  • the staples 10120, 10220 can be pushed down into their fully seated positions within the staple cavities 10110, 10210 before the second lubricant has dried.
  • the second lubricant is positioned between the staple legs 10122, 10222 and the staple cavity walls 10112, 10114, 10116, 10212, 10214, 10216 to at least partially retain the staples 10120, 10220 within the staple cavities 10110, 10210.
  • the uncoated staple tips of the staples 10120, 10220 are positioned below the deck surface 10105, 10205 but are still accessible due to the staple cavity openings in the staple deck 10105, 10205.
  • the second lubricant is applied to the staple deck 10105 and dripped or injected into the staple cavities 10110, 10210 to coat the uncoated portions of the staples 10120, 10220 and at least partially retain the staple 10120, 10220 within the staple cavity 10110, 10210 once dried.
  • the staples 10120, 10220 having uncoated and/or unlubricated portions may be positioned in the staple cartridge either fully or partially, and then the entire staple cartridge 10100, 10200 could be dipped or sprayed with the second lubricant. After the second lubricant is applied, and prior to the second lubricant drying, the staples 10120, 10220 are be pushed down into their fully seated position. Once the second lubricant dries it will at least partially retain the staples 10120, 10220 in the staple cavities 10110, 10210.
  • the staple cartridge, the stock used for making staples, and/or the staple themselves are coated with different adhesive polymers and/or lubricated with different lubricants and/or solutions of adhesive soap.
  • the stock material is coated with an adhesive polymer and then lubricated with a first lubricant, such as those described herein, prior to inserting the staples into a staple cartridge.
  • a first lubricant such as those described herein
  • a second lubricant is applied to the staples which is different than the first lubricant.
  • the first lubricant and the second lubricant are the same.
  • the staples are lubricated with a first lubricant, such as those described herein, prior to inserting the staples into a staple cartridge.
  • a first lubricant such as those described herein
  • the staples are lubricated with a second lubricant that is different than the first lubricant.
  • the first and second lubricant are the same.
  • the second lubricant is applied to the staples such that the second lubricant is not positioned intermediate the legs of the staples and the staple cavity walls.
  • the stock material is coated with an adhesive polymer and then lubricated with a first lubricant, such as those described herein, prior to inserting the staples into a staple cartridge.
  • a first lubricant such as those described herein
  • the staples are then positioned in a staple cartridge but not fully seated in 96 the staple cartridge.
  • the staples are lubricated with a second lubricant and then pressed down into the stapled cartridge into a fully seated position prior to the second lubricant drying.
  • the second lubricant is different than the first lubricant; however, other embodiments are envisioned wherein the first and second lubricants are the same.
  • the staples are lubricated with a first lubricant, such as those described herein, prior to inserting the staples into a staple cartridge.
  • the staples are then positioned in a staple cartridge but not fully seated in the staple cartridge.
  • the staples in the staple cartridge are lubricated with a second lubricant and then pressed down into the stapled cartridge to fully seated position prior to the second lubricant drying.
  • the second lubricant is different than the first lubricant.
  • the first and second lubricants are the same.
  • the stock material is coated with an adhesive polymer and then lubricated with an initial lubricant, such as those lubricants described herein, for example.
  • an initial lubricant such as those lubricants described herein, for example.
  • an intermediate lubricant is applied to the staples.
  • a final lubricant is applied to the staples and/or portions of the staple cartridge.
  • the initial lubricant, the intermediate lubricant, and the final lubricant are the same.
  • the initial lubricant, the intermediate lubricant, and the final lubricant are different.
  • the stock material is not coated with an adhesive polymer and is only lubricated with the initial lubricant.
  • the staples of a staple cartridge can be coated, or at least partially coated, with a first lubricant and a second lubricant.
  • the second lubricant is an entirely different type of lubricant than the first lubricant.
  • the first lubricant is a solution of LAE and sodium stearate
  • the second lubricant is a solution of LAE and calcium stearate, for example.
  • Other embodiments are envisioned where the first lubricant and the second lubricant are the same type of lubricant but have different concentrations.
  • the first and second lubricant solutions are made up of the same solvent(s) and solute(s) but have different concentrations of each.
  • the first lubricant is a solution of LAE and sodium stearate comprising a first ratio of LAE to sodium stearate
  • the second lubricant is a solution of LAE and sodium stearate 97 comprising a second ratio of LAE to sodium stearate that is different than the first ratio.
  • the first lubricant is a more diluted soap solution than the soap solution of the second lubricant.
  • the stock material and/or staples are made of a high silicone metal alloy that is coated using a lubricant that is highly anhygroscopic to limit bodily fluid infiltration to the underlying silicone metal.
  • lubricants that can be applied to the stock material and/or staples include magnesium stearate, among other lubricants and/or coatings described herein.
  • the stock material and/or staples are lubricated and dried to form a coating with a thin layer of LAE, a thin layer of LAE and sodium, and/or a thin layer of LAE and calcium stearate, for example.
  • a thin layer of coating is applied to staples before they are loaded into a staple cartridge.
  • a thicker more robust layer of lubricant is applied to the staples.
  • the thicker layer of lubricant is then dried, or permitted to dry, to produce a thicker coating on the staples.
  • the thin coating applied to the staples before the staples are inserted into the staple cartridge is comprised of a different material than the thick coating applied to the staples while the staples are stored in the staple cartridge.
  • the thin coating and the thick coating are comprised of the same material but in different concentrations, for example. In any event, a thicker layer of lubrication on the staples, and the staple cartridge, can be more resistant to larger volumes of water.
  • staples used in surgical procedures are metallic.
  • the stock material used to make the staples is impregnated or alloyed to make the staples more hydrophobic which slows or reduces the degradation of the staples when the staples are exposed to bodily fluids and/or other corrosive substances, for example.
  • polyether ether ketone (PEEK), polylactic acid (PLA), polyglycolide (PGA), and/or tamoxifen citrate (TMC) are used to impregnate the grain structure of the staple material to aid in sealing the pores in the material.
  • a magnesium or magnesium alloy is impregnated with PEEK, PLA, PGA, TMC, and/or combinations thereof, to produce a more hydrophobic staple that has reduced or slower degradation when exposed to bodily fluids and/or other corrosive elements.
  • the stock material is impregnated before the staples are made and/or the staples are impregnated 98 after they have been formed from the stock material.
  • the impregnated staples can be coated with one or more coatings or lubricants before the staple are loaded into a staple cartridge and /or one or more coatings or lubricants after the staples are loaded into the staple cartridge.
  • a less noble metal than the staple metal is placed in contact with the staple via a conductive solution and/or lubricant to serve as a sacrificial anode.
  • the sacrificial anode prevents or limits corrosion of a magnesium or magnesium alloy staple, for example.
  • the sacrificial anode comprising a less noble metal may be part of the staple cartridge or part of the staple loading equipment in the form of a conductive solution in contact with the magnesium or magnesium alloy staple.
  • a solution of less noble metal is used to lubricate the staple prior to insertion into the staple cartridge.
  • a solution of less noble metal in lubricant form is poured into the cavities containing the staples and dried.
  • the less noble material in lubricant solution once dried, will act as a sacrificial anode to reduce the corrosion of the more noble staple material positioned in the staple cavity.
  • the staple is magnesium alloy and a lubricant solution of magnesium or magnesium stearate is poured into the staple cavities to encapsulate the magnesium alloy staple.
  • the lubricant solution once dried, will act as a sacrificial anode to limit corrosion of the magnesium alloy staple.
  • a lubricant is poured into or onto portions of a staple cartridge containing staples therein and then freeze dried to retain the lubricant and/or staples in position.
  • Such an arrangement allows the staples to be retained in the staple cavities with a solution or lubricant freeze dried around the staples, for example.
  • the lubricant is freeze dried into the staple cavities prior to the insertion of the staples into the staple cavities.
  • the staples are inserted into the freeze dried lubricant to encapsulate the staples within the lubricant and retain the staples within the staple cavities.
  • a conductive lubricant is positioned around the staples within the staple cavities of a staple cartridge that can have an applied electrical voltage to prevent 99 corrosion of the staples while the voltage is applied to the conductive lubricant. Removing the voltage from the conductive lubricant will enable corrosion of the staples to proceed.
  • a conductive lubricant is flowed onto the staples prior to the staples being loaded into a staple cartridge.
  • the conductive lubricant can have an electrical voltage applied thereto from a power source, such as a battery, for example, by way of a wire connection, an electrical conduit, and/or any suitable electrical connection.
  • the electrical voltage will prevent or at least reduce the oxidation and/or corrosion of the staples until the staples are ready to be loaded into a staple cartridge and then packaged.
  • the conductive lubricant can be flowed onto the staple cartridge and onto the staples positioned therein once the staples are loaded into a staple cartridge.
  • a power source such as a battery, for example, is in electrical communication with the conductive lubricant via one or more conductive pathways in the staple cartridge.
  • the staple cartridge does not have the power source; instead, the power source is in the staple cartridge packaging which is placed in electrical communication with the conductive pathways in the staple cartridge when the staple cartridge is loaded into the staple cartridge packaging.
  • the electrical voltage is supplied from the power source to the conductive pathways in the staple cartridge and to the conductive lubricant coating on the staples to prevent the staples from degrading until the staple cartridge is loaded into a stapling instrument and/or even while the staple cartridge is loaded in a stapling instrument depending on the availability of a power source.
  • the staples immersed in the conductive coating are comprised of a magnesium alloy while the conductive coating contains a high concentration of magnesium ions, for example.
  • the voltage applied to the conductive coating is based on the half-cell potential related to a Pourbaix diagram of magnesium.
  • a lubricant that contains a high concentration of magnesium ions is applied to the stock material prior to creating the staples, the staples, and/or the staple cartridge and staples once the staples are inserted into the staple cartridge.
  • the staple material is magnesium or magnesium alloy and the lubricant contains a high concentration of magnesium ions such as magnesium stearate and/or magnesium lauryl sulfate, among others.
  • the lubricant provides enough magnesium ions to reduce or inhibit 100 further corrosion of the magnesium staples once the lubricant is applied to and/or dried on the magnesium or magnesium alloy staple material. This is based on the Nernst equation, for example.
  • FIG. 70 illustrates a surgical system 10300 comprising a staple assembly tool 10310 configured to insert staples 10320 stored therein into a staple cartridge 10330.
  • the staple cartridge 10330 may be the same or similar to the staple cartridge 10100 and/or the staple cartridge 10200 discussed above, for example.
  • the staple cartridge 10330 comprises a body portion 10332, a cartridge pan 10333, and a plurality of staple cavities 10334 defined in the body portion 10332. Each staple cavity 10334 defines an opening 10336 in a deck surface 10338 of the body portion 10332.
  • the staple cavities 10334 are configured to receive the staples 10320 therein and the cartridge pan 10333 is configured to prevent the staples 10320 and staple drivers, if present, from falling out of the bottom of the staple cartridge 10330.
  • the staples 10320 are configured to be placed into the staple cartridge 10330 by the staple assembly tool 10310, as discussed in greater detail below.
  • the staple assembly tool 10310 comprises a staple magazine 10312 which stores a plurality of the staples 10320 therein and a reciprocating staple stitcher 10314.
  • the staples 10320 may be the same or similar to the staples 10120 and/or the staples 10220 discussed above, for example.
  • the staples 10320 are spring loaded into the magazine 10312 such that the staples 10320 are biased toward an opening 10313 in the staple magazine 10312. When the opening 10313 is clear of the staple stitcher 10314, a staple 10320 is biased into the opening 10313 and held in place due to the spring loaded nature of the magazine 10312.
  • the staple stitcher 10314 is displaceable toward the staple cartridge 10330 from a first position into a second position (FIG. 70).
  • the staple stitcher 10314 is then retracted toward the staple magazine 10312 from the second position toward the first position.
  • the staple stitcher 10314 is manually actuatable between the first and second position by a user of the staple assembly tool 10310, for example.
  • the reciprocating staple stitcher 10314 of the staple assembly tool 10310 is actuated using an electric motor, a solenoid, and/or any other suitable actuating means.
  • the staple assembly tool 10310 is positioned above the staple cartridge 10330 such that the opening 10313 and the staple stitcher 10314 are aligned with one of the staple cavities 10334.
  • the staple stitcher 10314 is then moved from the first position toward the 101 second position to insert the staple 10320 positioned in the opening 10313 into one of the staple cavities 10334 of the staple cartridge 10330.
  • the staple stitcher 10314 is retracted toward the first position and another staple 10320 is biased into the opening 10313 once the opening 10313 is clear of the staple stitcher 10314.
  • the staple assembly tool 10310 is then moved to another location above the staple cartridge 10330 such that the opening 10313 and staple stitcher 10314 are aligned with a different staple cavity 10334.
  • the staple stitcher 10314 is actuated again from the first position toward the second position to place another staple 10320 into the different staple cavity 10334. This process can be repeated until all of the staple cavities 10334 are filled with staples 10320, for example.
  • a staple cartridge comprises a cover, or staple retainer, removably attached to the cartridge body that extends over the deck of the cartridge body and prevents, or at least inhibits, staples from falling out of the staple cavities while the staple retainer is attached to the cartridge body.
  • the stapler retainer is removed from the staple cartridge after the staple cartridge has been seated in a surgical stapling instrument but before the surgical stapling instrument is inserted into the patient.
  • the staple retainer comprises projections that extend downwardly into the staple cavities that not only prevent the staples from falling out of the staple cavities but also hold the staples in their unfired position, at least until the staple retainer is removed from the staple cartridge.
  • the staple retainer comprises a plastic portion that extends over the deck and metal portions attached to and/or embedded within the plastic portion that comprise the downwardly-extending projections.
  • the metal portions prevent, or at least inhibit, the staples from becoming stuck in the staple retainer and being removed from the staple cartridge when the stapler retainer is removed.
  • Various embodiments are disclosed herein where the geometry, material, and/or material characteristics the staples stored in a staple cartridge are tuned to provide a desired performance once implanted in a patient.
  • the staples disclosed herein comprise a chemical makeup that provides for absorption of the staples at an appropriate rate during the tissue healing window.
  • the absorbable staples are comprised of materials that compliment and support the natural tissue wound healing process. Moreover, the staples absorb at an absorption rate that is complimentary to, and coincides with, the natural wound healing process.
  • Various absorbable staples disclosed herein comprise three stages of absorption/degradation.
  • the first stage involves staples which are structurally complete and have not yet begun the absorption/degradation process.
  • the second stage involves staples which have begun the absorption/degradation process, but are still structurally present at the wound healing site.
  • the staples have been fully absorbed by the body at the wound healing site.
  • the absorbable staples comprise sub-elements, whether metal-based or polymer- based, which do not cause the wound healing site to become toxic as a result of excess oxidation of the staple materials.
  • the sub-elements of the absorbable staples also comprise absorption/degradation rates which coincide with the natural wound healing timeline, as will be discussed in greater detail below.
  • the absorbable staples support the healing tissue up until the organ tissue is self-sustaining as a result of the wound healing process.
  • the staples are configred to completely absorb into the wound healing site once the tissue is self- sustaining.
  • Embodiments of absorbable staples can comprise zinc and magnesium in some instances. Moreover, embodiments can comprise staples made of various alloys including zinc, magnesium, and/or other trace elements. Both zinc and magnesium have implications on bodily electrolyte levels and wound healing. Other trace elements can affect the wound healing process. Slightly elevated levels of zinc and magnesium can be beneficial and postively affect wound healing. However, drastically high levels and drastically low levels of zinc and magnesium negatively affect the would healing process. By way of background, zinc is a micronutrient that is essential to human health.
  • the phases of the physiologic wound healing process will be described in greater detail below.
  • 103 zinc supplementation has proven to be an overwhelming success in managing the delay of wound healing after surgery, which continues to be the frontline worry for surgeons.
  • excess zinc, as well as zinc-deficiency can hinder microbial elimination which can negatively affect wound healing. Signs of too much zinc include nausea, vomiting, loss of appetite, stomach cramps, diarrhea, and headaches.
  • An excess of zinc in the body for an extended period of time can lead to problems such as low copper levels, lower immunity, and low levels of HDL cholesterol.
  • Magnesium is a mineral the body uses as an electrolyte, meaning it carries electric charges around the body when dissolved in the blood. Magnesium levels impact bone health, cardiovascular function, and neurotransmission, among other functions. Most magnesium is stored in the bones. Hypermagnesemia occurs when there are excess levels of magnesium in the body. Patients with symptomatic hypermagnesemia can present different clinical manifestations depending on the level and the time in which the electrolytic disturbance has occurred. The most frequent symptoms and signs may include weakness, nausea, dizziness, and confusion.
  • Hemostasis is the first phase of wound healing which occurs immediately, or shortly after, bodily tissue sustaining an injury. Hemostasis involves the use of clotting factors to prevent further blood loss and to lay the foundation for the generation of tissue during the healing process.
  • Fibrin and platelets play an essential role in forming blood clots during the hemostasis phase. Platelets gather at the injury site during hemostasis and adhere to the injury site within the injured blood vessel. During hemostasis, activated platelets form fibrins on the surface, which form a net-like structure across the injury site.
  • Inflammation is the second stage of physiologic wound healing.
  • the inflammation stage can partially overlap with the hemostasis stage, as illustrated in FIGS. 39 and 40.
  • Proteoglycans play a crucial role in the inflammation stage.
  • Proteoglycans comprise a protein chain component called glycosaminoglycan in the extracellular matrix of tissue. Glycosaminoglycan chains provide for hydration and swelling in the tissue during the inflammation stage by attracting water into the extracellular matrix. The tissue swelling allows for the tissue to withstand compressional forces.
  • Proliferation is the third stage of physiologic wound healing.
  • the proliferation stage can partially overlap with the inflammation stage, as illustrated in FIGS. 39 and 40.
  • the 104 proliferation stage corresponds to the formation of granulation tissue and angiogenesis, or blood vessel formation.
  • Granulation tissue is new connective tissue and microscopic blood vessels that form on the surfaces of a wound.
  • the proliferation stage also includes production of fibroblasts, which are the most prominent type of cell found in connective tissue. Fibroblasts assist in maintaining the structural framework of tissue by secreting collagen proteins.
  • Phagocytes such as neutrophils, are able to destroy intracellular pathogens via reactive oxygen species (ROS).
  • ROS reactive oxygen species
  • Enzymes important for the generation of ROS precursors and bacterial clearance are nicotinamide adenine dinucleotide phosphate (NADPH)-oxidases.
  • NADPH nicotinamide adenine dinucleotide phosphate
  • Neutrophils play an essential role in the body’s immune response during the inflammation and the proliferation phases by acting as a barrier between the tissue would healing site and any microbial infections or pathogens.
  • Neutrophils remove any microbial infections and/or pathogens by way of phagocytosis.
  • An excess level of zinc can inhibit the production of NADPH - oxidases.
  • lymphocytes serve a more than one role at this stage during the wound healing process. Macrophages boost host immune defenses and remove dead cells in order to promote tissue restoration during the inflammation and proliferation phases. Lymphocytes are white blood cells that are part of the body’s immune response. There are two types of lymphocytes - B cells and T cells. B cells produce antibodies and T cells fight directly fight foreign invaders and serve to produce cytokines which activate other parts of the immune system.
  • FIGS. 40 and 41 generally illustrate the increase in specific types of cells at various stages during the physiologic wound healing process. For example, neutrophil production peaks around day two of the wound healing process. Macrophages appear to peak around day three of the wound healing process. Fibroblasts peak around days five to six of the wound healing process. Lymphocytes also appear to peak around day six of the wound healing process. Similarly, FIG. 40 also illustrates how different levels of neutrophils, macrophages, fibroblasts, and lymphocytes coincide with the sequential stages of the wound healing process. FIG. 42 illustrates the interplay among various cell types discussed above at different stages during the wound healing process.
  • the bio-corrosion rates of staples situated in a tissue environment can be altered.
  • the bio-corrosion rates of staples can be altered by introducing a secondary material that causes acceleration or deceleration of the bio-corrosion rates of the staples.
  • introduction of one or more other elements or materials can establish microgalvanic cells within the staple material to alter the electrode potential thereof, causing an increase or decrease of the bio-corrosion rate.
  • Other embodiments regarding introduction of secondary materials or elements to alter bio-corrosion rates of staples in tissue environments are described elsewhere herein.
  • the staples comprise a coating that keeps body fluids away from the surfaces of the staples and inhibits the onset of oxidation thereon.
  • the coating comprises MgF2.
  • the coating comprises a polymer coating.
  • the coating comprises an organic-inorganic hybrid coating.
  • the coating comprises a naturally formed protective layer of magnesium hydroxide.
  • the coating comprises a naturally formed protective layer of magnesium carbonate.
  • the coating comprises a naturally formed protective layer of magnesium hydroxy carbonate.
  • the coating comprises a naturally formed protective layer of magnesium phosphate.
  • the coating can comprise one of magnesium hydroxide, magnesium carbonate, magnesium hydroxy carbonate, or magnesium phosphate, alone or in combination in the presence of CC 2 and PO4 3 .
  • the staples comprise a coating that captures deposition thereon.
  • the bio-corrosion rates of staples can be altered by changing the pH level or the ionic aspect of the local fluid in the tissue environment, thereby changing the bio corrosion rates of the staples.
  • the pH level or the ionic aspect of the local fluid can be altered by altering the staples.
  • an active element is applied to the staple and then predetermined amount of time is waited. After the predetermined amount of time, a neutralizing or stabilizing element added to the staple.
  • the bio-corrosion rates of staples can be altered by integrating an adjunct into the tissue environment with the staples.
  • a system is provided that includes a first staple cartridge and a second staple cartridge.
  • the first staple cartridge comprises first staples comprised of a staple material and a first adjunct comprised of a first adjunct material.
  • the second staple cartridge comprises second staples comprised of the staple material and a second adjunct comprised of a second adjunct material that is different than the first adjunct material.
  • the first adjunct causes the first 106 staples to bio-corrode at a first rate.
  • the second adjunct causes the second staples to bio-corrode at a second rate that is different than the first rate.
  • the system provides a clinician with the ability to select between staple cartridges that include staples comprised of the same material, but that will bio-corrode at different rates based on the adjunct that is provided with the staple cartridge.
  • the material of the adjunct can be selected to increase or decrease the absorption rates of the staples depending on the particular application.
  • the adjunct is comprised of a material that adjusts the pH level of the tissue environment in which the staples are situated, thus increasing or decreasing the bio-absorption rate of the staples.
  • the adjunct is comprised of a material that can lower the local pH of the tissue environment, making the tissue environment more acidic, thus increasing or decreasing the bio-corrosion rates of the staples.
  • the adjunct ia comprised of a material that can increase the local pH of the tissue environment, making the tissue environment more basic, thus increasing or decreasing the bio-corrosion rates of the staples.
  • the adjunct is comprised of pure magnesium that acts as an anode within the tissue environment, thereby increasing or decreasing the absorption rates of the staples.
  • the adjunct is comprised of a material, such as zinc or iron, as examples, that cause magnesium-based staples, to degrade at a faster rate.
  • the staples comprise interrupters, such as a coating, a surface treatment, a surrounding material, or combinations thereof.
  • the interrupters interrupt materials, such as body fluid, within the tissue environment from coming into direct contact with the staples.
  • the interrupters inhibit onset of local oxidation, increasing the bio-corrosion rates of the staples.
  • the interrupters capture ions that drive oxidation and corrosion, thereby increasing or decreasing the bio-corrosion rates of the staples.
  • the interrupters include a catalyst that causes a change in the local tissue environment, thereby increasing or decreasing the bio-corrosion rates of the staples.
  • the staples comprise a coating that increases or decreases the rate of bio-corrosion rates of the staples based on the mechanism of action.
  • the mechanism of action can comprise oxidation.
  • the mechanism of action can comprise hydrolysis.
  • the mechanism of action can comprise galvanic corrosion, as described elsewhere herein.
  • the mechanism of action can comprise a single 107 replacement reaction between magnesium and hydrochloric acid.
  • the mechanism of action can comprise stress corrosion.
  • the staples are coated with a coating at the time of manufacture. In various embodiments, the staples are coated with a coating after the staples have been implanted within a tissue environment. In one embodiment, the staples are sprayed with a coating once they have been implanted in the tissue environment. In some embodiments, the staples are coated at a time after leaving the manufacturing facility, but prior to being implanted in a tissue environment. In one embodiment, the staples are coating while the staple cartridge is in the operating room. In various embodiments, the coating is applied in-situ through an adjunct. In various embodiments, the staples are partially coated with a coating at the time of manufacture and partially coated with a coating after the staples have been implanted within a tissue environment.
  • the staples are coated with a coating comprised of a first material at the time of manufacture and coated with a coating comprised of a second material different than the first material after the staples have been implanted in the tissue environment.
  • a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges.
  • the plurality of staple cartridges comprises a first staple cartridge including first staples that degrade at a first rate in a tissue environment and a second staple cartridge including second staples that degrade at a second rate that is different than the first rate in the tissue environment.
  • the system can comprise additional staple cartridges that include staples that degrade at different rates in the tissue environment.
  • the system can comprise six staple cartridges including staples comprised of one of the aforementioned materials listed in Table 1. Other embodiments are envisioned where the system comprises any number of staple cartridges including staples comprised of any of the materials disclosed by the present disclosure.
  • the staple cartridges are positioned in a respective packaging that includes an indicia thereon to inform the clinician of the degradation rates of the staples of the respective staple cartridges. Accordingly, when determining which staple cartridge to use for a particular stapling operation, a clinician can decide how fast or slow they want the staples to degrade. Based on the decision, the clinician can select a staple cartridge from among the plurality of staple cartridge according to their estimated degradation rates. For example, should a clinician decide they want staples to remain in the tissue environment for a longer period of time, the system provides the clinician with the ability to select a staple cartridge with a slower degradation rate compared to other staple cartridges of the system that have faster degradation rates.
  • the indicia of the package can comprise numbers, letters, words, symbols, and/or colors, as examples, that correspond to the degradation rate of the staples of the staple cartridge positioned in the packaging.
  • This indicia provides the clinician with a quick way of determining the degradation rates of the staples when making their selection of which staple cartridge to use for the stapling operation.
  • the indicia can comprise an indicia that informs the clinician of the rate of degradation of the staples relative to the other provided staple cartridges of the system, as will be described in more detail below.
  • the system can include a first packaging with a green indicia that indicates the staple cartridge in the packaging includes staples that degrade the fastest from among all of the staple cartridges in the system.
  • the system can further include a second packaging with a yellow indicia that indicates the staple cartridge in the packaging includes staples that degrade slower than the green package staple cartridge.
  • the system can include a third packaging with a red indicia that indicates that the staple cartridge in the packaging includes staples that degrade the slowest from among all of the staple cartridges in the system.
  • the color-based indicia can be based on a transition from green to red, as referenced above, where green is the fastest, red is the slowest, and transitional shades from green to red, such as orange, yellow, etc., can be used to order intermediate degradation speeds.
  • the color-based indicia can be based on the natural light wavelength bandwidth where red is the fastest, violet is the slowest, and intermediate colors and shades, such as orange, yellow, green, etc. can be used to order intermediate degradation speeds. Any suitable color-based indicia are contemplated by the present disclosure to indicate a relative speed of degradation rates to the clinician.
  • the system can include a first packaging with a first symbol, such as a rabbit, that indicates the staple cartridge in the packaging includes staples that degrade the fastest from among all of the staple cartridges in the system.
  • the system can also include a second packaging with a second symbol, such as a turtle, that indicates the staple cartridge in the packaging includes staples that degrade the slowest from among all of the staple cartridges in the system.
  • the packaging includes a speedometer symbol where the dial of the speedometer indicates relative degradation speed of the staples. Any suitable symbol-based indicia are contemplated by the present disclosure to indicate a relative speed of degradation rates to the clinician.
  • the system can include a first packaging with a first letter, such as an ‘A’, that indicates that the staple cartridge in the packaging includes staples that degrade the fastest from among all of the staple cartridges in the system.
  • the system can further include a second packaging with a second letter, such as a ‘C’, that indicates that the staple cartridge in the packaging includes staples that degrade slower than the ‘A’ packaging staple cartridge.
  • the system can also include a third packaging with a third letter, such as an ‘F’, that indicates that the staple cartridge in the packaging includes staples that degrade the slowest from 110 among all of the staple cartridges in the system.
  • the letter-based indicia can be based on a transition from A to F, as referenced above, where A is the fastest, F is the slowest, and letters in between, such as B, C, and D (even including + or -, such as B+ or B-, as an example) can be used to order intermediate speeds.
  • the letter-based indicia can be based on a transition from A to Z. Any suitable number-based indicia are contemplated by the present disclosure to indicate a relative speed of degradation rates to the clinician.
  • staples situated in a tissue environment can be in one of three states: a functional state, a non-functional state, or a dissolved state.
  • the functional state can be a state in which the staples perform their intended functions, such as clenching the tissue, to an acceptable level.
  • a staple can be in a functional state right after the staple has been implanted into the patient in a tissue environment.
  • the non-functional state can be a state in which the staples no longer adequately perform their intended function, but still remain implanted within the tissue environment.
  • a staple can transition from the functional state to the non-functional state after a period of time, defined as a functional timeframe, has elapsed.
  • the functional timeframe can be defined as an amount of time in which it takes a staple to fracture, or at least partially fracture, and lose its ability to clench the stapled tissue.
  • the functional timeframe can be a time it takes for one of the staple legs to fracture.
  • the functional timeframe can be a time it takes for the base of the staple to fracture.
  • the functional timeframe can be a time is takes for a staple leg to fracture away from the base of the staple.
  • the functional timeframe can be a time it takes for any portion of the staple to fracture that would cause a decrease in clenching pressure that the staple provides to the tissue.
  • the functional timeframe of the staples can be estimated and provided to a clinician when selecting a particular staple cartridge to use for a particular stapling operation. This provides the clinician with the ability to select a staple cartridge that includes staples that will be functional in the tissue environment for an estimated amount of time.
  • the functional timeframe can be correlated to the healing window of the tissue.
  • a clinician can select a staple cartridge such that the functional 111 timeframe of the staples reaches or exceeds the healing window of the tissue.
  • a clinician can select a staple cartridge such that the functional timeframe of the staples reaches or exceeds the healing window, but does not greatly exceed the healing window such that the staples are not implanted in the tissue longer than is necessary.
  • the functional timeframe can be defined as an amount of time in which it takes a staple to lose a certain percentage of its weight due to bio-corrosion in the tissue environment. Accordingly, with an estimated weight loss rate, such as those provided in the Table 1, the functional timeframe of the staples can be determined and provided to a clinician when selecting a particular staple cartridge to use for a particular stapling operation. This provides the clinician with the ability to select a staple cartridge that includes staples that will be functional at the stapled tissue for an estimated amount of time.
  • the estimated amount of time is about 30 days.
  • the estimated amounted of time is about 60 days.
  • the estimated amount of time is about 180 days.
  • the estimated amount of time is less than a year, such as about 6 months or about 9 months, as examples.
  • the percentage of weight lost during the functional timeframe is about 25%. In one embodiment, the percentage of weight lost during the functional timeframe is about 50%. In one embodiment, the percentage of weight lost during the functional timeframe is less than about 25%, such as about 5%, 10%, 15%, or 20%, for example. In one embodiment, the percentage of weight lost during the functional timeframe is between about 25% and about 50%, such as about 30%, 35%, 40%, or 45%, for example. In one embodiment, the percentage of weight lost during the functional timeframe is about 75%. In one embodiment, the percentage of weight lost during the functional timeframe is between about 50% and about 75%, such as about 55%, 60%, 65%, or 70%, for example.
  • the dissolved state can be a state in which all of the staple, or at least a substantial amount thereof, has been bio-absorbed by the patient.
  • a substantial amount means that about 10% of less of the structure of the staple remains.
  • a staple can transition from the non-functional state to the dissolved state after a period of time, defined as a non-functional timeframe, has elapsed.
  • the non-functional timeframe can be defined as an amount of time it takes all of the staple, or at least a substantial amount thereof, to bio-corrode in the tissue environment after the staple has reached 112 the non-functional state. Accordingly, with an estimated weight loss rate, such as those provided in the Table 1, the non-functional timeframe of the staples can be estimated and provided to a clinician when selecting a particular staple cartridge to use for a particular stapling operation.
  • a staple can transition from the functional state to the dissolved state after a period of time, defined as the life timeframe, has elapsed.
  • the life timeframe as an example, can be the sum of the functional timeframe and the non-functional timeframe, described above.
  • the life timeframe can be defined as an amount of time in which it takes a staple to bio-corrode completely, or at least substantially bio-corrode, in the tissue environment. Accordingly, with a known weight loss rate, such as those provided in the Table 1, the life timeframe of staples can be estimated and provided to a clinician when selecting a particular staple cartridge to use for a stapling operation. This provides the clinician with the ability to select a staple cartridge that includes staples that will be gone, or at least substantially gone, from stapled tissue within an estimated amount of time.
  • the life timeframe can be defined as an amount of time in which it takes a staple to lose a certain percentage of its weight due to bio-corrosion in the tissue environment. Accordingly, with a known weight loss rate, such as those provided in the Table 1, the life timeframe of staples can be determined and provided to a clinician when selecting a particular staple cartridge to use for a stapling operation. This provides the clinician with the ability to select a staple cartridge that includes staples that will be gone, or at least substantially gone, from stapled tissue within a known amount of time.
  • the percentage of weight lost during the life timeframe is about 50%. In one embodiment, the percentage of weight lost during the life timeframe is about 75%.
  • the percentage of weight lost during the life timeframe is between about 50% and about 75%, such as about 55%, 60%, 65%, or 70%, for example. In one embodiment, the percentage of weight lost during the life timeframe is about 100%. In one embodiment, the percentage of weight lost during the functional timeframe is between about 75% and about 100%, such as about 80%, 85%, 90%, or 95%, for example.
  • the system can include a first packaging with a first table that includes any of the functional timeframe, the non-functional timeframe, and the life timeframe, 113 of the staples positioned in a first staple cartridge in the first packaging.
  • the system can further include a second packaging with a second table that includes any of the functional timeframe, the non-functional timeframe, and the life timeframe, of the staples positioned in a second staple cartridge in the second packaging, where the functional, non-functional, and life timeframes between the first and second staple cartridges are different.
  • a staple will bio-degrade at a first rate in a first tissue environment and bio-degrade at a second rate different than the first rate in a second tissue 114 environment.
  • a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges.
  • the staple cartridges are positioned in a respective packaging that includes an indicia thereon, such as a table, a graph, a grid, or an array, as examples, to inform the clinician of the degradation rates of the staples of the respective staple cartridges in a plurality of tissue environments.
  • the packaging can have an indicia that includes a first column listing tissue environments, such as stomach tissue, lung tissue, liver tissue, etc., and a second column listing respective bio-corrosion rates for each tissue environment. Accordingly, when determining which staple cartridge to use for a particular stapling operation, a clinician can decide how fast or slow they want the staples to degrade in a particular tissue environment.
  • tissue environments such as stomach tissue, lung tissue, liver tissue, etc.
  • the clinician can select a staple cartridge from among the plurality of staple cartridge according to their estimated degradation rates in the plurality of tissue environments.
  • a clinician intending to staple stomach tissue can decide they want staples to remain in the tissue environment for a particular period of time.
  • the system provides the clinician with the ability to select a staple cartridge from among the plurality of staple cartridge knowing the approximate degradation rates of the staples in the stomach tissue environment.
  • a staple will bio-degrade at a first rate for a first period of time in a first tissue environment and bio-degrade at a second rate different than the first rate for a subsequent period of time in the first tissue environment. Accordingly, an embodiment is disclosed in which a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges.
  • the staple cartridges are positioned in a respective packaging that includes an indicia thereon, such as a table, a graph, a grid, or an array, as examples, to inform the clinician of the degradation rates of the staples of the respective staple cartridges for varying periods of time for a plurality of tissue environments.
  • the packaging can have an indicia that includes a first column listing tissue environments, such as stomach tissue, lung tissue, liver tissue, etc., a second column listing a respective bio-corrosion rate in the tissue environment for a first period of time, such as about 1 week, about 2 weeks, about 1 month, or about 3 months, as examples, and a third column listing a respective bio-corrosion rate in the tissue environment for a subsequent period of time after the first period of time, such as about 1 week, about 2 weeks, about 1 month, or about 3 months after the first period of time, as examples.
  • tissue environments such as stomach tissue, lung tissue, liver tissue, etc.
  • a second column listing a respective bio-corrosion rate in the tissue environment for a first period of time, such as about 1 week, about 2 weeks, about 1 month, or about 3 months, as examples
  • a third column listing a respective bio-corrosion rate in the tissue environment for a subsequent period of time after the first period of time, such as about 1 week, about 2 weeks, about 1 month, or about
  • a clinician when determining which staple cartridge to use for a particular stapling operation, a clinician can decide how fast or slow they want the staples to degrade for periods of time in a particular tissue environment. Based on the decision, the clinician can select a staple cartridge from among the plurality of staple cartridge according to their estimated degradation rates for particular periods of time in the plurality of tissue environments. It should be understood that the above-provided indicia with varying rates of bio-corrosion can include more than 2 columns of bio-corrosion rates to inform the clinician of the varying bio-corrosion rates of the staples over the life timeframe.
  • DMEM Modified Eagle's Medium
  • a staple will bio-degrade at a first rate and a first amount of H2 will be produced in a first tissue environment and bio-degrade at a second rate and a second amount of H2 will be produced in a second tissue environment.
  • a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges.
  • the staple cartridges are positioned in a respective packaging that includes an indicia thereon, such as a table, a graph, a grid, or an array, as examples, to inform the clinician of the degradation rates and H2 generation rates of the staples in the staple cartridges for a plurality of tissue environments.
  • FIG. 44 a graph is provided that illustrates corrosion rates (mg/cm 2 /day) against alloying elements (wt%) for magnesium-based alloys. As can be seen in 117
  • increasing wt% of the alloying element affects the corrosion rate of the magnesium- based alloy.
  • an increase in wt% of an alloying element from a first group of alloying elements results in a large increase in corrosion rate.
  • an increase in wt% of an alloying element from a second group of alloying elements results in a steady, less drastic increase in corrosion rate.
  • an increase in wt% of an alloying element from a third group of alloying elements results in a decrease in corrosion rate of the staples.
  • a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges comprising a first group of staple cartridges and a second group of staple cartridges.
  • the first group of staple cartridges includes staples comprised of a magnesium- based alloy alloyed with a first alloying element.
  • a first staple cartridge in the first group of staple cartridges includes staples alloyed with a first wt% of the first alloying element and a second staple cartridge in the first group of staple cartridges includes staples alloyed with a second wt% of the first alloying element that is different than the first wt% of the first alloying element.
  • the second group of staple cartridges includes staples comprised of a magnesium-based alloy alloyed with a second alloying element different than the first alloying element.
  • a first staple cartridge in the second group of staple cartridges includes staples alloyed with a first wt% of the second alloying element and a second staple cartridge in the second group of staple cartridges includes staples alloyed with a second wt% of the second alloying element that is different than the first wt% of the first alloying element.
  • each of the staple cartridges in the first and second groups of staple cartridges are positioned in a respective packaging that includes an indicia thereon which informs the clinician of the staple alloying element, the wt% of the alloying element, and the corrosion rate of the staples in the respective packaging. Accordingly, the system provides the clinician with the ability to select a staple cartridge from among the plurality of staple cartridges based on the known alloying element, the wt% of the alloying element, and the corrosion rate of the staples of the staple cartridge.
  • a clinician may decide that it is more proper to select a staple cartridge from the first group of staple cartridges where the staples are alloyed with the first alloying element as opposed to a staple cartridge from the second group of staple cartridges where the staples are alloyed with the second alloying element.
  • the clinician’s decision can be based on a variety of factors, such as the tissue environment, the patient’s medical record, or the alloys conductivity in the event that electrosurgery will also be performed in the tissue environment, as examples.
  • the clinician is then able to select a staple cartridge from the group according to the estimated corrosion rates, based on the wt% of the alloying element, giving the clinician the ability to control approximately how long the staples will be situated in the tissue environment.
  • FIG. 43 a graph is provided that illustrates elongation to failure (%) against yield stress (MPa) for pure zinc and a variety of zinc-based alloys.
  • pure zinc can have a low strength and plasticity, although this depends on how it is processed.
  • Zn-Mg offers good strength, but with ductility dropping beyond -0.1% Mg.
  • Mn strengthens zinc while maintaining or enhancing ductility.
  • Ca, Sr, and Fe offer low levels of strength with reduced ductility.
  • Zn-Al offers superior that can be increased by processing.
  • Cu improves tensile creep strength while maintaining ductility.
  • Li exhibit remarkable strength (which can be further increased) with reduced ductility; however, ductility can be improved by adding Mn.
  • Ag has high solubility in Mg, so strength is increased without ductility degradation.
  • Ti can be used to improve room temperature creep, especially in Zn-Cu alloys.
  • a system is provided to a user, such as a clinician, that includes a plurality of staple cartridges.
  • the plurality of staple cartridges includes a first staple cartridge that includes staples comprised of a first zinc-based alloy that has a first stress-strain profile.
  • the plurality of staple cartridges further includes a second staple cartridge that includes staples comprised of a second zinc-based alloy that has a second stress-strain profile that is different than the first stress strain profile.
  • the first and second staple cartridges are positioned in a respective packaging that includes an indicia thereon which informs the clinician of the staple alloying element and the associated stress-strain profile associated 119 therewith.
  • the system provides the clinician with the ability to select a staple cartridge from among the plurality of staple cartridges based on the known alloying element and their stress-strain profile. This allows the clinician to select between cartridges with staples comprised of different alloys, such as selecting a cartridge with staples comprised of a first alloy that may be more suitable for a particular tissue environment as opposed to a cartridge with staples comprised of a second alloy.
  • a clinician may decide that it is more appropriate to select a staple cartridge with staples alloyed with a first alloying element as opposed to a staple cartridge with staples alloyed with a second alloying element.
  • the clinician’s decision can be based on a variety of factors, such as the stresses that the staples are expected to experience in the tissue environment. Accordingly, the indicia illustrating the stress-strain profile of the staples allows the clinician to have greater confidence that the selected staple cartridge is suitable for the particular tissue environment.
  • the clinician’s decision can also be based on other factors, such as the patient’s medical record or the alloys conductivity in the event that electrosurgery will also be performed in the tissue environment, as examples.
  • the indicia can indicate suitable tissue environments that the staples are best used for, along with tissue environments that the staples should be avoid being used in.
  • the bio-corrosion rates of staples can be adjusted by using staples comprised of a zinc-based alloy.
  • Zinc-based alloys have increased mechanical properties when compared to magnesium-based alloys, allowing the staples have a smaller diameter compared to magnesium-based alloy staples.
  • the diameter of zinc-based alloy staples can be similar to that of diameter of traditional titanium staples.
  • the modulus of elasticity of zinc-based alloys is considerably higher, and more like titanium, when compared to magnesium-based alloys.
  • the staples are comprised of a 3 AL-2V titanium alloy, which has an ultimate strength of 76,900 - 200,000 psi (530- 1378 MPa), an elastic modulus of 1450 ksi, and is defined by the following composition: titanium (balance), vanadium (about 2.0 wt% to about 3.0 wt%), aluminum (about 2.5 wt% to about 3.5 wt%), hydrogen (about 0.015 wt% max), nitrogen (about 0.03 wt% max), carbon (about 0.10 % max), and iron (about 0.25 wt% 120 max).
  • the 3AL-2V titanium alloy has an ultimate strength similar to that of titanium staples, which is 49,900 - 200,000 psi (344-1378 MPa).
  • stiffer wires such as wires comprised of a zinc-based alloy, will effect unfolding or tear open loads of the staples, force to form and un-form the staples (i.e. staple line burst strength, opening partially formed staples), and tip penetration loads of the staples (i.e. penetration thru bronchus and trachea rather than crumple the staple leg).
  • stiffer wire such as wire comprised of a zinc-based alloy, enable improved staple leg guidance by the staple cartridge and driver features to better align the staple legs with the target tissue and resist rotation during deployment of the staples from the staple cartridge.
  • stiffer wire staples such as staples comprised of a zinc-based alloy
  • stiffer wire staples are better resistant to forces that can cause mis-alignment during deployment of the staples, such as forces experienced from tissue flow, adjunct skewing forces, or forces as a result of angular closure jaw mis alignment on the staple trajectory, as examples.
  • material properties of the staple such as the yield strength, will control the force required to form and un-form the staple when loaded by sealing tissue layers.
  • material properties of the staple such as hardness and ductility, control the magnitude of material cracking, fractures, or staple breaking. These harnesses help with yield strength by making the staple harder, but make the material more brittle and crack sensitive.
  • the lower tension properties of magnesium and zinc cause higher work hardening, which makes the staple more brittle. Accordingly, the closer the material properties of the staples are to titanium, such as the 3 AL-2V titanium alloy, as discussed above, the better the balance will be between ductility and hardness.
  • staples that dissolve quickly are comprised of metals that are not as strong as titanium and/or stainless steel and, as a result, such quickly dissolvable staples may release the patient tissue sooner than the stronger, slower-dissolving staples.
  • the innermost rows of staples i.e., the staple rows closest to the longitudinal knife slot, comprise a staple comprised of titanium, a titanium alloy, and/or stainless steel in each staple cavity while the outermost rows of staples and the intermediate rows of staples, i.e., the staple rows intermediate the innermost staple rows and outermost staple rows, have staples comprised of 121 magnesium and/or a magnesium alloy in each staple cavity.
  • the outermost staple rows and intermediate staple rows may release the patient tissue before innermost staple rows.
  • the innermost staple rows of a staple cartridge comprise a staple comprised of titanium, a titanium alloy, and/or stainless steel in each staple cavity while the outermost staple rows and the intermediate staple rows have staples comprised of zinc and/or a zinc alloy in each staple cavity.
  • the intermediate staple rows and the outermost staple rows have staples comprised of iron and/or an iron alloy in each staple cavity.
  • the outermost staple rows and the intermediate staple rows may release the patient tissue before the innermost staple rows.
  • the innermost staple rows of a staple cartridge include a staple comprised of a first magnesium alloy in each staple cavity
  • the intermediate staple rows include a staple comprised of a second magnesium alloy in each staple cavity which is different than the first magnesium alloy
  • the outermost staple rows include a staple comprised of a third magnesium alloy in each staple cavity that is different than the first magnesium alloy and the second magnesium alloy.
  • the first, second, and third magnesium alloys are selected such that the outermost staple rows release the patient tissue before the intermediate staple rows and the innermost staple rows.
  • the intermediate staple rows release the patient tissue before the innermost staple rows.
  • This same approach can be used with zinc alloys in various staple cartridges. This approach could also be used with iron alloys in various staple cartridges.
  • the first, second, and third magnesium alloys are selected such that the innermost staple rows release the patient tissue before the intermediate staple rows and the outermost staple rows. Similarly, the intermediate staple rows release the patient tissue before the innermost staple rows.
  • This same approach can be used with zinc alloys in various staple cartridges. This approach could also be used with iron alloys in various staple cartridges.
  • the innermost staple rows of a staple cartridge include staples comprised of pure magnesium and the intermediate staple rows and the outermost staple rows include staples comprised of a magnesium alloy. That said, in other examples, the pure magnesium staples can be placed in any suitable staple row within the staple cartridge. In any event, once implanted, the staples are part of a staple line in the patient where the pure 122 magnesium staples degrade before the magnesium alloy staples. The early degradation of the pure magnesium staples can increase the pH of the environment surrounding the staple line and slow down the degradation of the magnesium alloy staples.
  • the pure magnesium staples can act as anodes that draw, redirect, or focus the oxidation and absorption of the staple line toward the pure magnesium staples and away from the magnesium alloy staples, at least temporarily. Such an arrangement would allow the magnesium alloy staples to remain functional for a desired time period.
  • all of the staple rows within a staple cartridge comprise magnesium alloy staples but also include pure magnesium staples interdispersed throughout the staple rows.
  • a staple cartridge comprises one or more staple rows comprised of iron staples and/or iron staples interdispersed throughout the staple rows. In such examples, the iron staples focus the oxidation and absorption away from the magnesium alloy staples.
  • a staple cartridge comprises one ore more staple rows comprised of zinc staples and/or zinc staples interdispersed throughout the staple rows.
  • the zinc staples focus the oxidation and absorption away from the magnesium alloy staples.
  • one or more staples deployed in a staple line can provide an anodic effect relative to the other staples in the staple line.
  • implants - other than staples - can be implanted in a patient to provide an anodic effect that at least partially and at least temporarily focuses the oxidation and absorption on the non-staple implants.
  • the non-staple implants are comprised of lithium, sodium, and/or potassium, for example.
  • a staple line is comprised of pure magnesium staples and/or magnesium alloy staples and the non-staple implants comprise anodes that allow the magnesium staples and the magnesium alloy staples to remain functional for a desired period of time.
  • the non-staple implants are comprised of a material that is less noble than magnesium.
  • a staple pattern includes longitudinal rows of staples 7000 implanted in patient tissue T along an incision I.
  • a non-staple implant 7100 is also present in the staple pattern.
  • the non-staple implant 7100 bioabsorbs and dissolves away before the staples 7000.
  • a powder is introduced onto a staple line and/or onto the patient tissue surrounding the staple line that comprises a sacrificial anodic material.
  • the powder comprises magnesium 123 particles.
  • the magnesium particles are mixed in dry, or at least substantially dry, sodium stearate.
  • a staple cartridge is covered in at least one such powder such that at least some of the powder is transferred to the patient tissue when the patient tissue is clamped against the staple cartridge.
  • the powder is stored in a staple cavity defined in the staple cartridge such that the powder is ejected from the staple cartridge by a staple driver during the staple firing stroke.
  • the powder is packed into one or more staple cavities that also have staples stored therein. In other instances, the powder is packed into one or more staple cavities that do not have a staple positioned therein. In at least one such instance, such staple cavities are positioned in the outermost staple rows.
  • the powder is contained in and/or on an implantable adjunct attached to the deck of the staple cartridge such that the powder is implanted with the adjunct during the staple firing stroke.
  • the sacrificial anodic material is contained in and/or is present on tape adhered to the staple cartridge. In at least one embodiment, the sacrificial anodic material is suspended in a gel, for example, on the staple cartridge.
  • a sacrificial anodic material is applied to the patient tissue before the patient tissue is stapled and/or cut by spraying the sacrificial anodic material onto the patient tissue via a pressurized aerosol, for example, and or deposited onto the patient tissue via a syringe, for example.
  • the sacrificial anodic material can be applied via these techniques after the patient tissue has been stapled and/or cut.
  • the staples and the anodic material implanted within patient tissue are electrically connected. Such electrical connection can be made by body fluids within the patient.
  • a powder including sacrificial anodic material discussed above, electrically interconnects the staples of an implanted staple line.
  • the powder includes silver and/or aluminum powder contained therein, for example.
  • the powder includes an electrically conductive material that is more noble than the magnesium such that the oxidation and bioabsorption processes are not redirected, or at least substantially redirected, to the electrically conductive material.
  • a staple cartridge comprises an electrically conductive wire, such as a wire mesh, for example, on the deck of the staple cartridge that is implanted with the staples.
  • the wire is comprised of silver and/or aluminum, for example.
  • a staple cartridge comprises an implantable adjunct including electrically conductive powder contained therein and/or includes an electrically conductive wire mesh that is in contact with the staples once the staples have been fired and implanted in the patient tissue.
  • a sacrificial material can be used to direct or focus the oxidation and bioabsorption processes of the body away from the staples for a period of time such that the stapled and incised patient tissue has sufficient time to heal.
  • the time in which the sacrificial material provides this effect depends on the mass or amount of sacrificial material that is used. More mass provides more time. In this way, the type and amount of sacrificial material, or materials, can be selected so as to tune the degradation of the staples.
  • galvanic corrosion can occur between staples implanted within a patient that are comprised of different metals.
  • staples comprised of a first material act as an anode and staples comprised of a second material act as a cathode.
  • the anodic staples and the cathodic staples are electrically connected by an electrolytic fluid introduced into and/or onto the staple line.
  • the electrolytic fluid includes, but is not limited to, Na+, Ca2+, K+, Mg2+, Zn2+, C1-, and/or F1-, for example.
  • the electrolytic fluid provides a means for ion migration away from the staples to prevent charge build-up that would otherwise stop and/or slow the galvanic reaction between the staples.
  • corrosion inhibitors such as sodium nitrite and/or sodium molybdate, for example, can be introduced into the galvanic system to slow the galvanic reaction between the staples.
  • a staple is entirely comprised of a single material.
  • a staple can be entirely comprised of pure magnesium or, alternatively, a magnesium alloy.
  • a staple can be entirely comprised of a first magnesium alloy or, alternatively, a second alloy.
  • a staple is comprised of two or more different materials.
  • a staple wire can be comprised of an inner core comprised of one metal and an outer portion surrounding the inner core that is comprised of another metal.
  • the inner core is comprised of pure magnesium and the outer portion is comprised of a magnesium alloy.
  • the inner core is comprised of a magnesium alloy and the outer portion is comprised of magnesium.
  • An electroplating process can be used to apply one metal and/or metal alloy onto another.
  • the rate in which such staples are bioabsorbed can change over time after 125 they have been implanted into a patient owing to the bioabsorption of the outer portion occurring at one rate and the bioabsorption of the inner core occurring at a different rate.
  • the bioabsorption of a staple can be slower through an outer portion comprised of a magnesium alloy and then faster through an inner core comprised of magnesium, for example.
  • a galvanic reaction can be present between the inner core and the outer portion of a staple, especially when the outer portion is breached during bioabsorption and electrolytic fluids are in contact with the inner core and the outer portion simultaneously.
  • Such embodiments may have to be used within a given time owing to the ongoing galvanic reaction between the metals, even before the staples are implanted in a patient.
  • a staple comprises a first portion comprised of a first metal and a second portion comprised of a second metal.
  • a staple comprises a crown and first and second legs extending from the crown where the crown is comprised of a first material and the legs are comprised of a second material.
  • the crown is comprised of a magnesium alloy and the legs are comprised of pure magnesium.
  • the legs are attached to the crown through a welding process, for example.
  • the welds between the crown and the legs occurs in the bends of the staples which creates an interface or weak spot for oxidation and bioabsorption processes of the body to attack.
  • a galvanic reaction can be present between the first and second materials of the crown and legs, especially when the staples are introduced to electrolytic fluids within a patient.
  • the interface between the legs and the crown comprises a galvanic interface which can kickstart the bioabsorption of the staple in that location and can assure that the staples are quickly bioabsorbed and/or quickly made non-functional. Similar to the above, such embodiments may have to be used within a given time owing to the ongoing galvanic reaction between the metals, even before the staples are implanted in a patient.
  • two staples are stored in all of the staple cavities in a staple cartridge, or in at least some of the staple cavities of a staple cartridge.
  • the two staples stored in a staple cavity are simultaneously ejected from the staple cartridge and deformed against the anvil during the firing stroke.
  • such examples can be used to obtain various advantages.
  • staples that dissolve quickly are comprised of metals that are not as strong as titanium and/or stainless steel and, as a result, such quickly dissolvable staples may release the patient tissue sooner than the stronger, slower-dissolving staples.
  • the innermost rows of staples i.e., the staple rows closest to the longitudinal knife slot, comprise two staples in each staple cavity while the outermost rows of staples and the intermediate rows of staples, i.e., the staple rows intermediate the innermost staple rows and outermost staple rows, have only one staple in each staple cavity.
  • the outermost staple rows and intermediate staple rows may release the patient tissue before innermost staple rows.
  • one staple within a double-staple cluster may release the patient tissue while the other staple in the double-staple cluster continues to clench the patient tissue for at least a while longer.
  • the outermost staple rows and the intermediate staple rows may release the patient tissue in about 20 days while the innermost staple rows release the patient tissue in about 30 days, for example.
  • the outermost staple rows and the intermediate staple rows may release the patient tissue in about 30 days while the innermost staple rows release the patient tissue in about 45 days, for example.
  • the innermost staple rows hold onto the patient tissue about 1.5 times longer than the outermost staple rows and the intermediate staple rows.
  • the innermost staple rows hold onto the patient tissue about 2 times longer than the outermost staple rows and the intermediate staple rows.
  • the innermost staple rows hold onto the patient tissue about 2.5 times longer than the outermost staple rows and the intermediate staple rows.
  • the innermost staple rows have a single staple in each staple cavity comprised of stainless steel
  • the intermediate staple rows have two staples in each staple cavity comprised of magnesium
  • the outermost staple rows have a single staple in each staple cavity comprised of magnesium.
  • the outermost staple rows release the patient tissue, then the intermediate staple rows, and then the innermost staple rows.
  • the staple rows closest to the longitudinal incision in the patient tissue holds onto the tissue the longest.
  • the intermediate staple rows hold onto the patient to the tissue the longest.
  • the early dissolution of the outermost staple rows increases blood flow to the incised tissue margin and the early 127 dissolution of the innermost staple rows directly provides nutrients to the incised tissue margin.
  • all of the staple cavities in a staple cartridge comprises two staples stored therein.
  • at least some of the staples in the double-staple clusters are comprised of different materials.
  • the innermost staple cavities of a staple cartridge each has two magnesium or magnesium alloy staples stored therein
  • the intermediate staple cavities each has one magnesium or magnesium alloy staple and one zinc or zinc alloy staple stored therein
  • the outermost staple cavities each as two zinc or zinc alloy staples stored therein.
  • a staple cartridge 8300 comprises a cartridge body 8350 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 8350 comprises three longitudinal rows of staple cavities 8210’” defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities 8210”’ defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • Each staple cavity 8210’” has two staples 8220”’ removably stored therein.
  • a staple cartridge 8400 comprises a cartridge body 8450 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 8450 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • the outermost rows of staple cavities has two staples 8220”’ removably stored in each staple cavity, the innermost rows of staple cavities has a single staple 8220’ stored in each staple cavity, and the intermediate rows of staple cavities has a single staple 8220’ stored in each staple cavity. Referring to FIG.
  • a staple cartridge 7400 comprises a cartridge body 7450 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 7450 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • a proximal group of staple cavities has a single staple 8220’ stored in each staple cavity and the staple cavities distal to the proximal group has two staples 9220’” removably stored therein.
  • the mechanical properties of a staple can be tuned to alter the biodegradation rate of the staple.
  • the surface of the staple can be modified to increase and/or decrease the biodegradation rate of the staple.
  • smoother staples have less exposed surface area than rougher staples and, as a result, smoother staples have less surface area to be exposed to fluids within the patient and less material that can be oxidized at a given time.
  • staples undergo a tumbling and/or polishing process to smoothen the staples so as to decrease the bioabsorption rate of the staples.
  • staples undergo an abrading process, for example, to roughen the staples so as to increase the bioabsorption rate of the staples.
  • the surfaces of the staples can be broken so as to permit the absorption mechanism to penetrate below the surfaces and/or exterior portions of the staples and increase the bioabsorption rate of the staples.
  • the exterior portions of the staples have surface hardening, heat treating, and/or a different grain structure that is different than the interior portions of the staples which can slow the biodegradation process.
  • Such exterior portions can be scored and/or ground, for example, such that the absorption mechanism can penetrate below the exterior portions at the outset of the staples being implanted in the patient.
  • the cross-section of certain areas in a staple can be reduced to create an attack point for the biodegradation process which can cause the staple to fail within a desired time frame.
  • Thinner cross-sections fail faster than thicker cross-sections.
  • one or more portions of the staple wire is knurled, grooved, scored, extruded, and/or rolled, for example, such that the thickness of the staple wire is different in some portions of the staple wire than others.
  • a wire staple 3200 comprises a crown 3210 and legs 3220 extending from the crown 3210.
  • the wire staple 3200 further comprises an abraded region 3290 on each leg 3220 which causes the legs 3220 to fail in the abraded region 3290 before the other regions of the wire staple 3200 during the bioabsorption of the wire staple 3200 in the patient.
  • the abraded regions 3290 of the legs 3220 comprise the top of the formed staple configuration which allows the clenched tissue to be released away from the crown 3210 as the wire staple 3200 dissolves.
  • a wire staple 3300 comprises a crown 3310 and legs 3320 extending from the crown 3310.
  • the wire staple 3300 further comprises a knurled region 3390 on each leg 3320 129 which causes the legs 3320 to fail in the abraded region 3390 before the other regions of the wire staple 3300 during the bioabsorption of the wire staple 3300 in the patient.
  • the abraded regions 3390 of the legs 3320 comprise the top of the formed staple configuration which allows the clenched tissue to be released away from the crown 3310 as the wire staple 3300 dissolves.
  • a staple cartridge comprises a first group of staples in the innermost staple rows, a second group of staples in the intermediate staple rows, and a third group of staples in the outermost staple rows.
  • the first group of staples comprises staples having a surface roughness Ra within a first range
  • the second group of staples comprises staples having a surface roughness Ra within a second range that is different than the first range
  • the third group of staples comprises staples have a surface roughness Ra within a third range that is different than the first range and the second range.
  • the first, second, and third ranges of the surface roughness Ra i.e., average surface roughness, can partially overlap or not overlap at all.
  • the first range is higher than the second range, and the second range is higher than the third range. That is to say that the first group of staples have a rougher surface than the second group of staples, and the second group of staples have a rougher surface than the first group of staples.
  • the first group of staples bioabsorbs faster than the second group of staples, and the second group of staples bioabsorbs faster than the third group of staples.
  • the first range is lower than the second range, and the second range is lower than the third range.
  • a staple cartridge comprises a first group of staples in a proximal-most group of staple cavities, a second group of staples in a distal-most group of staple cavities, and a third group of staples in an intermediate group of staple cavities intermediate the proximal-most group and the distal-most group.
  • the first group of staples comprises staples having a surface roughness Ra within a first range
  • the second group of staples comprises staples having a surface roughness Ra within a second range that is different than the first range
  • the third group of staples comprises staples have a surface roughness Ra within a third range that is different than the first range and the second range.
  • the first, second, and third ranges of the surface roughness Ra can partially overlap or not overlap at all.
  • the first range is higher than the second range, and the second range is higher than the third range. That is to say that the first group of staples have a rougher 130 surface than the second group of staples, and the second group of staples have a rougher surface than the first group of staples.
  • the first group of staples bioabsorbs faster than the second group of staples, and the second group of staples bioabsorbs faster than the third group of staples.
  • the first range is lower than the second range, and the second range is lower than the third range.
  • the first group of staples and the second group of staples bioabsorb faster than the third group of staples.
  • the ends of two consecutive staple firings in the patient tissue will overlap resulting in a high density cluster of staples that makes the patient tissue stiff.
  • the proximal-most and/or the distal-most group of staples can dissolve faster than the other staples so as to permit the patient tissue subjected to the high density staple cluster to become flexible quickly.
  • a staple comprises a crown, first and second legs, and bends connecting the first and second legs to the crown where the surface of the bends is rougher than the crown and the first and second legs.
  • the bends will deteriorate faster than the crown and the first and second legs when the staple is implanted in a patient.
  • the staple will fracture at the bends of the staple and release the patient tissue while the crown and first and second staple legs continue to bioabsorb.
  • the staple legs have a rougher surface than the bends and the crown and, as a result, the staple legs will bioabsorb faster.
  • the staples of a staple cartridge can be subjected to different surface treatments to change the time in which the staples crack, fracture, and/or dissolve once the staples are implanted in a patient.
  • a staple cartridge can comprise groups of staples stored in the staple cartridge where the staples of each group have a different surface roughness profile.
  • a staple cartridge includes a first group of staples where each staple has a first surface roughness profile, a second group of staples where each staple has a second surface roughness profile, and a third group of staples where each staple has a third surface roughness profile.
  • the staples of the first group of staples have not undergone a surface roughening process - the staples of the second group of staples have a crown, first and second legs, and bends connecting the legs to the crown that have been 131 roughened through an abrading process - and the entire exterior surface of the staples in the third group of staples have been roughened through an abrading process.
  • the staples in the third group of staples bioabsorb faster than the staples in the second group of staples and, likewise, the staples in the second group of staples bioabsorb faster than the staples in the first group of staples.
  • the first group of staples is stored in the innermost rows of staple cavities defined in a staple cartridge
  • the second group of staples are stored in the intermediate rows of staple cavities
  • the third group of staples are stored in the outermost rows of staple cavities.
  • the third group of staples are stored in the distal-most staple cavities of a staple cartridge
  • the second group of staples are stored in the proximal-most staple cavities of the staple cartridge
  • the first group of staples are stored in the staple cavities intermediate the second and third groups of staples.
  • the staples stored in a staple cartridge are comprised of wire having the same diameter, or at least substantially the same diameter.
  • one or more of the staple rows in a staple cartridge is comprised of wire having a smaller diameter than the other staple rows.
  • the outermost staple rows in a staple cartridge have staples with a thinner diameter and may provide a smaller, or lighter, clenching force to the patient tissue than the staples closest to the tissue cutline that have a thicker diameter.
  • the innermost staple rows in a staple cartridge have staples with the thickest diameter and the intermediate staple rows have staples with a diameter in-between the diameters in the inner staple row and the outer staple row.
  • the thinner staples will fracture and release the patient tissue before the thicker staples fracture and release the patient tissue.
  • Such an arrangement can place the staples that last the longest along the incision, or margin, in the patient tissue which may be the last portion of the patient to heal after a procedure.
  • the innermost rows of staples in a staple cartridge have the thinnest diameter while the outermost rows of staples have the thickest diameter.
  • the staples furthest away from the incision in the patient tissue will last the longest and give the tissue margin more space to heal.
  • a staple cartridge 7800 comprises a cartridge body 7850 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 7850 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and 132 three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • the outermost rows of staple cavities has a single staple 8220’ stored in each staple cavity
  • the innermost rows of staple cavities has a single staple 7820’ stored in each staple cavity
  • the intermediate rows of staple cavities has a single staple 7820” stored in each staple cavity.
  • a staple cartridge 8000 comprises a cartridge body 8050 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 8050 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • a staple cartridge 8100 comprises a cartridge body 8150 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 8150 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • a proximal group of staple cavities has a single staple 8220’ stored in each staple cavity and the staple cavities distal to the proximal group has a single staple 7820’ removably stored therein.
  • the staples implanted into patient tissue from the distal end of one staple cartridge may overlap with staples implanted into the patient tissue from the proximal end of another staple cartridge. Such overlap can make the patient tissue stiff.
  • the staples stored in the proximal end and/or the distal end of a staple cartridge can have a thinner diameter than the other staples stored in the staple cartridge.
  • a distal group of staples stored in the distal end of a staple cartridge have a thinner wire diameter than the staples stored in the proximal end of the staple cartridge and the intermediate portion of the staple cartridge extending between the proximal end and the distal end.
  • a proximal group of staples stored in the proximal end of a staple cartridge have a thinner wire diameter than the staples stored in the distal end of 133 the staple cartridge and the intermediate portion of the staple cartridge extending between the proximal end and the distal end.
  • a staple cartridge comprises anodic elements stored in the proximal end and/or the distal end of the staple cartridge that, once implanted, direct or focus the oxidation and bioabsorption toward the overlap region.
  • the staples stored in the proximal-most staple cavities of a staple cartridge have a thicker wire diameter than the staples stored in the other staple cavities in the staple cartridge.
  • the deployment of the thicker staples at the beginning of the staple firing stroke pushes the anvil away from the staple cartridge and maintains a desired gap height between the anvil and the staple cartridge.
  • the staples in the distal-most staple cavities of a staple cartridge have a thicker wire diameter than the staples in the other staple cavities which can assist in maintain a desired gap between the anvil and the staple cartridge at the end of the staple firing stroke.
  • proximal staples and/or the distal staples can be stiffer than the staples in the middle of the staple cartridge which can assist in positioning the anvil.
  • the staples of a staple cartridge are coated with at least one coating which delays, slows, and/or otherwise controls the bioabsorption of the substrates, or frames, of the staples.
  • a wire staple 5500 comprises a substrate including a crown 5510 and legs 5520 extending from the crown 5510.
  • the staple 5500 further comprises a coating 5590 on the substrate.
  • the coating 5590 is in an unabsorbed state. Thereafter, referring to FIGS. 45B and 45C, the coating 5590 and the substrate bioabsorb until the staple 5500 is completely dissolved, as illustrated in FIG. 45D.
  • the staples are implanted in the patient tissue at the same time that the tissue is incised and hold the tissue together while the tissue heals. Measured from this point in time, the patient tissue needs a certain amount of time to heal before the staples are no longer needed. This timeframe can be referred to as the healing window.
  • tissue healing can be long process that can include 134 tissue remodeling over time and can be different from patient to patient and different from tissue type to tissue type.
  • healing window is the amount of time needed before the incised tissue achieves a predicted desirable stability and/or strength.
  • the healing window is about 30 days while, in some instances, the healing window is about 60 days, for example.
  • Longer healing windows can be about 100 days, about 180 days, or about 365 days, for example, depending on the type of tissue and the procedure performed, among other things.
  • the time between FIGS. 45A and 45D, i.e., the time between implantation and full dissolution exceeds the healing window. That being said, in various embodiments disclosed herein, it is desirable for the staples to be completely absorbed shortly after the healing window has been exceeded.
  • the shortest amount of time possible between the end of the healing window and the full dissolution of the staples is desired. Having said that, it is desirable for the staples to retain functionality throughout the healing window and apply a clenching force or pressure to the tissue during the healing window. After the healing window has been exceeded, the functionality can be lost prior to the complete dissolution of the staples. As discussed further below, one or more staple coatings can be used to tune the time in which the staples lose functionality and/or become completely dissolved.
  • the substrates of the staples are formed from wire.
  • the wire is coated after the wire is formed into a staple form.
  • a length of wire is cut from a spool of wire such that the length of wire has a first end and a second end.
  • the length of wire is sheared such that the staple tips are sheared to their final shape and sharpness while, in other instances, the length of wire undergoes additional stamping and/or tip sharpening processes to bring the staple tips into their final shape and sharpness.
  • the length of wire is bent to create a staple form 6700 including a crown 6710, a first leg 6720 extending from the crown 6710, and a second leg 6720 extending from the crown 6710. That said, other embodiments are envisioned in which a staple form comprises a crown and only one leg.
  • the length of wire and/or the staple form can undergo one or more treating processes which affect the mechanical properties of the wire substrate and/or prepare the surface of the staple form 6700 to receive a coating 6790.
  • a length of wire and/or a staple form is heat treated before it is coated.
  • a length of wire and/or a staple form is exposed 135 to phosphoric acid, hydrochloric acid, and/or magnesium fluoride before the coating process.
  • Such processes can clean the surface of the length of wire and/or the staple form, among other things.
  • a length of wire and/or a staple form are ultrasonically cleaned with isopropyl alcohol and/or acetone, for example.
  • the surface of a length of wire and/or a staple form are pre-treated with micro-arc plasma process, a hydrothermal treatment process, and/or a plasma electrolytic oxide process, for example.
  • the staple form is coated with one or more coatings that can mechanically and/or chemically bond to the wire substrate and then loaded into a staple cartridge.
  • the coating is applied to the wire substrate by a spraying process, for example.
  • the coating 6790 is sprayed onto the staple form 6700 using one or more spray jets 6370 to create a coated staple 6700’.
  • a spray jet 6370 is positioned on one side of the staple form 6700 and another spray jet 6370 is positioned on the opposite side of the staple form 6700 such that the entire staple form 6700 is coated.
  • the coating is applied the wire substrate by a sputtering process, for example.
  • the coating is applied to the wire substrate by a chemical vapor deposition process, for example.
  • paralene, fluoropolymers, and/or silicone for example, are deposited on the staples using a chemical vapor deposition process.
  • all of the bending, stamping, and/or tip sharpening processes have already been completed before the staples are coated. Such an approach prevents, or at least reduces the possibility of the coating, or coatings, from cracking and/or delaminating from the substrate of the staple, for example, during the staple manufacturing process.
  • the staple wire is already coated when the length of wire is cut from the spool of wire.
  • the coating is applied to the wire substrate and then wound up on a spool.
  • the coating is applied to the wire substrate by a continuous extrusion process, for example.
  • the coating is applied to the wire substrate during a continuous electroplating process, for example.
  • the wire substrate is comprised of magnesium and the plating is compatible with the magnesium so as to not initiate corrosion within the magnesium prior to being implanted in a patient.
  • the coating is applied to the wire substrate by a continuous chemical vapor deposition process, for example.
  • the 136 coatings in these examples are applied to the wire substrate prior the wire substrate being sheared, stamped, bent, and/or sharpened, for example, to make the staples.
  • the coating comprises a hard shell polymer coating capable of withstanding the stresses and strains created during the staple forming process without cracking and/or delaminating from the wire substrate.
  • the coating is comprised of polylactic acid (PLA), polyglycolic acid (PGA), poly-L-lactic acid (PLLA), polyurethane (PU), and/or polytrimethylene carbonate (PTMC), for example.
  • PLA, PLA, and PGA are all synthetic bioabsorbable polymers often used in biomedical applications.
  • the coating is comprised of poly lactic-co-glycolic acid (PGLA) 65:35, the chemical makeup of which is about 65% glycolide and about 35% lactide, for example.
  • the coating is comprised of poly(N-vinylcaprolactam) (PNVCL), for example.
  • the coating is formulated by a sol-gel coating process, for example.
  • the coating is comprised of carbonate, for example. In any event, such coatings are sufficiently lubricious to undergo the staple manufacturing process without being damaged, or at least significantly damaged.
  • the coated wire can be further coated with sodium stearate and/or a mixture of sodium stearate and ethyl lauroyl arginate (LAE), for example, which can act as a lubricant and reduce the possibility of the coated wire being damaged during the staple manufacturing process.
  • LAE ethyl lauroyl arginate
  • the sodium stearate and/or a mixture of sodium stearate and LAE can facilitate the insertion of the staples into the staple cavities of a staple cartridge.
  • uncoated wire stock 6250 is drawn from a wire spool and then sprayed with a coating 6290 via spray jets 6230 and 6270.
  • the coating 6290 is extruded onto the wire stock 6250.
  • the coated wire stock 6250 is then sheared by a shearing knife 6240 to create a length of wire that is then stamped into a staple form 6260 by a die 6280. That being said, it is possible that the coating 6290 on the wire stock 6250 may become scratched and/or otherwise damaged in the die 6280.
  • the shearing process cuts the coating 6290 on the wire stock 6250 and creates uncoated surfaces on the staple tips of the staple form 6260. Absent more, such damage to the coating and/or exposed surfaces of the substrate metal can create focal 137 points, either intentionally or unintentionally, for the oxidation and bioabsorption processes within the patient.
  • a wire staple form 6300 comprises a crown 6310, legs 6320, and bends 6330 connecting the legs 6320 to the crown 6310.
  • the tips 6325 of the staple legs 6320 have exposed metal.
  • the coating 6390 on the bends 6330 has become thin, stretched, strained, and/or cracked as a result of the forming process.
  • the wire staple form 6300 is sprayed with coating 6395 via spray jets 6370, for example, which covers the exposed staple tips 6325 and covers up defects in the coating 6390 including any defects present on the staple bends 6330.
  • the coatings 6390 and 6395 can be comprised of the same material or different materials.
  • staples 6300’ have been made from staple forms 6300 and the staples 6300’ can be loaded into a staple cartridge.
  • a plurality of staple forms 6300 are loaded into a staple cartridge 6600 and an additional coating 6395 is applied to the staple forms 6300 while the staple forms 6300 are stored in the staple cartridge 6600 to make staples 6300” out of the staple forms 6300.
  • the staple cartridge 6600 comprises staple cavities 6610 defined therein and drivers 6500 configured to push the staples 6300” out of the staple cavities 6610 during a staple firing stroke.
  • the coating 6395 is sprayed down onto the staple forms 6300 from a spray jet 6370 through the top openings of the staple cavities 6610.
  • the coating 6395 is present on the leg tips, the inner surfaces of the legs and bends, and the top surface of the staple crown of the staples 6300”; however, gaps in the coating may exist on the outside surfaces of the legs and/or on the bottom surface of the staple crown depending on how well the coating 6395 can flow onto those surfaces.
  • a staple form 6800 comprises a substrate including a crown 6810, legs 6820, and bends 6830 connecting the legs 6820 to the crown 6810.
  • the staple form 6800 further comprises a coating 6890 on most of the substrate. More specifically, similar to the 138 above, the leg tips 6825 comprise bare surfaces and the coating 6890 on the bends 6830 may be cracked as a result of the manufacturing process.
  • the staple form 6800 is heated by a heating element 6870 to partially melt and/or lower the viscosity of the coating 6890 such that the coating 6890 levels itself to fill in the gaps in the coating 6890 and/or even out thin spots in the coating 6890 such as in the bends 6830.
  • the staple forms 6800 have become staples 6800 and are permitted to cool and/or are actively cooled with a fan and/or a refrigeration process, for example.
  • the staples 6800’ are reflowed before the staples 6800 are loaded into a staple cartridge.
  • the staples 6800 are reflowed after the staples 6800 have been loaded into a staple cartridge. In such instances, defects in the coating created during the staple loading process can be cured by the reflow process.
  • the coated wire stock and/or the coated staples can be coated with a lubricant during the staple manufacturing process and/or during the staple loading process.
  • the lubricant can reduce friction between the coated wire stock and/or coated staples and adjacent contact surfaces and/or otherwise reduce damage to the coating on the staples.
  • the lubricant comprises sodium stearate, LAE, a soap, an anti microbial agent, and/or combinations thereof, for example.
  • uncoated staple wire stock 5600 comprises a circular, or an at least substantially circular, cross-section; however, staple wire stock can have any suitable cross- section, such as square and/or rectangular, for example.
  • the staple wire stock 5600 is coated with a coating 5690.
  • the staple wire stock 5600 is coated with a thinner coating 5690’. Less time is needed to bioabsorb he thinner coating 5690’ than the coating 5690 with all other things being equal. As such, the oxidation and bioabsorption of the underlying staple wire stock 5600 will occur sooner once implanted in a patient when the thinner coating 5690’ is used.
  • the staple wire stock 5600 is coated with a coating 5690” that is thicker than the coating 5690. More time is needed to bioabsorb the thicker coating 5690” than the coating 5690 with all other things being equal. As such, the oxidation and bioabsorption of the underlying staple wire stock 5600 will occur later once implanted in a patient when the thicker coating 5690” is used. 139
  • the coating applied to the staple wire stock 5600 is sufficiently elastic and/or is sufficiently ductile to move with the underlying wire stock 5600 during the staple manufacturing process and/or staple firing process.
  • the coating forms a mechanical bond with the staple wire stock 5600 and, in various instances, the coating forms a chemical bond with the staple wire stock 5600.
  • the staple wire stock 5600 can be coated with a dusty coating 5690’”.
  • the dusty coating 5690”’ can be adhered to the staple wire stock 5600 via an electrostatic charge and/or a binding medium, for example.
  • two or more coatings are applied to the staple wire stock 5600.
  • a first coating 5690’ is applied to the staple wire stock 5600.
  • the entirety of a staple substrate is covered in the first coating 5690’.
  • the first coating 5690’ is entirely covered with a second coating 5695’. That said, other embodiments are envisioned where only a portion of the staple substrate is covered in the first coating 5690’ and/or only a portion of the first coating 5690’ is covered with the second coating 5690”.
  • additional coatings are used.
  • the penetration depth of a coating into the staple wire stock can be limited and, in many instances, a coating does not penetrate into the staple wire stock below the surface of the staple wire stock.
  • the outer portions of a staple wire stock 5700 can be turned into an intrinsic coating 5790.
  • the intrinsic coating 5790 is the result of heat treating, for example.
  • an external coating 5795 can be applied to the intrinsic coating 5790.
  • the staple wire stock 5600 comprises solid wire stock.
  • the staple wire stock 5600 does not have internal openings absent the typical voids in the grain structure and/or the presence of random inclusions, for example.
  • staple wire stock 5800 is hollow.
  • the staple wire stock 5800 comprises an internal cavity 5880 which is present throughout the length of the staple wire stock 5800.
  • a substance can be present in the internal cavity 5880.
  • the internal cavity 5880 is filled, or at least partially filled, with one or more medicaments 5885.
  • the medicament 5855 140 comprises an antibiotic, for example, that is released into the patient once the staple wire stock 5800 has been sufficiently dissolved.
  • a staple wire stock 5980 comprises an internal core 5980.
  • the internal core 5980 is comprised of a first metal and the surrounding portion of the staple wire stock 5980 is comprised of a second, or different, metal.
  • the internal core 5980 is comprised of pure magnesium while the surrounding portion of the staple wire stock 5980 is comprised of magnesium alloy, for example.
  • the bioabsorption rate of the surrounding portion is slower than the bioabsorption rate of the internal core 5980.
  • the strength of a staple comprised of the staple wire stock 5980 may retain its functional strength for a while and then fail quickly.
  • the internal core 5980 is comprised of a magnesium alloy while the surrounding portion of the staple wire stock 5980 is comprised of pure magnesium, for example.
  • the bioabsorption rate of the surrounding portion is faster than the bioabsorption rate of the internal core 5980.
  • a staple comprised of the staple wire stock 5980 may bioabsorb quickly down to the internal core 5980 which may provide early strain relief to the stapled tissue.
  • a staple 6000 comprises a substrate including a crown 6010, legs 6020, and bends 6030 connecting the legs 6020 to the crown 6010.
  • the staple 6000 further comprises a coating 6090 on the substrate.
  • the coating 6090 has a uniform, or an at least substantially uniform, thickness on the substrate including, further to the above, on the staple tips 6025 and on the inner and outer surfaces of the bends 6030.
  • the oxidation and/or bioabsorption processes may not favor or attack any particular part of the staple 6000 over another.
  • the staple 6000 can bioabsorb evenly.
  • a staple has a non-uniform coating thickness and/or different coatings on different portions of the staple.
  • a staple 6100 comprises a substrate including a crown 6110, legs 6120, and bends 6130 connecting the legs 6120 to the crown 6110.
  • the staple 6100 is also coated.
  • the legs 6120 are coated with a first coating 6190 that is comprised of a first material and has a first thickness and the crown 6110 is coated with a second coating 6190’ that is comprised of a second material, that is different than the first material, and has a second thickness that is different than the first thickness.
  • the bends 6130 are coated with a third coating 6190” that is comprised of the first material but has a thickness that 141 is less than the first thickness.
  • the first material has a faster absorption rate than the second material.
  • the time needed to dissolve the coating 6190 on the legs 6120 is less than the time needed to dissolve the coating 6190’ on the crown 6110.
  • the legs 6120 will bioabsorb and/or fracture before the crown 6110 allowing for an early release of the patient tissue.
  • the time needed to dissolve the coating 6190” on the bends 6130 is less than the time needed to dissolve the coating 6190 on the legs 6120 as the material of the 6190’ ’ coating is the same as the 6190 coating but is thinner.
  • the bends will bioabsorb and/or fracture before the legs 6120 and the crown 6110 providing for an even earlier release of the patient tissue.
  • the second material of the crown coating 6190’ has a faster absorption rate than the first material of the leg coating 6190 and bend coating 6190”.
  • the time needed to bioabsorb and/or fracture the crown 6110 can be the same as or less than the time needed to bioabsorb and/or fracture the legs 6120 and/or the bends 6130.
  • a staple coating comprises polymer surfactant coatings.
  • a staple coating comprises poloxamers including block polymers of poly(ethylene oxide) (PEO) and/or polypropylene oxide) (PPO), for example.
  • a staple coating comprises bulky side chains which can limit and/or slow water access to materials in the staple that the water can degrade via steric hindrance effects.
  • a staple coating comprises polymers having bulky side chains.
  • a staple coating comprises one or more polymers having a polarity.
  • a staple coating comprises one or more materials that are hydrophobic that slow the degradation of the staple.
  • a staple coating comprises a polymer that is hydrophobic and has a polarity.
  • a staple is coated with a first layer having a polarity and a second layer on the first layer that has one or more hydrophobic materials.
  • a staple is coated with a material that mimics gastric mucosa. Such staples may be particularly useful when stapling stomach tissue, for example.
  • a staple is coated with one or more glycoproteins.
  • a staple coating includes one or more antimicrobial agents such as triclosan and/or chlorhexidine, for example.
  • a staple coating includes one or more coagulants.
  • a staple coating includes one or more 142 anti-coagulants, such as sirolimus, for example.
  • a staple coating includes one or more proliferative agents that promotes tissue growth.
  • a staple coating comprises one or more immuno-suppressants.
  • a staple coating comprises a cancer treatment, such as paclitaxel, for example.
  • a staple coating can comprise two or more layers, each of which having a different drug contained therein.
  • a staple coating can comprise a second layer on the staple substrate that has a second drug contained therein and a first layer on the second layer that has a first drug contained therein.
  • the staple is bioabsorbed, in such embodiments, the first drug is released as the first layer is being bioabsorbed and then the second drug is released as the second layer is being bioabsorbed.
  • a staple includes a hydrogen carbonate coating or a coating layer that includes hydrogen carbonate.
  • the staple coating comprises at least one of CaHCC , Mg[0H]C02, and/or strontium, for example.
  • a staple coating is biodegradable.
  • a staple coating is not biodegradable but is biocompatible.
  • a staple coating comprises parylene N, parylene C, parylene D, parylene HT and/or combinations thereof, for example.
  • parylene can be deposited onto a metal staple substrate using a chemical vapor deposition process.
  • magnesium staples comprise radiopaque alloys.
  • magnesium staple alloys include silver and/or barium, for example.
  • radiopaque elements such as silver and/or barium, for example, are present in one or more coatings on the magnesium staples.
  • the magnesium staples are more readily apparent in radiographs.
  • magnesium comprises various naturally 143 occurring isotopes such as Mg-25 and Mg-26, for example, that exist in a natural occurring ratio.
  • magnesium staples can comprise a higher concentration of Mg-25 and/or Mg-26 such that, when the magnesium of the staples is bioabsorbed and excreted through urine, for example, the increased presence of the magnesium isotopes in the patient’s urine can be readily detected which would reveal that the magnesium staples are being or have been bioabsorbed.
  • the ratio of the Mg-25 and the Mg-26 in the magnesium staples is different than the naturally occurring ratio and, as a result, the clinician can know that the increased levels of Mg-25 and Mg-26 in the patient’s urine is from the implanted staples by verifying that the different ratio of Mg-25 and Mg-26 exists in the urine.
  • a staple comprises a substrate and a coating on the substrate which delays the bioabsorption of the substrate and/or slows the bioabsorption of the substrate.
  • a staple comprises a substrate and two or more coatings on the substrate.
  • the coatings can provide different effects and/or work co-operatively to provide an effect.
  • a staple comprises a metal substrate and a bioabsorbable coating on only a portion of the substrate.
  • the uncoated portion of the staple is immediately exposed to water and/or other degradation factors in the patient once the staple is implanted in patient tissue. As such, the uncoated portion of the staple starts to bioabsorb right away at the bioabsorption rate of the metal.
  • the coated portion of the staple is impermeable when the staple is implanted and, as a result, the coating prevents the substrate underlying the coating from being bioabsorbed, at least initially. As the coating is bioabsorbed, the coating becomes at least partially permeable and the water and/or other degradation factors can begin to access the substrate underlying the coating.
  • the coating becomes more and more permeable, water and/or other degradation factors have more and more access to the underlying substrate which increases the effective bioabsorption rate of the underlying substrate.
  • the coating Once the coating has been bioabsorbed, the entire substrate is exposed and can bioabsorb at the bioabsorption rate of the metal.
  • the degradation of the substrate underlying the coating was delayed and then slowed.
  • the bioabsorption of the coating can cause the coating to elude into the environment, or tissue, surrounding the implanted staple and effect the tissue environment.
  • the coating is comprised of one or more polymers which, once released into the tissue environment, make the pH of the tissue environment more 144 acidic and/or drive the tissue environment below a pH of 7.
  • the tissue environment becomes more and more acidic as more and more coating is bioabsorbed.
  • the increasing acidity of the tissue environment increases the rate in which the exposed portions of the staple substrate are dissolved.
  • the staple may be sufficiently functional for a period of time after it has been implanted in the patient tissue and then fail and dissolve suddenly. Such embodiments are useful where it is desired for the staples to hold the patient tissue together during the tissue healing window and then disappear as soon as possible thereafter.
  • a staple comprises a metal substrate, a second, or inner, bioabsorbable coating on the metal substrate, and a first, or outer, bioabsorbable coating on the second bioabsorbable coating.
  • the first coating is impermeable when the staple is implanted and protects the second layer and the metal substrate from water and/or degradation factors. Once the first coating starts to bioabsorb, the first coating becomes at least partially permeable and, as a result, the second coating becomes exposed to water and/or degradation factors which begin to bioabsorb the second coating. At this point, the second coating is impermeable and protects the metal substrate from the water and/or degradation factors.
  • the first coating is comprised of one or more polymers which, once released into the tissue environment, lower the pH, make the pH of the tissue environment more acidic, and/or drive the tissue environment below a pH of 7.
  • the tissue environment becomes more and more acidic as more and more first coating is bioabsorbed.
  • the increasing acidity of the tissue environment increases the rate in which the second coating is dissolved.
  • the second coating is comprised of one or more polymers which, once released into the tissue environment, lower the pH, make the pH of the tissue environment more acidic, and/or drive the tissue environment below a pH of 7.
  • the dissolution of the first and second coatings can create an environment that quickly dissolves the metal substrate once it is exposed.
  • the staple may be sufficiently functional for a period of time after it has been implanted in the patient tissue and then fail and dissolve suddenly. Such embodiments are useful where it is desired for the staples to hold the patient tissue together during the tissue healing window and then disappear as soon as possible thereafter.
  • the first coating and/or the second coating can comprise hyaluronic acid, lactic acid, and/or hydrochloric acid, for example, which lowers the pH, or increases the acidity of the tissue environment surrounding the staple when the coatings elude into the surrounding tissue environment.
  • the first coating and/or the second coating release ionic salts into the tissue environment as they are bioabsorbed which can lower the pH of the tissue environment and/or drive the tissue environment below a pH of 7.
  • the first coating and/or the second coating comprise a substance, such as a drug and/or nutrient, for example, that, once released into the tissue environment, causes a physiologic response in the patient which causes the patient’s body to lower the pH in the tissue environment surrounding the staple and/or drive the tissue environment below a pH of 7.
  • a substance released from the staple coatings can create a pro-inflammation response in the patient that accelerates the bioabsorption of the staple.
  • the bioabsorption of the first coating can be antagonistic to the second coating and/or the underlying metal substrate.
  • the bioabsorption of the second coating can be antagonistic to the underlying metal substrate.
  • a staple comprises a metal substrate, a first coating comprised of a first material on the metal substrate, and a second coating comprised of a second, or different, material on the metal substrate.
  • the first coating is on the legs of the staple and the second coating is on the crown of the staple.
  • the first coating and the second coating are adjacent to one another and may partially overlap one another.
  • the first coating is configured to bioabsorb faster than the second coating.
  • the eluded first coating can accelerate or speed up the bioabsorption of the second coating. In other embodiments, however, the eluded first coating can delay, decelerate, and/or slow down the bioabsorption of the second coating and/or underlying metal substrate. In a way, in such embodiments, the first coating can have a protective effect on the second coating and/or the underlying metal substrate even though the bioabsorption of the second coating and/or underlying metal substrate may have already started. In at least one embodiment, the first coating comprises nutrients that increase the pH of the tissue environment surrounding the staple and/or drive the local tissue environment to an 146 alkaline level, i.e., above a pH of 7.
  • the first coating comprises alkaline phosphate and/or an enzyme that exhibits anti-inflammatory effects by dephosphorylating inflammation triggering moieties (ITMs) like bacterial lipopolysaccharides and extracellular nucleotides, for example.
  • the first coating comprises an alkalizing agent such as bicarbonate, for example.
  • the first coating comprises a substance that, once eluded into the patient, provokes a physiologic response in the patient that increase the pH of the tissue environment surrounding the staple.
  • the first coating comprises electrolyte buffers such as sodium, calcium, and/or potassium, for example, which can bind acids surrounding the staple.
  • a staple comprises a metal substrate, a second, or inner, coating on the metal substrate, and a first, or outer, coating on the second coating.
  • the first coating can elude into the tissue environment surrounding the staple and have an alkaline effect in the tissue environment which delays and/or slows the bioabsorption of the second coating and the metal substrate.
  • the time needed to bioabsorb the staple can be increased by the first coating.
  • the second coating can elude into the tissue environment and also have an alkaline effect in the tissue environment which further delays and/or slows the bioabsorption of the metal substrate.
  • the first coating has an alkaline effect on the surrounding tissue environment and the second coating has an acidic effect on the surrounding tissue environment.
  • the bioabsorption of the staple can begin slowly and then accelerate to fracture and/or dissolve the staple once the second coating begins to elude and countermand the effects of the first coating.
  • a staple cartridge comprises a longitudinal row of first staples and a longitudinal row of second staples stored therein.
  • the first staples have a first coating thereon and the second staples have a second coating thereon which is different than first coating.
  • the first coating is configured to bioabsorb faster than the second coating.
  • the staple cartridge further comprises a longitudinal slot defined therein which is configured to receive a tissue cutting knife that cuts the patient tissue during the staple firing stroke.
  • the longitudinal row of 147 first staples and the longitudinal row of second staples are stored on the same side of the longitudinal knife slot.
  • the first staples and the second staples are implanted in the patient tissue on the same side of the tissue incision and are, thus, in close proximity to one another.
  • the longitudinal row of first staples and the longitudinal row of second staples are stored on opposite sides of the longitudinal knife slot.
  • the first staples and the second staples are implanted in the patient tissue on opposite sides of the tissue incision. In either event, the elution of the first coating from the first staples can affect the tissue environment surrounding the second staples and affect the bioabsorption of the second staples.
  • the bioabsorption of various staple coatings can begin as soon as the staples are implanted in the patient. In other embodiments, the bioabsorption of a staple coating does not begin until a triggering event has occurred.
  • the staple coating is responsive to the presence of an enzyme that, once present in the vicinity of the staple coating, can trigger the bioabsorption process of the staple coating.
  • the patient’s body can release enzymes during the tissue healing response which trigger the bioabsorption of the staple coating.
  • the triggering event can comprise heat and/or radiation, for example, which can be exposed to the staples once the staples have been implanted in the patient tissue.
  • the triggering event can occur after the surgical procedure has been completed. Moreover, although the triggering even can occur in situ, the triggering event can occur ex vivo.
  • a staple pattern implanted in patient tissue T comprises a longitudinal row of staples 7000 positioned along incision I.
  • the staple pattern further comprises two longitudinal rows of staples 7000’ adjacent to the longitudinal row of staples 7000.
  • the staples 7000’ are comprised of a substrate and/or coating that causes the staples 7000’ to bioabsorb and dissolve faster than the staples 7000.
  • the staples closest to the incision margin hold onto the patient tissue T longer than the other staples in the staple pattern, as reflected in FIGS. 73B-73D.
  • Such an arrangement allows flexibility in the patient to develop before the incised tissue is finally released.
  • a staple cartridge 7500 comprises a cartridge body 7550 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 7550 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • the innermost rows of staple cavities has a single wire staple 7520’ stored in each staple cavity
  • the outermost rows of staple cavities has a single staple 8220’ stored in each staple cavity
  • the intermediate rows of staple cavities has a single staple 8220” stored in each staple cavity.
  • a staple cartridge 7600 comprises a cartridge body 7650 including a deck comprising a proximal end and a distal end and a longitudinal slot 8260 extending from the proximal end toward the distal end.
  • the cartridge body 7650 comprises three longitudinal rows of staple cavities defined in the deck on a first lateral side of the longitudinal slot 8260 and three longitudinal rows of staple cavities defined in the deck on a second, or opposite, side of the longitudinal slot 8260.
  • a proximal group of staple cavities has a single staple 8220’ stored in each staple cavity and the staple cavities distal to the proximal group has a single staple 7520’ removably stored therein.
  • a staple pattern is created in patient tissue as a result of several consecutive cartridge firings, it is possible for the distal staples of one staple cartridge firing to overlap with the proximal staples of the next staple cartridge firing.
  • the faster-absorbing staples 8220’ can bioabsorb and/or dissolve leaving behind the slower-absorbing staples 7520’.
  • the integrity of the entire staple pattern is maintained as at least some staples of the overlapped staples bioabsorb and/or dissolve at the same rate as the non-overlapped staples.
  • staples 7000 and 7000’ overlap in various locations within a staple pattern to provide such a result.
  • Such arrangements may be particularly useful in lung tissue. Having said that, various embodiments are envisioned in which the bioabsorption of the proximal staples and the distal staples of a staple cartridge can be tuned to achieve a desired result.
  • a staple pattern implanted in patient tissue T comprises a longitudinal row of staples 7200 positioned along an incision I in the patient tissue T.
  • the staple 149 pattern also comprises two outer longitudinal rows of staples 7000 adjacent to the inner longitudinal row of staples 7200.
  • the staples 7200 are larger than the staples 7000 and, absent other considerations, the staples 7200 bioabsorb slower than the staples 7000.
  • a staple pattern implanted in patient tissue T is similar to the staple pattern depicted in FIG.
  • the staples 7300 have a different size than the staples 7000 and 7200 and may bioabsorb and/or dissolve at a different rate than the staples 7000 and 7200.
  • the staples 7200 are also comprised of a different material than the staples 7000 and 7200 and, as a result, may bioabsorb and/or dissolve at different rate than the staples 7000 and 7200.
  • a staple is comprised of a metal wire.
  • a staple is stamped from a sheet of material.
  • the teachings provided herein with regard to wire staples are equally applicable to stamped staples.
  • the teachings provided herein with regard to stamped staples are equally applicable to wire staples.
  • the sheet of material used to manufacture the stamped staples from is comprised of a homogenous, or an at least substantially homogenous, sheet of material.
  • the sheet of material comprises two or more layers.
  • a process of manufacturing stamped staples may subject the stamped staples to less cold- working and/or less residual stresses than a process of manufacturing wire staples.
  • Such lower residual stresses in stamped staples may reduce the possibility of cracking and/or fracturing in the stamped staples, especially in the transitions between the crown and the staple legs.
  • transitions may not be bent to form a substantially V-shaped staple, for example, like a wire may be bent to form a similar shape.
  • the diameter of a staple wire can be reduced and/or stamped to create a thinner cross-section in the bends of a wire staple; however, such processes can comprise cold-working of the metal wire to achieve such thinner cross-sections.
  • Stamped staples can be stamped into any suitable configuration with only the cold-working needed during the stamping process, or processes.
  • the transitions between the crown and the staple legs in a stamped staple are thinner than the crown, for example.
  • the legs of a stamped staple are tapered.
  • the bases of the staple legs are wider than the tips of the staple legs, for example.
  • the crown is thicker than the staple legs and the transitions, for example.
  • staples are stamped from a sheet of material having two or more layers.
  • the sheet of material comprises three layers - an inner layer positioned intermediate two outer layers.
  • the outer layers are stiffer than the inner layer.
  • the inner layer of the staple is comprised of magnesium.
  • the inner magnesium layer can act as a sacrificial anode which allows the stamped staple to deteriorate from the inside out.
  • the outer layers of the stamped staple are comprised of a magnesium alloy while the inner layer is comprised of pure magnesium, for example.
  • the outer layers can be alloyed such that the inner layer biodegrades slower than the outer layers.
  • one or both of the outer layers are comprised of a hydrophobic material which delays and/or slows the deterioration of the staple.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Surgical Instruments (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des cartouches d'agrafes comprenant des agrafes bioabsorbables. Les agrafes sont conçues de telle sorte qu'elles sont bioabsorbables dans un délai souhaité.
EP22724894.5A 2021-05-10 2022-05-06 Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables Pending EP4178458A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186519P 2021-05-10 2021-05-10
US17/718,838 US20220354486A1 (en) 2021-05-10 2022-04-12 System of surgical staple cartridges comprising absorbable staples
PCT/IB2022/054211 WO2022238840A1 (fr) 2021-05-10 2022-05-06 Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables

Publications (1)

Publication Number Publication Date
EP4178458A1 true EP4178458A1 (fr) 2023-05-17

Family

ID=81750732

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22724894.5A Pending EP4178458A1 (fr) 2021-05-10 2022-05-06 Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables

Country Status (4)

Country Link
EP (1) EP4178458A1 (fr)
JP (1) JP2024518072A (fr)
MX (1) MX2023013318A (fr)
WO (1) WO2022238840A1 (fr)

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3187308A (en) 1961-07-03 1965-06-01 Gen Electric Information storage system for microwave computer
US3157308A (en) 1961-09-05 1964-11-17 Clark Mfg Co J L Canister type container and method of making the same
US3200208A (en) 1962-07-02 1965-08-10 Oak Mfg Co Rotary selector switch construction with rotor interlocking means
US5403312A (en) 1993-07-22 1995-04-04 Ethicon, Inc. Electrosurgical hemostatic device
US7000818B2 (en) 2003-05-20 2006-02-21 Ethicon, Endo-Surger, Inc. Surgical stapling instrument having separate distinct closing and firing systems
US7905902B2 (en) 2003-06-16 2011-03-15 Ethicon Endo-Surgery, Inc. Surgical implant with preferential corrosion zone
US20060052825A1 (en) 2003-06-16 2006-03-09 Ransick Mark H Surgical implant alloy
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US7669746B2 (en) 2005-08-31 2010-03-02 Ethicon Endo-Surgery, Inc. Staple cartridges for forming staples having differing formed staple heights
US7673781B2 (en) 2005-08-31 2010-03-09 Ethicon Endo-Surgery, Inc. Surgical stapling device with staple driver that supports multiple wire diameter staples
US7670334B2 (en) 2006-01-10 2010-03-02 Ethicon Endo-Surgery, Inc. Surgical instrument having an articulating end effector
US7464849B2 (en) 2006-01-31 2008-12-16 Ethicon Endo-Surgery, Inc. Electro-mechanical surgical instrument with closure system and anvil alignment components
US20070175955A1 (en) 2006-01-31 2007-08-02 Shelton Frederick E Iv Surgical cutting and fastening instrument with closure trigger locking mechanism
US7422139B2 (en) 2006-01-31 2008-09-09 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting fastening instrument with tactile position feedback
US7845537B2 (en) 2006-01-31 2010-12-07 Ethicon Endo-Surgery, Inc. Surgical instrument having recording capabilities
US7665647B2 (en) 2006-09-29 2010-02-23 Ethicon Endo-Surgery, Inc. Surgical cutting and stapling device with closure apparatus for limiting maximum tissue compression force
US7753245B2 (en) 2007-06-22 2010-07-13 Ethicon Endo-Surgery, Inc. Surgical stapling instruments
US8308040B2 (en) 2007-06-22 2012-11-13 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulatable end effector
US8561870B2 (en) 2008-02-13 2013-10-22 Ethicon Endo-Surgery, Inc. Surgical stapling instrument
US8371491B2 (en) 2008-02-15 2013-02-12 Ethicon Endo-Surgery, Inc. Surgical end effector having buttress retention features
US7980443B2 (en) 2008-02-15 2011-07-19 Ethicon Endo-Surgery, Inc. End effectors for a surgical cutting and stapling instrument
US8210411B2 (en) 2008-09-23 2012-07-03 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument
US9050083B2 (en) 2008-09-23 2015-06-09 Ethicon Endo-Surgery, Inc. Motorized surgical instrument
US8608045B2 (en) 2008-10-10 2013-12-17 Ethicon Endo-Sugery, Inc. Powered surgical cutting and stapling apparatus with manually retractable firing system
US8220688B2 (en) 2009-12-24 2012-07-17 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument with electric actuator directional control assembly
JP5721017B2 (ja) 2010-06-25 2015-05-20 フォート ウェイン メタルス リサーチ プロダクツ コーポレーション 医療デバイス用のバイメタル複合ワイヤ、バイメタル複合ワイヤから形成されるステント、及びバイメタル複合ワイヤとステントを製造する方法
US8733613B2 (en) 2010-09-29 2014-05-27 Ethicon Endo-Surgery, Inc. Staple cartridge
US9307989B2 (en) 2012-03-28 2016-04-12 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorportating a hydrophobic agent
US9332974B2 (en) * 2010-09-30 2016-05-10 Ethicon Endo-Surgery, Llc Layered tissue thickness compensator
US9351730B2 (en) 2011-04-29 2016-05-31 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising channels
US8752699B2 (en) 2010-09-30 2014-06-17 Ethicon Endo-Surgery, Inc. Implantable fastener cartridge comprising bioabsorbable layers
US9592050B2 (en) 2010-09-30 2017-03-14 Ethicon Endo-Surgery, Llc End effector comprising a distal tissue abutment member
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
US9398911B2 (en) 2013-03-01 2016-07-26 Ethicon Endo-Surgery, Llc Rotary powered surgical instruments with multiple degrees of freedom
US9345481B2 (en) 2013-03-13 2016-05-24 Ethicon Endo-Surgery, Llc Staple cartridge tissue thickness sensor system
US9883860B2 (en) 2013-03-14 2018-02-06 Ethicon Llc Interchangeable shaft assemblies for use with a surgical instrument
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9795384B2 (en) 2013-03-27 2017-10-24 Ethicon Llc Fastener cartridge comprising a tissue thickness compensator and a gap setting element
US9801626B2 (en) 2013-04-16 2017-10-31 Ethicon Llc Modular motor driven surgical instruments with alignment features for aligning rotary drive shafts with surgical end effector shafts
US9700311B2 (en) 2013-11-08 2017-07-11 Ethicon Llc Tissue ingrowth materials and method of using the same
US9826977B2 (en) 2014-03-26 2017-11-28 Ethicon Llc Sterilization verification circuit
US9820738B2 (en) 2014-03-26 2017-11-21 Ethicon Llc Surgical instrument comprising interactive systems
US20150272580A1 (en) 2014-03-26 2015-10-01 Ethicon Endo-Surgery, Inc. Verification of number of battery exchanges/procedure count
US9844369B2 (en) 2014-04-16 2017-12-19 Ethicon Llc Surgical end effectors with firing element monitoring arrangements
JP6612256B2 (ja) * 2014-04-16 2019-11-27 エシコン エルエルシー 不均一な締結具を備える締結具カートリッジ
US10016199B2 (en) 2014-09-05 2018-07-10 Ethicon Llc Polarity of hall magnet to identify cartridge type
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US10117649B2 (en) 2014-12-18 2018-11-06 Ethicon Llc Surgical instrument assembly comprising a lockable articulation system
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US10188385B2 (en) 2014-12-18 2019-01-29 Ethicon Llc Surgical instrument system comprising lockable systems
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US9943309B2 (en) 2014-12-18 2018-04-17 Ethicon Llc Surgical instruments with articulatable end effectors and movable firing beam support arrangements
US10045779B2 (en) 2015-02-27 2018-08-14 Ethicon Llc Surgical instrument system comprising an inspection station
US9993258B2 (en) 2015-02-27 2018-06-12 Ethicon Llc Adaptable surgical instrument handle
US10180463B2 (en) 2015-02-27 2019-01-15 Ethicon Llc Surgical apparatus configured to assess whether a performance parameter of the surgical apparatus is within an acceptable performance band
US9808246B2 (en) 2015-03-06 2017-11-07 Ethicon Endo-Surgery, Llc Method of operating a powered surgical instrument
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
US10687806B2 (en) 2015-03-06 2020-06-23 Ethicon Llc Adaptive tissue compression techniques to adjust closure rates for multiple tissue types
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft
US10045776B2 (en) 2015-03-06 2018-08-14 Ethicon Llc Control techniques and sub-processor contained within modular shaft with select control processing from handle
US10548504B2 (en) 2015-03-06 2020-02-04 Ethicon Llc Overlaid multi sensor radio frequency (RF) electrode system to measure tissue compression
US10441279B2 (en) 2015-03-06 2019-10-15 Ethicon Llc Multiple level thresholds to modify operation of powered surgical instruments
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
US9895148B2 (en) 2015-03-06 2018-02-20 Ethicon Endo-Surgery, Llc Monitoring speed control and precision incrementing of motor for powered surgical instruments
US10617412B2 (en) 2015-03-06 2020-04-14 Ethicon Llc System for detecting the mis-insertion of a staple cartridge into a surgical stapler
US9924961B2 (en) 2015-03-06 2018-03-27 Ethicon Endo-Surgery, Llc Interactive feedback system for powered surgical instruments
US10335149B2 (en) 2015-06-18 2019-07-02 Ethicon Llc Articulatable surgical instruments with composite firing beam structures with center firing support member for articulation support
US10835249B2 (en) 2015-08-17 2020-11-17 Ethicon Llc Implantable layers for a surgical instrument
US11103248B2 (en) 2015-08-26 2021-08-31 Cilag Gmbh International Surgical staples for minimizing staple roll
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10433837B2 (en) 2016-02-09 2019-10-08 Ethicon Llc Surgical instruments with multiple link articulation arrangements
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10258331B2 (en) 2016-02-12 2019-04-16 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US20170231628A1 (en) 2016-02-12 2017-08-17 Ethicon Endo-Surgery, Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10307159B2 (en) 2016-04-01 2019-06-04 Ethicon Llc Surgical instrument handle assembly with reconfigurable grip portion
US10285705B2 (en) 2016-04-01 2019-05-14 Ethicon Llc Surgical stapling system comprising a grooved forming pocket
US10456140B2 (en) 2016-04-01 2019-10-29 Ethicon Llc Surgical stapling system comprising an unclamping lockout
US11284890B2 (en) 2016-04-01 2022-03-29 Cilag Gmbh International Circular stapling system comprising an incisable tissue support
US11607239B2 (en) 2016-04-15 2023-03-21 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US11000278B2 (en) 2016-06-24 2021-05-11 Ethicon Llc Staple cartridge comprising wire staples and stamped staples
USD850617S1 (en) 2016-06-24 2019-06-04 Ethicon Llc Surgical fastener cartridge
USD847989S1 (en) 2016-06-24 2019-05-07 Ethicon Llc Surgical fastener cartridge
USD822206S1 (en) 2016-06-24 2018-07-03 Ethicon Llc Surgical fastener
USD826405S1 (en) 2016-06-24 2018-08-21 Ethicon Llc Surgical fastener
USD833608S1 (en) 2016-11-14 2018-11-13 Ethicon Llc Stapling head feature for surgical stapler
US10675026B2 (en) 2016-12-21 2020-06-09 Ethicon Llc Methods of stapling tissue
US20180168625A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Surgical stapling instruments with smart staple cartridges
US10624635B2 (en) 2016-12-21 2020-04-21 Ethicon Llc Firing members with non-parallel jaw engagement features for surgical end effectors
US10856868B2 (en) 2016-12-21 2020-12-08 Ethicon Llc Firing member pin configurations
US10835247B2 (en) 2016-12-21 2020-11-17 Ethicon Llc Lockout arrangements for surgical end effectors
US10888322B2 (en) 2016-12-21 2021-01-12 Ethicon Llc Surgical instrument comprising a cutting member
US20180168619A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Surgical stapling systems
US10667810B2 (en) 2016-12-21 2020-06-02 Ethicon Llc Closure members with cam surface arrangements for surgical instruments with separate and distinct closure and firing systems
US20180168650A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Connection portions for disposable loading units for surgical stapling instruments
US10945727B2 (en) 2016-12-21 2021-03-16 Ethicon Llc Staple cartridge with deformable driver retention features
US11191539B2 (en) 2016-12-21 2021-12-07 Cilag Gmbh International Shaft assembly comprising a manually-operable retraction system for use with a motorized surgical instrument system
US10695055B2 (en) 2016-12-21 2020-06-30 Ethicon Llc Firing assembly comprising a lockout
US10426471B2 (en) 2016-12-21 2019-10-01 Ethicon Llc Surgical instrument with multiple failure response modes
US10568625B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Staple cartridges and arrangements of staples and staple cavities therein
US11419606B2 (en) 2016-12-21 2022-08-23 Cilag Gmbh International Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
US11134942B2 (en) 2016-12-21 2021-10-05 Cilag Gmbh International Surgical stapling instruments and staple-forming anvils
US10993715B2 (en) 2016-12-21 2021-05-04 Ethicon Llc Staple cartridge comprising staples with different clamping breadths
US10687810B2 (en) 2016-12-21 2020-06-23 Ethicon Llc Stepped staple cartridge with tissue retention and gap setting features
US10499914B2 (en) 2016-12-21 2019-12-10 Ethicon Llc Staple forming pocket arrangements
US20180168615A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
USD836198S1 (en) 2017-02-17 2018-12-18 Ethicon Llc Staple cartridge for a surgical stapler
US20180353175A1 (en) 2017-06-13 2018-12-13 Ethicon Llc Surgical Fastener with Broad Spectrum MMP Inhibitors
US10939911B2 (en) 2017-06-13 2021-03-09 Ethicon Llc Surgical stapler with end effector coating
US11678881B2 (en) 2017-12-28 2023-06-20 Cilag Gmbh International Spatial awareness of surgical hubs in operating rooms
US11100631B2 (en) 2017-12-28 2021-08-24 Cilag Gmbh International Use of laser light and red-green-blue coloration to determine properties of back scattered light
US20190200906A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Dual cmos array imaging
US11202570B2 (en) 2017-12-28 2021-12-21 Cilag Gmbh International Communication hub and storage device for storing parameters and status of a surgical device to be shared with cloud based analytics systems
US11076921B2 (en) 2017-12-28 2021-08-03 Cilag Gmbh International Adaptive control program updates for surgical hubs
US10932872B2 (en) 2017-12-28 2021-03-02 Ethicon Llc Cloud-based medical analytics for linking of local usage trends with the resource acquisition behaviors of larger data set
US11058498B2 (en) 2017-12-28 2021-07-13 Cilag Gmbh International Cooperative surgical actions for robot-assisted surgical platforms
US11069012B2 (en) 2017-12-28 2021-07-20 Cilag Gmbh International Interactive surgical systems with condition handling of devices and data capabilities
US11672605B2 (en) 2017-12-28 2023-06-13 Cilag Gmbh International Sterile field interactive control displays
US10966791B2 (en) 2017-12-28 2021-04-06 Ethicon Llc Cloud-based medical analytics for medical facility segmented individualization of instrument function
US10892899B2 (en) 2017-12-28 2021-01-12 Ethicon Llc Self describing data packets generated at an issuing instrument
US11432885B2 (en) 2017-12-28 2022-09-06 Cilag Gmbh International Sensing arrangements for robot-assisted surgical platforms
US20190201115A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Aggregation and reporting of surgical hub data
US11132462B2 (en) 2017-12-28 2021-09-28 Cilag Gmbh International Data stripping method to interrogate patient records and create anonymized record
US11266468B2 (en) 2017-12-28 2022-03-08 Cilag Gmbh International Cooperative utilization of data derived from secondary sources by intelligent surgical hubs
US20190206555A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Cloud-based medical analytics for customization and recommendations to a user
US10849697B2 (en) 2017-12-28 2020-12-01 Ethicon Llc Cloud interface for coupled surgical devices
US11410259B2 (en) 2017-12-28 2022-08-09 Cilag Gmbh International Adaptive control program updates for surgical devices
US11166772B2 (en) 2017-12-28 2021-11-09 Cilag Gmbh International Surgical hub coordination of control and communication of operating room devices
US10987178B2 (en) 2017-12-28 2021-04-27 Ethicon Llc Surgical hub control arrangements
US10944728B2 (en) 2017-12-28 2021-03-09 Ethicon Llc Interactive surgical systems with encrypted communication capabilities
US11419630B2 (en) 2017-12-28 2022-08-23 Cilag Gmbh International Surgical system distributed processing
US11969142B2 (en) 2017-12-28 2024-04-30 Cilag Gmbh International Method of compressing tissue within a stapling device and simultaneously displaying the location of the tissue within the jaws
US11179208B2 (en) 2017-12-28 2021-11-23 Cilag Gmbh International Cloud-based medical analytics for security and authentication trends and reactive measures
US20190201139A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Communication arrangements for robot-assisted surgical platforms
US20190201112A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Computer implemented interactive surgical systems
US11864728B2 (en) 2017-12-28 2024-01-09 Cilag Gmbh International Characterization of tissue irregularities through the use of mono-chromatic light refractivity
US20190205567A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Data pairing to interconnect a device measured parameter with an outcome
US11857152B2 (en) 2017-12-28 2024-01-02 Cilag Gmbh International Surgical hub spatial awareness to determine devices in operating theater
US20190206561A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Data handling and prioritization in a cloud analytics network
US20190201140A1 (en) 2017-12-28 2019-07-04 Ethicon Llc Surgical hub situational awareness
US11259806B2 (en) 2018-03-28 2022-03-01 Cilag Gmbh International Surgical stapling devices with features for blocking advancement of a camming assembly of an incompatible cartridge installed therein
US11471156B2 (en) 2018-03-28 2022-10-18 Cilag Gmbh International Surgical stapling devices with improved rotary driven closure systems
US11207067B2 (en) 2018-03-28 2021-12-28 Cilag Gmbh International Surgical stapling device with separate rotary driven closure and firing systems and firing member that engages both jaws while firing
US11096688B2 (en) 2018-03-28 2021-08-24 Cilag Gmbh International Rotary driven firing members with different anvil and channel engagement features
US11278280B2 (en) 2018-03-28 2022-03-22 Cilag Gmbh International Surgical instrument comprising a jaw closure lockout
US20190298353A1 (en) 2018-03-28 2019-10-03 Ethicon Llc Surgical stapling devices with asymmetric closure features
US11197668B2 (en) 2018-03-28 2021-12-14 Cilag Gmbh International Surgical stapling assembly comprising a lockout and an exterior access orifice to permit artificial unlocking of the lockout
US11219453B2 (en) 2018-03-28 2022-01-11 Cilag Gmbh International Surgical stapling devices with cartridge compatible closure and firing lockout arrangements
CN209360781U (zh) * 2018-04-25 2019-09-10 东莞立德生物医疗有限公司 吻合器用吻合钉
US11083458B2 (en) 2018-08-20 2021-08-10 Cilag Gmbh International Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions
US11253256B2 (en) 2018-08-20 2022-02-22 Cilag Gmbh International Articulatable motor powered surgical instruments with dedicated articulation motor arrangements
US11039834B2 (en) 2018-08-20 2021-06-22 Cilag Gmbh International Surgical stapler anvils with staple directing protrusions and tissue stability features
US11291440B2 (en) 2018-08-20 2022-04-05 Cilag Gmbh International Method for operating a powered articulatable surgical instrument
US10912559B2 (en) 2018-08-20 2021-02-09 Ethicon Llc Reinforced deformable anvil tip for surgical stapler anvil
US10856870B2 (en) 2018-08-20 2020-12-08 Ethicon Llc Switching arrangements for motor powered articulatable surgical instruments
US20200054321A1 (en) 2018-08-20 2020-02-20 Ethicon Llc Surgical instruments with progressive jaw closure arrangements
US10779821B2 (en) 2018-08-20 2020-09-22 Ethicon Llc Surgical stapler anvils with tissue stop features configured to avoid tissue pinch
US11045192B2 (en) 2018-08-20 2021-06-29 Cilag Gmbh International Fabricating techniques for surgical stapler anvils
US11207065B2 (en) 2018-08-20 2021-12-28 Cilag Gmbh International Method for fabricating surgical stapler anvils
US10842492B2 (en) 2018-08-20 2020-11-24 Ethicon Llc Powered articulatable surgical instruments with clutching and locking arrangements for linking an articulation drive system to a firing drive system
EP3613449A1 (fr) 2018-08-23 2020-02-26 Biotronik Ag Amélioration de la couche polymère dans des dispositifs dégradables
USD926318S1 (en) 2018-12-28 2021-07-27 Cilag Gmbh International Surgical stapler deck with tissue engagement recess features
US20200345356A1 (en) 2019-04-30 2020-11-05 Ethicon Llc Intelligent firing associated with a surgical instrument
US11903581B2 (en) 2019-04-30 2024-02-20 Cilag Gmbh International Methods for stapling tissue using a surgical instrument
US11432816B2 (en) 2019-04-30 2022-09-06 Cilag Gmbh International Articulation pin for a surgical instrument
US20200345357A1 (en) 2019-04-30 2020-11-05 Ethicon Llc Intelligent firing associated with a surgical instrument
US11426251B2 (en) 2019-04-30 2022-08-30 Cilag Gmbh International Articulation directional lights on a surgical instrument
US11648009B2 (en) 2019-04-30 2023-05-16 Cilag Gmbh International Rotatable jaw tip for a surgical instrument
US11471157B2 (en) 2019-04-30 2022-10-18 Cilag Gmbh International Articulation control mapping for a surgical instrument
US11452528B2 (en) 2019-04-30 2022-09-27 Cilag Gmbh International Articulation actuators for a surgical instrument
US20200345359A1 (en) 2019-04-30 2020-11-05 Ethicon Llc Tissue stop for a surgical instrument
WO2020247383A1 (fr) 2019-06-03 2020-12-10 Fort Wayne Metals Research Products Corp Alliages résorbables à base de magnésium
US11229437B2 (en) 2019-06-28 2022-01-25 Cilag Gmbh International Method for authenticating the compatibility of a staple cartridge with a surgical instrument
US11771419B2 (en) 2019-06-28 2023-10-03 Cilag Gmbh International Packaging for a replaceable component of a surgical stapling system
US11534167B2 (en) * 2020-05-28 2022-12-27 Covidien Lp Electrotaxis-conducive stapling

Also Published As

Publication number Publication date
MX2023013318A (es) 2024-02-12
WO2022238840A1 (fr) 2022-11-17
JP2024518072A (ja) 2024-04-24

Similar Documents

Publication Publication Date Title
US11890004B2 (en) Staple cartridge comprising lubricated staples
US20220370065A1 (en) Dissimilar staple cartridges with different bioabsorbable components
WO2022238847A1 (fr) Commande adaptative d'un instrument d'agrafage chirurgical sur la base d'un type de cartouche à agrafes
US20220370064A1 (en) Method for delivering a staple in situ paired to the in situ environment
EP4171396A1 (fr) Commande adaptative d'un instrument d'agrafage chirurgical sur la base d'un type de cartouche à agrafes
EP4178458A1 (fr) Système de cartouches d'agrafes chirurgicales comprenant des agrafes absorbables
WO2022238844A1 (fr) Agrafe chirurgicale absorbable comprenant un revêtement
WO2022238836A1 (fr) Agrafe bioabsorbable comprenant des mécanismes de ralentissement de l'absorption de l'agrafe
EP4196016A2 (fr) Ensembles d'emballage pour cartouches d'agrafes chirurgicales contenant des agrafes bioabsorbables
CN117597074A (zh) 包括用于减慢可生物吸收钉的吸收的机制的可生物吸收钉
CN117615717A (zh) 包含涂层的可吸收外科钉
CN118159204A (zh) 包括可吸收钉的外科钉仓的系统
CN117580515A (zh) 用于装有可生物吸收钉的外科钉仓的包装组件
CN117940075A (zh) 外科缝合器械的基于钉仓类型的适应性控制
CN117580516A (zh) 具有不同可生物吸收部件的相异的钉仓

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20240718